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The work presented in this dissertation primarily entails determining specific structural and
functional features involved with glutamate transport by the excitatory amino acid transporters
(EAAT1-5). This research derives from a study of X-ray crystal structures of an homologous
archaeal transporter. Broadly, using computational methods to probe EAAT homology models
born from the archaeal structures, we describe novel Na+ and K+ coordination sites and present a model for sequential cation and substrate binding and unbinding during the transport
cycle. A secondary focus of this dissertation was computational modeling of two other proteins:
the HIV gp120 envelope protein (gp120) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1).
The study of gp120 involved a three-dimensional statistical analysis of amino acid substitutions
that occur during early infection of clade A HIV, indicating that during early infection substitutions are non-random and co-locate in regions associated with receptor binding. The computational component of the study involving NQO1 used molecular docking of two lavendamycin
analogues into the NQO1 active site. Here we showed that relative scores of docked poses of
the analogues were consistent with in vitro evaluations. All the studies presented in this dissertation were collaborative efforts that linked in silico work with in vitro analysis.
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Chapter 1: Background and significance
Introduction
Glutamate is the neurotransmitter responsible for conducting much of the excitatory
signaling in the mammalian central nervous system (CNS) and is involved in synaptic plasticity
necessary for learning and memory (Bortolloto et al., 1999; Curtis and Johnston 1974; Fonnum
1984). A crucial component of glutamatergic signaling in the CNS involves clearance of
glutamate from the synaptic cleft by excitatory amino acid transporters (EAATs) (Diamond and
Jahr, 1997). This dissertation focuses on discerning functionally critical aspects of EAAT
structure through computational modeling.
Not surprisingly, much work toward understanding glutamate transport and EAAT
structure and function had already been completed prior to work presented here. The following
paragraphs will introduce the relevant research necessary to understand my own work, as well
as provide a roadmap for the following chapters in my dissertation. First, I will introduce, in a
general sense, functional characteristics of the EAATs in the CNS. Then I will consider the
literature most relevant to my own research, and finally I will present an overview of my
dissertation.
Glutamate uptake by the EAATs halts synaptic transmission and mediates toxicity
stemming from overstimulation of surrounding neurons. Dysfunction of the EAATs has been
well documented and is implicated in neurodegenerative diseases such as Alzheimer’s disease
and amyotrophic lateral sclerosis (ALS) and brain insults such as ischemia and epilepsy
(Behrens et al., 2002; Carlsson and Carlsson, 1990; Choi, 1992; Ingram et al., 2000; Su et al.,
2003; for reviews see Grewer and Rauen, 2005; Beart and O’Shea, 2007). There are five
known mammalian subtypes of the transporters (EAAT1-5) each with distinct expression
profiles within the CNS. Broadly, EAAT1 and EAAT2 are expressed on glial membranes
throughout the CNS and are responsible for the majority of glutamate uptake, with EAAT1
predominant in the cerebellum and EAAT2 localizing primarily in the cortex and forebrain
(Furuta et al., 1997). EAATs3-5 are expressed on neuronal membranes with EAAT3 widely
expressed throughout the CNS, EAAT4 localizing to the cerebellum, and EAAT5 localizing to
retinal neurons (Arriza et al., 1997; Fairman et al., 1995; Kania et al., 1995; for reviews see
Bunch et al., 2009; Kanai and Hediger, 2004).
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Transport by the EAATs is an active process, coupling the thermodynamically favorable
transport of cations to power the transport of glutamate against its membrane concentration
gradient. In the alternating access carrier model proposed by Yernool et al. (2004), two αhelical, hairpin loops (HP1 and HP2) gate the co-transport of glutamate with three Na+ ions
and one proton, and the subsequent antiport of one K+ ion. This creates an electrogenic
process transporting two net positive charges across the membrane. Additionally, the binding
of Na+ and glutamate activates an uncoupled chloride conductance that may help regulate
neuronal excitatory response (Vandenberg et al., 2008; Veruki et al., 2006). Furthermore, in
the absence of glutamate, Na+ induces three separate currents: an uncoupled leak
conductance carried by chloride ions (reviewed in chapter 2), a leak current carried by Na+,
and a transient, capacitive current that can be blocked by addition of non-transportable
inhibitors (Kanai et al. 1995; Melzer et al., 2003; Otis et al., 1997; Ryan et al., 2004; Wadiche
and Kavanaugh, 1995; Wadiche and Kavanaugh, 1998).
The EAATs belong to the glutamate transporter family which contain structurally similar
but functionally diverse transmembrane transport proteins including mammalian neutral amino
acid transporters (ASCTs), bacterial C4-dicarboxylate transporters, and archaeal aspartate
transporters (Slotboom et al., 1999a). In 2004 an X-ray crystal structure of an homologous
archaeal aspartate transporter (GltPh) was solved and to date five other GltPh crystal structures
have been published. These structures revealed details about the EAATs including their
trimeric form in both inward and outward facing orientations, movement of HP2 which provides
a mechanism for extracellular substrate access, and the positions of cation and substrate/
inhibitor binding sites. Many aspects of glutamate transport, however, remain murky and
without clarification of these details, the mechanism of transport cannot be accurately derived.
The GltPh structure
The GltPh transporters have approximately 35% sequence identity with the EAATs with a
much higher conservation of residues implicated in substrate binding, ion binding, and anion
conductance (figure 1a; Bendahan et al., 2000; Kavanaugh et al., 1997; Ryan et al., 2004),
suggesting conservation of the basic architecture and transport mechanism. Therefore to
better understand transport in the EAATs, it is helpful to be acquainted with structural details of
the six homologous GltPh X-ray crystal structures. The first structure, published in 2004, was of
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hairpin loops (HP1 and HP2) (figure 1b-c). The trimeric complex forms a bowl that penetrates
approximately 30Ås into the extracellular side of the cell membrane (figure 2a). Of the more
recently published structures, two are bound with aspartate where HP2 is gated in a closed
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conformation) and cyan (TBOA-bound, open conformation). Bound TBOA is depicted in stick representation
(Boudker et al., 2007).
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One of the outward-facing, aspartate-bound structures was resolved with two thallium
ions that are posited by the authors as surrogates for Na+ ions (figure 3). These two bound
ions reveal a partial substrate binding order; site 1 binds deep within the overall binding pocket
before the amino acid substrate is bound, and site 2, which is available only when HP2 is in
L-TBOA

the closed conformation, binds after substrate is bound. Both of the resolved cations are
coordinated in part by the highly conserved NMDG sub-domain that disrupts the TM7 α-helix
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disruption of the TM7 α-helix stabilizes cation coordination at site 2 (figure 3). The influence of
the NMDG motif extends also to amino acid binding by allowing tertiary constraints critical for
the formation of the amino acid binding site and orientation of HP2 (Yernool et al., 2004;
Boudker et al., 2007).

R447
D444

HP2
Na2
Na1

HP1
Figure 3. Ribbon representation of aspartate-bound GltPh with Na+ depicted at Tl+ density sites 1 and 2. Stick
representations of bound aspartate and residues responsible for acidic amino acid recognition are represented as
sticks and are labeled with the EAAT3 sequence. The blue colored portion of the ribbon indicates the conserved
NMDG β-bridge region implicated in Na+ and amino acid substrate binding.

Very recently Reyes et al. (2009) capitalized on EAAT1 cysteine cross-linking data
published in 2004 by Ryan et al. who showed that residues in TM2 are proximal to residues in
HP2. The residues in question are 25Ås apart in outward facing GltPh structures yet are crosslink competent in the presence of substrate, indicating that the transporter samples
conformations very different from the outward facing conformations. Reyes et al. (2009) crosslinked the analogous residues in GltPh (cysteine point mutations K55C/A364C) to stabilize the
alternately-oriented transporter for crystallization. The resulting structure revealed that trimer
subunits contain two structurally rigid domains, one of which stays anchored in the membrane
(the trimerization domain) while the other moves approximately 18Ås across the membrane
(the transport domain) (figure 4a,b). The domains are hinged at the TM2-3 and TM5-6 loops
and during transport cause unwinding of α-helices in TM2, TM3, and TM5 and extension of the
TM6 α-helix. The rigidity of the two domains is impressive showing a 0.6Å root mean square
distance (r.m.s.d.) when the outward facing domains are superimposed with the inward facing
structure. The authors also show that the substrate free form of GltPh rapidly samples the
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cross-link competent state, suggesting that cation and substrate binding/release, and not
actual transport, are the thermodynamically linked steps. The resolution of the structure is
somewhat low at 3.5–3.9 Ås, however the authors were able to resolve electron densities for
bound aspartate and two sodium ions that coincided extremely well with the outward facing
thallium and aspartate bound structure. This is less surprising, of course, when considering the
outward facing structures were used as scaffolds for modeling the inward facing diffraction
NATURE

patterns (i.e. through molecular replacement techniques).
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transport domain is allowed. Movement of the transport domain
towards the cytoplasm also significantly increases its exposure to
the intracellular solvent. Notably, although the total exposed cytoplasmic surface area increases from ,1,300 Å2 in the wild type to
,4,200 Å2 in GltPh(55C/364CHg), the fraction of the apolar area
changes only modestly from 57% to 63%. Both
6 values are well within
the range reported for the solvent-exposed area of soluble proteins23.

The analysis of the evolutionary conservation reveal
acting residues within the trimerization domain as w
two alternative interfaces of the transport domain ar
served (Fig. 3c, d). The high conservation of HP2 surf
the reported transport inhibition of the mammalia
chemical modification of cysteines in HP2 (refs 24–28
with this region being involved in specific prote
observed in GltPh(55C/364CHg). The disengageme

of two different inverted
repeats
(figure
1b;of Crisman
2009;
Yernool
et al.,
membranes,structural
suggesting that
a sufficient
range
motions of et
theal., which
provide
92% and
88%2004;
of the total buried ar

Reyes et al., 2009). HP1 and the N-terminal half of TM7 can be inverted and superimposed
onto HP2-loop and the N-terminal portion of TM8 with an r.m.s.d. of 2.5Ås while TM4-6 can be
superimposed on TM1-3 with an r.m.s.d. of 6Ås in the outward facing orientation and 4.3Ås in
the inward facing orientation. These structural repeats help to define the interface between the
cytoplasmic and the extracellular portions of the trimerization domain (Reyes et al., 2009).
More fundamentally and assuming the structural repeats are linked to gene duplication events,
the repeats also indicate that structural conservation, if not sequence conservation, is
maintained at a sub-domain level.
Similarities between EAATs and GltPh
The first two results chapters of this dissertation rely on the homology between the EAATs
and GltPh. It is therefore important to consider similarities and differences between these
transporters. First, on a broad scale, GltPh is an archaeal transporter found in Pyrococcus
horikoshii and is highly selective for aspartate over other amino acids (Boudker et al., 2007;
Ryan et al., 2009). Similar to the EAATs, GltPh transport is coupled to three Na+ ions but, unlike
the EAATs, is not coupled to proton transport or K+ countertransport (Ryan et al., 2009;
Groeneveld and Slotboom, 2010). The sequence identity between GltPh and the EAATs is
approximately 35% with higher identity in regions associated with substrate binding and anion
conductance (Yernool et al., 2004; figure 1a). Discussed above but important to reiterate here
is the deletion in TM4 in GltPh. Again, this deletion restricts reliable homology modeling to
regions with high sequence conservation and due to the potential for amplified error, excludes
all but extremely short molecular dynamics simulations of orthologous EAAT systems.
With this in mind, the overall reliability of homology models based on seemingly diverse
structures is questionable. However, the high sequence identity between the transporters in
areas responsible for substrate binding and transport indicates regions of very high structural
compatibility. Specifically, conservation of residues responsible for acidic amino acid binding in
EAAT transmembrane 8 is conserved in GltPh with two residues known to confer substrate
specificity (R447 and D444 in EAAT3) directly interacting with bound aspartate in the GltPh
crystal structure in a manner consistent with the literature (figure 3; Bendahan et al., 2000;
Boudker et al., 2007; Teichman and Kanner, 2007). Likewise, the NMDG sub-domain in TM7 is
highly conserved throughout the glutamate transporter family and its involvement in Na+ and
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substrate binding in the EAATs is supported by the GltPh structures (Borre and Kanner, 2001;
Boudker et al., 2007; Tao et al., 2006; Zarbiv et al., 1998). Other structural motifs such as the
GltPh HP1 and HP2 are also consistent with cross-linking and mutation data in the EAATs
(Slotboom et al., 1999; Grunewald et al., 1998).
Architectural conservation without sequence conservation is also a relatively established
paradigm. For example, the sequence identity for the lactose permease and the glycerol-3phosphate antiporter (both are proteins in Escherichia coli) is considered random at
approximately 15%. However, published X-ray crystal structures reveal the proteins as
structurally almost identical with an r.m.s.d. of approximately 2.8Ås (Abramson et al., 2004).
Although this is merely one example it shows that structural conservation can be maintained
without sequence conservation. Thus, the consistency between structural facets of the EAATs
revealed through electrophysical, mutation and cross-linking studies and the GltPh X-ray crystal
structures is well described (Yernool et al., 2004; Boudker et al., 2007; Reyes et al., 2010) and
would indicate sufficient evidence for EAAT modeling based on published GltPh sequence
alignments (Yernool et al., 2004).
The substrate binding site
The GltPh crystal structures provide insights into substrate binding interactions with much
of the functional implications for these interactions derived from kinetic and mutation studies.
Below I discuss key structural and functional features involving substrate recognition and
translocation that will help delineate the substrate binding region.
The binding site incorporates several structural sub-domains. First, as previously
touched-on, the structure of the substrate binding site is formed by the highly conserved βbridge sequence that disrupts the TM7 α-helix (figure 3). This sequence has been implicated in
Na+, K+, and glutamate binding and translocation (Yernool et al., 2004; Rosental et al., 2006;
Tao et al., 2006) and performs at least two very distinct functions: 1. The β-bridge forms a
platform for substrate binding possibly allowing sufficient room in the HP2 occluded
conformation for glutamate binding and K+ countertransport, and 2. the β-bridge structure
introduces into TM7 an α-helix dipole critical for site 2 Na+ coordination (Yernool et al., 2004;
Reyes et al., 2009).
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The second structural domain defining the substrate binding site is the amphipathic αhelix of TM8 which holds residues responsible for substrate identification. Specifically,
Bendahan et al. (2000) demonstrated that an arginine residue (R447 in EAAT3) conserved
throughout all glutamate transporters but neutralized in neutral amino acid transporters is
responsible for acidic amino acid recognition. This residue, when mutated to cysteine,
abolishes glutamate transport and instead allows transport of alanine and serine (Bendahan et
al., 2000). Likewise Teichman and Kanner (2007) demonstrated that an aspartate residue
(D444 in EAAT3) conserved in all homologous amino acid transporters (EAATs, ASCTs, and
archaeal aspartate transporters) but neutralized in bacterial C4-dicarboxylate transporters is
responsible for recognition of amino acid substrates. Together these residues enforce EAAT
substrate specificity (figure 3).
The third defining motif of the substrate binding arena are the hairpin loops (HP1 and
HP2) that are the proposed gatekeepers to the intracellular and extracellular fluids (Boudker et
al., 2007). As discussed above, the exact mechanism for HP1 gated access has yet to be
determined though constraints on HP1 inhibit transport (Shlaifer and Kanner, 2007). The
mechanism for HP2 gated access is much better understood. Boudker et al. (2007)
demonstrated HP2 movement with two GltPh crystal structures revealing HP2 in the occluded,
closed conformation and HP2 swung open to accommodate inhibitor binding (figure 2b).
Molecular dynamics simulations of GltPh systems also show rapid movement of HP2 (Huang
and Tajkhorshid, 2008).
Inhibitor specificity between EAAT subtypes is a more subtle affair. Specifically, EAAT2
has a different affinity profile for competitive inhibitors than other EAATs, though the EAAT2
amino acid sequence within the substrate binding arena is almost identical to EAAT1 and
EAAT3 (figure 1a. Red highlighted regions are implicated in binding and transport. GLT-1 is
alternative nomenclature for EAAT2). The exception to this sequence conservation lies within
the hairpin region of HP2 which includes serine substitutions in EAAT2. Point mutations in
EAAT1 substituting EAAT2 serine residues for the EAAT1 sequence show increased affinity for
EAAT2 subtype specific inhibitors (Zhang and Kanner, 1999; Huang et al., 2009). Huang et al.
(2009) propose that the specificity that these EAAT2 substitutions incur are indirect and reflect
subtle divergence in the HP2 occluded conformation. Molecular dynamics simulations reported
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here in chapter 3 support Huang’s proposition showing small deviations in HP2 positioning
disproportionately affect Li+ coordination over Na+.
Mechanism of transport
Yernool et al. (2004) on analysis of their freshly minted X-ray structure proposed an
alternating access model for transport with extracellular access gated by HP2 and intracellular
access gated by HP1. Boudker et al. (2007) refined this model with crystal structures resolving
the two Tl+ binding sites and showing HP2 conformational changes. Specifically, the
aspartate-bound GltPh structure revealed Tl+ densities at sites 1 and 2 while the TBOA-bound
GltPh structure includes only one Tl+ density (site 1) and shows HP2 swung open to
accommodate the bulky benzene ring of 3-br-TBOA. With these structures as a guide, Boudker
et al. contend that substrate binds the transporter when HP2 is in the open conformation and
after Na+ is bound at site 1. This is followed by HP2 closure, binding of Na+ at site 2, and
subsequent release through a less well characterized HP1 movement. Kinetic studies show
that K+ countertransport resets the transporter for the next round of substrate binding and
translocation (Bergles et al., 2002; Grewer et al., 2000; Otis et al., 1997; Wadiche and
Kavanaugh, 1998). Molecular dynamics simulations (Huang and Tajkhorshid, 2008;
Shrivastava et al., 2008) and studies involving fluorescently labeled HP2 (see chapter 3)
support that HP2 gates access during substrate binding. HP1 movement in the outward facing
structure however is tightly constrained by TM2 rendering the loop immobile. The recently
solved inward facing structure resolves this issue through the conformational change of the
transport domain from outward to inward facing orientations which releases HP1 from TM2
constraints (Reyes et al., 2009). This appears to validate the global conformational mechanism
of the gated, alternating access model proposed by Yernool et al. in 2004 (figure 5). Chapters
2 and 3 of this dissertation expand on Yernool’s model with evidence for a third Na+ site as well
as two K+ sites that could form part of the K+ countertransport pathway. We also show that
sodium induces the HP2 open conformation possibly through uncharacterized Na+ sites.
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is strictly maintained: in the outward facing state, when HP2 opens to
expose the substrate and ion binding sites to the extracellular solution, HP1 is secured in the closed state, packed against TM2 and
TM5. Conversely, in the inward facing state HP2, the extracellular
gate, is locked closed upon displacing HP1.
As has been suggested previously39, coupling of the substrate transport to the energy of the ionic gradients is established via synergistic
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and 200 mM CaCl2, and crystallized at 4 uC by hanging-drop vapour diffusion.
Crystals were cryoprotected by allowing the drop to dry until its volume was
reduced by 50%. SeMet substituted protein was expressed as described previously8 and crystallized as above. Diffraction data were indexed, integrated and
scaled using the HKL-2000 package41. Further analyses were performed using
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Molecular dynamics and GltPh
Computational molecular dynamics (MD) has traditionally allowed limited insights into the
probable workings and movements within a molecular system. The far greater processor
speeds of later generation computers coupled with more accurate and efficient algorithms that
better estimate interactions at atomic and even quantum levels have greatly reduced the
limitations of MD simulations. Even with these advances MD simulations of complicated
systems (systems with 50,000 to 100,000 atoms) are still constrained by computational power
and cumulative errors and rarely reach beyond 50 nanoseconds. This is, of course, a limited
amount of time to derive movement within a protein. However, recent publications reporting on
the molecular dynamics of GltPh models show conformational changes during low nanosecond
simulations (Huang and Tajkhorshid, 2008; Shrivastava et al., 2008), suggesting insights into
the mechanics of EAAT transport are attainable.
To effectively mimic a transmembrane protein system the models must, not surprisingly,
be embedded into a lipid bi-layer with water molecules added above and below the membrane
to simulate an aqueous environment. Ions are added to both neutralize the system and to
better imitate a functional reality. The most computationally expensive problem in MD
simulations is calculating long- and short-range electrostatic interactions. For our purposes,
electrostatic involvements are estimated using Ewald summations which sum short-range
interactions (normally less than 4Ås) with real space resolution while simplifying long-range

11

interactions using Fourier transformations. Other variables such as pressure, energy, and heat
capacities (thermodynamic properties of a system) and atomic positions and momentum
(kinetic properties of a system) are calculated using statistical mechanics to estimate probable
atomic positions and movement by applying experimentally derived thermodynamic properties.
Cation coordination
In chapters 2 and 3 of this dissertation we utilize an electrostatic mapping program called
VALE (Nayal and Di Cera,1993) that scans computational models of proteins for groupings of
oxygen atoms to map potential cation coordination sites. These sites are scored through a
fairly simple algorithm that incorporates empirically derived cation specific values with gridbased distances from oxygen atoms (see methods in chapter 2). This enabled us to predict
novel cation sites for Na+ and K+. In the following section I discuss structural aspects of cation
binding sites with an emphasis on K+ and Na+.
The membrane flux of Na+ and K+ complexed with the EAATs help fuel glutamate
transport allowing up to a 10,000-fold concentration of glutamate (Schousboe and Divac,
1979). To deconstruct the mechanisms that allow this rather impressive driving force it is
important to address how metal ions complex with proteins. A third of known macromolecules
are metalloproteins (Castagnetto et al., 2002) with cations functioning to stabilize substrate
protein interactions, drive catalysis and transport, and as allosteric modulators (Suelter, 1970;
Page and Di Cera, 2006). Many macromolecules have evolved to take advantage of K+ and Na
+

because of their availability in the environment. Determining how these specific cations

coordinate with macromolecules requires kinetic and structural analysis. A review of
metalloprotein crystal structures revealed that amino acid main chain carbonyl groups and side
chain oxygens are the predominant donor groups for cation coordination, with rare
coordination through the nitrogen lone pair of histidine’s imidazole side chain (Harding, 2004).
Figure 6 lists aspects of common bioactive metals showing K+ and Na+ prefer octahedral and
trigonal bipyramidal geometries (Harding, 2002; http://tanna.bch.ed.ac.uk).
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Metal
atomic number

Na+
sodium
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O of ser, thr
O of asn, gln

Usual coordination trigonal bipyramidal, trigonal bipyramidal,
square pyramidal,
square pyramidal,
geometry
octahedral
octahedral

O main-chain
O of asp, glu
O of ser, thr
O of asn, gln
N of his

O main-chain
O of asp, glu
O of ser, thr
O of asn, gln
N of his

octahedral

octahedral

Typical metaloxygen distance (Å)

2.35 - 2.45

2.75 - 2.85

2.45 - 2.45

2.05 - 2.15

Relative abundance
in PDB

96

72

358

177

Figure 6. Compilation of common cation coordination donor atoms and geometries found in Protein Data Bank
structures. ‘O main-chain’ stands for the protein main-chain carbonyl oxygen atom. Relative abundance in PDB is
abundance of proteins containing the respective cation in the Protein Data Bank as of 2002. The table was
adapted from Harding, 2002; Harding 2004; and http://tanna.bch.ed.ac.uk.

Structural studies have proven to be non-trivial especially when assigning electron
densities to Na+ and K+ from X-ray scatter patterns. Na+, for example, has a small ionic radius
(0.96Å) which is difficult to resolve in even high resolution structures (usually requiring
resolutions of <1.6Å) (Harding, 2002). Na+ also has the same valence as a water molecule and
can be difficult to differentiate from water (Nayal and Di Cera, 1996). Likewise K+ has a
comparable ionic radius to water and can be similarly confused. Crystallographers circumvent
this issue by using higher density surrogate cations. Boudker et al. (2007), for example, used
thallium to gain a resolvable density in their GltPh structures. They demonstrated the relevance
of the Tl+ densities to Na+ binding through competition assays showing that the densities
vanish when the crystals are soaked in salt buffers containing both cations. Cation promiscuity
such as this cannot always be assumed and even subtle alterations can alter a site’s capacity
to complex with a specific cation. A good example of this is a glutamate to aspartate mutation
in EAAT3 (E374D) which eradicates K+ countertransport (Kavanaugh et al., 1997).
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Summary and overview of subsequent chapters
This initial chapter has provided a literature review and the necessary context for
understanding chapters 2 and 3, which focus on EAAT structure and function. Chapters 4
explores the application and potential of computer modeling in different scenarios and chapter
5 considers avenues for future research. The following paragraphs provide an overview of the
findings presented in chapters 2-4.
In chapter 2 we use electrostatic mapping of EAAT3 homology models and GltPh
structures to determine novel cation coordination sites. We present three Na+ sites, two of
which overlap the thallium densities resolved in the aspartate-bound structure reported by
Boudker et al. (2007) and one new site capable of coordinating Na+ but not Tl+. We also
describe a K+ site that overlaps the substrate binding site providing a possible mechanism for
glutamate exclusion during the coutertransport hemicycle. Together these sites suggest
mechanisms for coupling the thermodynamically unfavorable transport of glutamate to the
thermodynamically favorable transport of Na+ and antiport of K+.
In chapter 3 we integrate computational and electrophysical data to deconstruct cation
and substrate binding order and release in the EAATs and present an incomplete but complex
model showing sodium dependent HP2 movement precedes the HP2 occluded state. We also
use electrostatic mapping combined with molecular dynamics simulations to investigate Na+
release from inward facing EAAT and GltPh models.
Chapter 4 of my dissertation shows how the application of computer modeling benefitted
three collaborative studies, each involving different systems. The first study, published in 2004
(Poss et al., 2004) used comparative statistical analyses of homology models of variant Clade
A HIV envelope proteins to help determine residues important during early infection. The
second study (Hassani et al., 2005) evaluated novel lavendamycin analogues for their potential
as anti-tumor agents. As part of the evaluation process, we used computational molecular
docking of the analogue substrates into their targeted protein (NAD(P)H:quinone
oxidoreductase (NQO1)) to help determine interactions that promote potency. The third study
(Leary et al., submitted) used molecular docking to determine interactions between a potent
EAAT1 and EAAT2 inhibitor (β-2-fluorenyl-aspartylamide, or 2-FAA) and found 2-FAA
interactions differ from inhibitor interactions determined in the TBOA-bound GltPh crystal
structure. Overall, the addition of a computational element to these investigations helped
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validate and interpret in vitro work and led to a more refined understanding of the respective
mechanisms of actions.
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The	
  transport	
  of	
  glutamate	
  is	
  coupled	
  to	
  the	
  co-‐transport	
  of	
  three	
  Na ions	
  and	
  the	
  countertransport	
  of	
  
one	
  K ion.	
  In	
  addition	
  to	
  this	
  carrier-‐type	
  exchange	
  behaviour,	
  glutamate	
  transporters	
  also	
  behave	
  as	
  
chloride	
  channels.	
  The	
  chloride	
  channel	
  activity	
  is	
  strongly	
  inﬂuenced	
  by	
  the	
  cations	
  that	
  are	
  involved	
  
in	
   coupled	
   ﬂux,	
   making	
   glutamate	
   transporters	
   representative	
   of	
   the	
   ambiguous	
   interface	
   between	
  
carriers	
   and	
   channels.	
   In	
   this	
   paper,	
   we	
   review	
   the	
   interaction	
   of	
   alkali	
   cations	
   with	
   glutamate	
  
transporters	
   in	
   terms	
   of	
   these	
   diverse	
   functions.	
   We	
   also	
   present	
   a	
   model	
   derived	
   from	
   electrostatic	
  
mapping	
  of	
  the	
  predicted	
  cation-‐binding	
  sites	
  in	
  the	
  X-‐ray	
  crystal	
  structure	
  of	
  the	
  Pyrococcus	
  horikoshii	
  
transporter	
   GltPh	
   and	
   in	
   its	
   human	
   glutamate	
   transporter	
   homologue	
   EAAT3.	
   Two	
   predicted	
  
Na -‐binding	
   sites	
   were	
   found	
   to	
   overlap	
   precisely	
   with	
   the	
   Tl densities	
   observed	
   in	
   the	
  
aspartate-‐bound	
  complex.	
  A	
  novel	
  third	
  site	
  predicted	
  to	
  favourably	
  bind	
  Na (but	
  not	
  Tl )is	
  formed	
  by	
  
interaction	
   with	
   the	
   substrate	
   and	
   the	
   occluding	
   HP2	
   loop.	
   A	
   fourth	
   predicted	
   site	
   in	
   the	
   apo	
   state	
  
exhibits	
   selectivity	
   for	
   K over	
   both	
   Na and	
   Tl .	
   Notably,	
   this	
   K site	
   partially	
   overlaps	
   the	
  
glutamate-‐binding	
   site,	
   and	
   their	
   binding	
   is	
   mutually	
   exclusive.	
   These	
   results	
   are	
   consistent	
   with	
  
kinetic	
  and	
  structural	
  data	
  and	
  suggest	
  a	
  plausible	
  mechanism	
  for	
  the	
  ﬂux	
  coupling	
  of	
  glutamate	
  with	
  
Na and	
  K ions.	
   	
  
+	
   	
  

+

+	
  

+	
  

+	
  

+	
  

+	
  

+

+	
  

+	
  

+	
  

1.	
  INTRODUCTION	
   	
  
In	
   order	
   to	
   maintain	
   chemical	
   neurotransmission,	
  
prompt	
   removal	
   of	
   neurotransmitter	
   following	
   synaptic	
  
release	
   must	
   occur.	
   This	
   is	
   necessary	
   for	
   terminating	
  
the	
   actions	
   of	
   the	
   transmitter	
   on	
   the	
   postsynaptic	
   cell	
  
and	
   for	
   maintaining	
   speciﬁcity	
   of	
   synaptic	
   communi-‐
cation.	
  In	
  the	
  case	
  of	
  glutamate,	
  the	
  principal	
  excitatory	
  
neurotransmitter	
  in	
  the	
  nervous	
  system	
  of	
  vertebrates,	
  
it	
   is	
   also	
   necessary	
   to	
   control	
   extracellular	
   transmitter	
  
levels	
   in	
   order	
   to	
   prevent	
   excitotoxic	
   damage	
   from	
  
excessive	
   receptor	
   activity.	
   This	
   task	
   is	
   chieﬂy	
   accom-‐
plished	
  through	
  reuptake	
  mediated	
  by	
  excitatory	
  amino	
  
acid	
  transporters	
  (EAAT1–5;	
  SLC1A1–5)	
  present	
  in	
  the	
  
plasma	
  membranes	
  of	
  glia	
  and	
  neurons	
  throughout	
  the	
  
nervous	
   system	
   (Tzingounis	
   &	
   Wadiche	
   2007).	
   A	
  
hallmark	
   of	
   glutamate	
   uptake	
   is	
   co-‐transport	
   with	
  
Na and	
   H and	
   countertransport	
   of	
   K ,	
   indicative	
   of	
   a	
  
mixed	
   co-‐transport–exchange	
   carrier	
   mechanism	
  
(Kanner	
   &	
   Sharon	
   1978).	
   Another	
   hallmark	
   of	
   the	
  
transporters	
  is	
  an	
  intrinsic	
  chloride	
  conductance	
  that	
  is	
  
generally	
   increased	
   during	
   transport	
   in	
   cells	
   expressing	
  
exogenous	
   or	
   endogenous	
   transporters	
   (Fairman	
   et	
   al.	
  
1995;	
   Picaud	
   et	
   al.	
   1995;	
   Wadiche	
   et	
   al.	
   1995;	
   Billups	
   et	
  
al.	
   1996;	
   Wadiche	
   &	
   Kavanaugh	
   1998).	
   A	
   number	
   of	
  
studies	
   have	
   addressed	
   questions	
   about	
   the	
   detailed	
  
mechanism	
   of	
   glutamate	
   uptake	
   and	
   chloride	
   channel	
  
gating,	
   but	
   questions	
   still	
   remain	
   about	
   fundamental	
  
features	
  such	
  as	
  the	
  binding	
  order	
  of	
  transported	
   	
  
+

+

+
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solutes	
  and	
  the	
  location	
  of	
  binding	
  sites	
  and	
  permeation	
  
pathways	
   (for	
   reviews	
   see	
   Danbolt	
   (2001),	
   Grewer	
   &	
  
Rauen	
  (2005)	
  and	
  Tzingounis	
  &	
  Wadiche	
  (2007)).	
   	
  
The	
  solution	
  of	
  the	
  crystal	
  structure	
  of	
  GltPh,	
  a	
  glutamate	
  
transporter	
   homologue	
   from	
   Pyrococcus	
   horikoshii,	
  
represents	
   a	
   critical	
   advance	
   towards	
   a	
   better	
  
understanding	
   of	
   the	
   transport	
   mechanism.	
   The	
  
transporter	
   has	
   a	
   trimeric	
   architecture	
   (Yernool	
   et	
   al.	
  
2004).	
   Each	
   of	
   the	
   three	
   subunits	
   has	
   eight	
   trans-‐
membrane	
  domains	
  with	
  two	
  re-‐entrant	
  helical	
  hairpin	
  
loops	
  (HP1	
  and	
  HP2)	
  that	
  dip	
  into	
  the	
  membrane	
  from	
  
opposite	
   sides	
   (ﬁgure	
   1).	
   Structural	
   evidence	
   suggests	
  
that	
   each	
   subunit	
   in	
   the	
   trimer	
   binds	
   its	
   amino	
   acid	
  
substrate	
   independently	
   of	
   the	
   others	
   (Yernool	
   et	
   al.	
  
2004;	
   Boudker	
   et	
   al.	
   2007).	
   Functional	
   evidence	
   also	
  
supports	
   the	
   idea	
   that	
   each	
   subunit	
   operates	
   as	
   both	
   a	
  
self-‐contained	
   glutamate	
   transporter	
   and	
   chloride	
  
channel	
  (Grewer	
  et	
  al.	
  2005;	
  Koch	
  et	
  al.	
  2007;	
  Leary	
  et	
  
al.	
  2007).	
   	
  
2.	
  COMPUTATIONAL	
  METHODS	
   	
  
Human	
   EAAT3	
   sequence	
   (GenBank;	
   http://www.ncbi.	
  
nlm.nih.gov)	
   and	
   the	
   EAAT3	
   R447C	
   mutant	
   sequence	
  
were	
   aligned	
   with	
   the	
   Protein	
   Data	
   Bank	
   (PDB)	
  
sequences	
   for	
   the	
   GltPh	
  homologue	
   (2NWX	
   and	
   2NWW;	
  
Yernool	
   et	
   al.	
   2004;	
   Boudker	
   et	
   al.	
   2007).	
   Homology	
  
models	
   were	
   built	
   by	
   threading	
   the	
   aligned	
   EAAT3	
  
sequences	
   along	
   their	
   respective	
   PDB	
   coordinates	
   using	
  
the	
  
SwissProt	
  
server	
  
(http://swissmodel.	
  
expasy.org//SWISS-‐MODEL.html).	
  The	
  resulting	
  models	
  
were	
   optimized	
   through	
   local	
   energy	
   minimizations	
   of	
  
regions	
  with	
  steric	
  and	
  electrostatic	
  interference	
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Figure 1. GltPh structure model based on Yernool et al. (2004). (a) Three subunits form a bowl that penetrates the plasma
membrane. One of the subunits is depicted with aspartate and two bound TlC (Boudker et al. 2007). (b) Single subunit overlays
of the occluded (green) and open (blue) conformations with aspartate bound to the occluded form. The arrow highlights the
HP2-loop conformational change between the open and occluded forms.

using the AMBER7 force field in the TRIPOS SYBYL7.3
platform. Valence shell mapping and calculations were
performed using the FORTRAN program VALE (courtesy of
Enrico Di Cera and Thierry Rose; Washington
University, St Louis, MO) using a 3.4 Å probe radius
and a grid size of 0.1 Å ( Nayal & Di Cera 1994) on
GltPh and homology model PDB files. Only coordination sites within a 10 Å radius of the substrate
a-carbon imported from the aspartate-bound crystal
structure were considered as candidates for the NaCand KC-binding sites. Calculations for each cation–
oxygen pair are given by nZ(R/R 1)KN, where R is the
distance of an oxygen atom to the cation; R 1 is the
distance given valenceZ1.0; and N is an empirically derived exponent specific to each cation (Nayal &
Di Cera 1994, 1996; Page & Di Cera 2006). The
values for R 1 and N were determined through the
analysis of metal-oxide crystal structures and define an
estimated ideal bond strength as nZ1.0. Although all
pertinent regions of the 10 Å binding arena are likely
to be water accessible, no water molecules were
included in the valence mapping in order to reduce
noise (Nayal & Di Cera 1994). Consistent with recent
studies, we chose a valence cut-off of nZ0.9 for likely
candidate-binding sites (Ogawa & Toyoshima 2002;
Rakowski & Sagar 2003; Page & Di Cera 2006). The
three-dimensional coordinates of valence maps that
contain multiple, clustered valence sites within a 2 Å
radius were included as a single site and we reported
the highest estimated valance within each site.
L-Glutamate was docked using GOLD (http://www.
ccdc.cam.ac.uk/) into the EAAT3 and GltPh models
either containing NaC or KC, as determined by
valence mapping, or containing no cations. The topranked structures determined by CHEMSCORE (http://
www.ccdc.cam.ac.uk/) were incorporated into the
appropriate models and average rankings from three
separate GOLD docking runs were reported. In order
to evaluate estimations of absolute affinity of
substrates in different models, DG scores were
extracted form CHEMSCORE and reported as an average
over the three docking runs. In order to optimize
models, iterative valence mapping and docking runs
were performed.
Phil. Trans. R. Soc. B (2009)

3. THERMODYNAMIC COUPLING OF GLUTAMATE
AND CATION FLUXES
Influx of glutamate, NaC and HC, and efflux of KC,
during a transport cycle results in a net flow of positive
charge into the cell that can be recorded with a voltage
clamp circuit. A tight stoichiometric coupling is
inferred from the effects of these cations’ concentration
gradients on the reversal potential of the pharmacologically isolated transport current. The transporter
reversal potential (the equilibrium membrane potential
at which there is no net transport) follows the
predictions of the free energy equation for the coupled
transport of one glutamate molecule with one proton
and three NaC ions and countertransport of one KC
ion during each uptake cycle (Zerangue & Kavanaugh
1996a; Levy et al. 1998). An overarching question
concerns the mechanism of this tight coupling. The
simplest type of theoretical kinetic scheme consistent
with the data is an alternating access carrier model
(Jardetzky 1966). The precise binding order of ions
and glutamate is unresolved; the kinetic data suggest
that one or two of the three NaC ions bind before
glutamate (Tzingounis & Wadiche 2007). The solution
of two crystallized structural states of GltPh has
provided critical new information and suggests a
possible structural mechanism for an alternating access
transport scheme (Boudker et al. 2007). The trimer
subunits contain eight transmembrane domains
(TM1–8) and two a-helical, re-entrant hairpin loops
(internal HP1 and external HP2). Gouaux and
colleagues have suggested that these loops could
function as gates, allowing alternating substrate access.
In the aspartate-bound state, aspartate is occluded
between the tips of the two re-entrant loops, and charge
pairing between the bound aspartate and residues
including a conserved arginine in TM8 of the
transporter stabilizes the complex. Two anomalous
densities can be resolved that are associated with the
replacement of NaC by TlC in the aspartate complex.
By contrast, in crystals produced from transporter
complexed with the bulky non-transported inhibitor
D,L-threo-b-benzoylaspartic acid (TBOA), the external
HP2 loop is swung outwards, approximately 10 Å, and
one of the ion densities is disrupted. These data suggest
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site 3

site 2
site 1
Figure 2. Identification of a novel sodium site in EAAT3. (a) Sodium sites 1–3 (red spheres) are depicted, showing the proximity
of sites 1 and 3 to the crystal structure thallium sites (purple spheres) identified by Boudker et al. (2007). The site 2-bound ion
interacts with the HP2 helix dipole and the g-carboxyl group of docked glutamate (orange sticks). Overlaid with the docked
glutamate molecule is the aspartate (white sticks) that was resolved in the crystal structure. The HP1 loop is depicted in cyan,
with the occluding HP2 loop in dark blue. (b) NaC docked at site 3 is coordinated by a-carboxyl groups in the HP2 loop and by
the g-carboxylate of bound glutamate.

a possible docking trajectory and structural gating
mechanism for the first hemicycle of an alternating
access kinetic scheme (figure 1). A presumed third
state, which would allow the substrate and the cations
access to the cytoplasm, has thus far eluded
crystallization.
4. THERMODYNAMICALLY UNCOUPLED
CHLORIDE FLUX
In addition to the flux of stoichiometrically coupled
ions, chloride flux also occurs through the transporters
(for a review, see Tzingounis & Wadiche (2007). This
was first suggested by the presence of a chloride current
associated with the activation of the native glutamate
transporters in retinal neurons and glia (Eliasof &
Werblin 1993; Picaud et al. 1995; Billups et al. 1996;
Eliasof & Jahr 1996), and it has also been demonstrated
to occur with EAATs exogenously expressed in
different cell systems ( Fairman et al. 1995). The
channel is also found in neutral amino acid transporter
members of the eukaryotic SLC1 family (Zerangue &
Kavanaugh 1996b). At some synapses, the chloride
conductance appears to play feedback roles in synaptic
signalling, which are entirely distinct from the effects of
uptake on glutamate dynamics ( Veruki et al. 2006;
Wersinger et al. 2006). The chloride channel itself
seems to be intrinsic to the transporter, as the mutation
of specific residues leads to discrete changes in anion
channel properties (Ryan et al. 2004; Huang &
Vandenberg 2007). The chloride channel function is
also conserved in a reconstituted bacterial homologue,
further supporting the idea of a channel in the
transporter structure (Ryan & Mindell 2007). The
net current activated by glutamate (reflecting both
the stoichiometrically coupled and ClK currents) has a
distinct reversal potential in each EAAT isoform,
suggesting that each has a fixed and unique ClK
current magnitude relative to the stoichiometrically
coupled current. The relative magnitude of anion
conductance : coupled current follows the sequence
EAAT4wEAAT5OEAAT1OEAAT3OEAAT2. In
each transporter, the anion conductance displays a
Phil. Trans. R. Soc. B (2009)
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chaotropic selectivity sequence SCN KOClOK
4O
K
K
K
K
NOK
SCN K
is
3 OI OCl OF [gluconate .
approximately 70-fold more permeant than ClK
(Wadiche & Kavanaugh 1998). The glutamate-dependent anion conductance is strongly affected by the
identity of the alkali cation co-transported with glutamate; LiC can substitute for NaC in some isoforms to
support glutamate transport but is much less efficacious at activating the anion conductance (Borre &
Kanner 2001). With NaC present, there is a tonic anion
conductance in the absence of glutamate (Bergles &
Jahr 1997; Tao et al. 2006).
Replacement of ClK with impermeant anions such
as gluconate does not affect the transport of glutamate
( Wadiche et al. 1995). Thus, ClK flux may be
considered thermodynamically uncoupled from
glutamate flux, and seems to involve a channel-like
mechanism instead. Indeed, glutamate-dependent
anion current fluctuations have been observed with
endogenous and exogenous transporter expressions
that are consistent with a stochastically gated channel
that is kinetically related to the glutamate transport
cycle (Picaud et al. 1995; Wadiche & Kavanaugh
1998). Kinetic analysis of the glutamate concentration
dependence of transport and chloride conductance
suggests that each subunit in the trimer harbours both a
chloride channel and a glutamate transporter, and each
subunit functions independently (Koch et al. 2007;
Leary et al. 2007). Kinetic models may be able to unify
the distinct channel and transport functions by
representing a subset of the Markov states in the
transport cycle as open-channel states (Grewer et al.
2000; Otis & Kavanaugh 2000; Bergles et al. 2002).
5. STRUCTURAL MODEL FOR FLUX COUPLING
An initial picture of the interaction of alkali cations with
glutamate transporters has emerged from anomalous
difference maps seen in TlC-soaked GltPh crystals
(Boudker et al. 2007). Two densities were seen
that were selectively diminished by NaC. One of
these (site 2) was not seen in transporters complexed
with TBOA, which also caused a large outward
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Table 1. Electrostatic calculations for NaC- and KC-binding sites in EAAT3. (Sites 1–4 refer to potential cation-binding sites
within 10 Å of the amino acid-binding site for the EAAT3 homology models and the GltPh X-ray crystal structures. The EAAT3
and GltPh models used for the valence calculations are in either the HP2-loop open or HP2-loop closed conformations and
either the substrate-bound (glutamate or aspartate) or apo form.)

EAAT3
sodium
EAAT3wtjopenjapo
EAAT3wtjopenjL-glu
EAAT3wtjclosedjapo
EAAT3wtjoccludedjL-glu
thallium
EAAT3wtjopenjapo
EAAT3wtjclosedjapo
EAAT3wtjoccludedjL-glu
potassium
EAAT3wtjopenjapo
EAAT3wtjopenjL-glu
EAAT3wtjclosedjapo
EAAT3wtjoccludedjL-glu
caesium
EAAT3wtjopenjapo
EAAT3wtjclosedjapo
EAAT3wtjoccludedjL-glu
GltPh
sodium
GltPhjopenjapo
GltPhjopenjL-asp
GltPhjoccludedjL-asp
thallium
GltPhjopenjTBOA
GltPhjoccludedjL-asp

site 1

site 2

0.80
0.80
1.04
1.04

!0.3
!0.3
0.93
0.93

0.91
0.80
0.78

!0.3
0.84
0.79

!0.3
!0.3
!0.3

0.56
0.94
!0.3

1.16
1.16
1.13
1.13

!0.3
!0.3
1.21
1.21

!0.3
!0.3
0.87
!0.3

1.11
!0.3
1.44
!0.3

1.03
0.71
0.71

!0.3
0.83
0.83

!0.3
!0.3
!0.3

0.90
1.07
!0.3

1.27
1.27
1.05

0.56
0.56
1.05

1.09
1.07

0.46
1.08

displacement of the HP2 loop (figure 1). Because the
crystal diffraction resolution was insufficient to localize
NaC ions interacting with GltPh, and owing to the
possibility that the TlC sites might not accurately
represent these sites, we used the electrostatic mapping
algorithm VALE (Nayal & Di Cera 1994) to examine
potential NaC-, KC- and TlC-binding sites in the
transporter. Electrostatic calculations with this algorithm have been successfully used to predict NaC- and
KC-binding sites in proteins including the NaC, KCATPase (Nayal & Di Cera 1996; Ogawa & Toyoshima
2002; Rakowski & Sagar 2003).
The GltPh and EAAT3 models used for the valence
calculations consist of four basic structures: the two
loop conformers (HP1 open or closed) with or without
the bound amino acid substrate (see figure 1 and §2).
A total of four binding sites were identified corresponding to potential ion coordination sites above the 0.9
valence cut-off within a 10 Å radius of the substratebinding site. In several of these ion-binding sites, the
valence was dependent on the loop position and the
presence or absence of glutamate or aspartate (table 1).
For both the GltPh and the EAAT3 models, two sites
(sites 1 and 2) are predicted, which correspond very
well (less than 1.4 Å) to the TlC densities resolved in
the occluded GltPh crystal structure determined by
Boudker et al. (figure 2; table 1). The valence of site 1 is
relatively independent of substrate binding and loop
conformation, and is therefore likely to coordinate a
sodium ion before glutamate is bound. By contrast,
site 2 is coordinated by dipoles formed from a-helices
Phil. Trans. R. Soc. B (2009)

site 3

0.72
0.72
0.62
0.91

0.91
0.91
0.61
!0.3
!0.3

site 4

0.84
!0.3
0.97
!0.3

0.81
!0.3
!0.3
!0.3
!0.3

in the closed HP2 loop and TM7. This is consistent
with the crystal structures, where one TlC density
(site 1) was unaffected by the HP2-loop state, but the
second density (site 2) was lost in the TBOA-bound
open-loop state (Boudker et al. 2007).
Electrostatic mapping of EAAT3 also revealed a
coordination shell for a novel site (site 3, figure 2)
whose interaction with NaC was favoured by bound
glutamate. NaC is predicted to be more stably
coordinated in the occluded, substrate-bound state
(nZ0.91) than in either the open or closed apo states
(nZ0.72 or 0.62, respectively; table 1). This glutamate
effect arises from the contribution of a ligating oxygen
to the site 3 coordination shell by the g-carboxyl group
of bound glutamate. Steric and van der Waals
constraints between the bound ion and the occluding
HP2 loop may also confer sodium selectivity at site 3,
which shows poor predicted KC and TlC valences
(n!0.3). Site 3 thus represents a potential third NaCselective binding site that could participate in cooperative binding of glutamate (figure 2). Valence modelling
of GltPh predicts a tenuous coordination for NaC in site
3 (nZ0.61), but does not predict a viable coordination
site for TlC at this site (n!0.3), which is consistent
with the absence of TlC density at site 3 in GltPh.
Electrostatic mapping also predicts a fourth cationbinding site in the transporter (figure 3). Site 4 exhibits
a marked selectivity for KC over NaC (table 1; figure 3).
This site also substantially overlaps the glutamate/
aspartate-binding site. It includes a contribution from
carboxyl groups of D444, a residue that is essential for
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(b)
asp444

Figure 3. Interactions of KC at site 4. (a) Site 4 overlaps with the aspartate-binding site in the crystal structure of the aspartatebound archaeal homologue. (b) Bound KC is predicted to interact directly with D444, a residue also involved in glutamate
binding ( Teichman & Kanner 2007).
Table 2. Substrate docking studies showing the effects of NaC
on binding affinity in the EAAT3 homology models and the
GltPh X-ray crystal structures. (The HP2-loop occluded or
open models were docked with L-glutamate and L-aspartate
using the GOLD software program and the structures were
scored using CHEMSCORE, where higher CHEMSCORE values
reflect better fitness for docked poses. All models contained
either no NaC ions or NaC ions at site 1 (Na1), sites 1 and 2
(Na1CNa2), sites 1 and 3 (Na1CNa3) or sites 1, 2 and 3
(Na1CNa2CNa3).)

asp440

arg447
asp444

CHEMSCORE DG (kJ molK1)
EAAT3jL-glujno Najoccluded
EAAT3jL-glujNa1joccluded
EAAT3jL-glujNa1C
Na2joccluded
EAAT3jL-glujNa1C
Na3joccluded
EAAT3jL-glujNa1CNa2C
Na3joccluded
GltPhjL-glujNa1C
Na2joccluded
GltPhjL-glujNa1CNa2C
Na3joccluded
GltPhjL-aspjNa1C
Na2joccluded
GltPhjL-aspjNa1CNa2C
Na3joccluded

13.17
14.36
14.11

K17.08
K18.01
K17.83

17.61

K26.20

18.45

K27.00

14.74

K23.54

18.42

K26.35

20.68

K24.00

23.71

K28.00

Figure 4. Potential binding pocket interactions facilitating
coordinated substrate and NaC binding (see §6).

The docking results in conjunction with the valence
estimates for site 3 in the glutamate-bound and apo
forms suggest that NaC bound at site 3 stabilizes bound
glutamate in the correct orientation by interacting with
the glutamate g-carboxyl group.

glutamate binding (Teichman & Kanner 2007). Because
KC binding to this site is predicted to be mutually
exclusive with glutamate binding (tables 1 and 2), it is an
interesting candidate for a KC countertransport site.
In order to further identify glutamate–cation
interactions and to quantify the reciprocal effects of
cations on glutamate affinity, we docked glutamate into
the EAAT3 homology model using the GOLD docking
program and estimated relative affinity using the
CHEMSCORE scoring algorithm (Ferrara et al. 2004).
We also extracted the DG component of the CHEMSCORE function in order to estimate the magnitude of
energy change between the different conformational
and cation-bound protein states. As expected from
valence mapping, docking results indicate that NaC
positioned at site 3 increases the estimated affinity of
glutamate for the EAAT3-binding site, as reflected by
both the CHEMSCORE and DG calculations (table 2).
Phil. Trans. R. Soc. B (2009)
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6. CONCLUSIONS
A combination of crystallographic, kinetic and electrostatic modelling data is beginning to provide a framework for understanding the mechanisms underlying the
coupled fluxes of glutamate and alkali cations in
glutamate transporters. Electrostatic modelling is
consistent with crystallographic data, indicating that
binding site 2 for NaC, coordinated by dipoles formed
from the a-helices in the HP2 loop and TM7, is
favoured by the transporter state in which the substrate
is occluded. The highly conserved NMDG motif that
disrupts the a-helix in TM7 facilitates dipole
interactions with NaC and suggests a possible ubiquitous NaC ion-binding site across all homologous
transporters. Boudker et al. suggest that NaC (TlC)
binding to this site may act to lock the HP2 loop into
the occluded conformation. Our data help to substantiate this idea as well as indicate that glutamate
must be bound and occluded in order for the closed
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HP2-loop conformation to be stable. This implies that
NaC binding at site 2 must occur concurrently with or
following glutamate binding.
Analysis of the electrostatic mapping indicates a novel
binding site for a third sodium ion that is not seen as a
TlC density in the GltPh crystal structure. This is
consistent with the poor valence predicted for TlC at
this site (table 1). Cooperative binding of NaC and
glutamate is a kinetic hallmark of the transporters. The
g-carboxyl group of glutamate is required for the stable
coordination of NaC at site 3, and occupancy of site 3 by
NaC has a reciprocal effect on glutamate affinity,
suggesting a mechanism for this cooperativity. In a recent
molecular dynamics study of GltPh, interactions between
bound glutamate carboxyl groups and NaC were found
to stabilize the complex in the binding pocket, consistent
with this notion (Shrivastava et al. 2008).
Residue R447 in EAAT3 also interacts with
the g-carboxyl group of glutamate and is responsible
for the recognition of acidic amino acid substrates (Bendahan et al. 2000; Yernool et al. 2004).
Neutralization of an aspartate residue (D440) proximal
to R447 in TM8 reduces both glutamate and NaC
apparent affinities (Tao & Grewer 2007). The effect of
this mutation on NaC binding was exclusive to the
glutamate-bound but not the apo form of the transporter. Our electrostatic mapping of NaC at site 3 could
explain these findings through an interaction of D440
with R447 that positions R447 for glutamate binding
(figure 4). Thus, neutralization of D440 would disrupt
the orientation of R447, which, in turn, would disrupt
the interaction of the transporter with the glutamate
g-carboxyl group. The binding of NaC at site 3 would be
reciprocally affected by reducing the likelihood that
glutamate is situated for NaC coordination.
The properties of the NaC coordination sites identified by electrostatic mapping suggest that site 1 may be
occupied before glutamate binding, while the sites 2 and
3 involve coordinated interactions with bound glutamate
and the HP2 loop. The KC-selective binding site
predicted here is coordinated in part by D444, which
has been shown to affect substrate affinity in EAAT3
(Teichman & Kanner 2007) and is part of the aspartatebinding site in the GltPh crystal structure (Boudker et al.
2007). The interaction of KC at this site excludes
binding of amino acid substrates (table 1; figure 3),
and thus could provide a simple potential mechanism for
KC countertransport, another hallmark of glutamate
transporter function (Kanner & Sharon 1978).
This work was supported by grants from the NIH
(NS033270, RR015583).
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Chapter 2: A model for sequential binding in glutamate transporters
D.C. Holley, G.P. Leary, and M.P. Kavanaugh
Center for Structural and Functional Neuroscience, Departments of Biomedical and
Pharmaceutical Sciences, University of Montana, Missoula, MT
Abstract
Excitatory amino acid transporters (EAAT1-5) clear the synaptic cleft of glutamate after
synaptic transmission through an electrogenic process, coupling thermodynamically
unfavorable glutamate transport to thermodynamically favorable co-transport of a proton and
3Na+ and the countertransport of 1K+. There are several X-ray crystal structures of an
homologous archaeal transporter resolved in both outward (facing the cytosol) and inward
(facing the extracellular fluid) conformations. The crystal structures poised in the outwardfacing conformation show access to substrate binding is gated by a hairpin re-entrant loop
(HP2) that is either oriented in open or occluded conformations (Boudker et al., 2007). Here we
assemble physical and computational data into an incomplete but consistent and cohesive
model for sequential transport. We deconstruct Na+ cooperativity during the early transport
hemi-cycle into two sodium dependent processes that contribute either to HP2 movement or
substrate translocation. Specifically, we provide evidence that Na+ cooperatively locks HP2 into
an open conformation prior to glutamate binding and then into the occluded, closed
conformation after glutamate is bound. Electrostatic mapping of the inward-facing model
reveals decreased capacities at sites 2 and 3 for Na+ coordination relative to the outwardfacing model. This is partially borne out during molecular dynamics simulations of the inwardfacing conformation of GltPh that show Na+ release from site 2. We also characterize a possible
pathway for K+ translocation that includes a novel site coordinated by a residue implicated in
EAAT countertransport. Furthermore, we show that Na+ can replace K+ as the
countertransported cation which is consistent with our previously published electrostatic
evaluation of EAAT3 identifying a K+ coordination site that also coordinates Na+ (Holley and
Kavanaugh 2009).

Introduction
Clearance of extracellular glutamate is mediated by excitatory amino acid transporters
(EAAT1-5) and is critical to terminate synaptic transmission and preventing potentially toxic
over-stimulation of nearby nerve cells (Levy et al., 1998; Pines and Kanner 1990). Transport of
glutamate is electrogenic, driven by the co-transport of 3Na+ and one proton and the
countertransport of 1K+ (Kavanaugh et al., 1997; Levy et al., 1998). Previous studies show that
glutamate cannot bind until K+ is released into the extracellular solution, suggesting a
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conformational change that resets the transport cycle after K+ unbinds (Kavanaugh et al.,
1997; Mim et al., 2007).
The first X-ray crystal structure of an homologous archaeal transporter (GltPh) revealed
an outward-facing homotrimer forming an aqueous bowl penetrating the extracellular side of
the plasma membrane (Yernool et al., 2004). The trimer subunits contain eight transmembrane
domains (TM1-8) and two α-helical, re-entrant hairpin loops (HP1 and HP2) that are thought to
gate transport. Several subsequent GltPh structures have been published including a structures
with bound inhibitor (DL-threo-β-benzoylaspartate or TBOA) locking HP2 in an open
conformation and a structure with aspartate and two thallium ions with HP2 oriented in an
occluded (closed) conformation (Boudker et al., 2007). The Tl+ densities are thought to be
surrogates for Na+ coordination sites in GltPh which is supported by the recently published
inward-facing GltPh structure reporting two Na+ densities that correlate well with the Tl+
densities in the outward-facing GltPh (Reyes et al.2009). The inward-facing structure also
revealed that each trimer subunit is divided into two structurally rigid domains dubbed the
trimerization and transport domains. According to Reyes et al., the trimerization domain
anchors the subunit in the membrane, while the transport domain moves approximately 18Ås
across the membrane to deliver bound substrate. The domains are hinged at the TM2-3 loop
and TM5-6 and transport to the cytoplasm unwinds α-helices in TM2, TM3, and TM5 and
extends the TM6 α-helix. The anchored trimerization domain consists of transmembranes 1, 2,
4 and 5 and includes the 3-4 loop.
Recently we published an electrostatic evaluation of cation coordination sites in EAAT3
homology models. The evaluation revealed three stably coordinated cation sites within 10Å of
the substrate binding site (figure 1). Two of the sites correspond well to the two Tl+ sites
resolved in the thallium-laden GltPh crystal structure, while one novel cation site is coordinated
by α-carboxyl groups near the bend in HP2 and by the γ-carboxyl group of docked glutamate
(Holley and Kavanaugh, 2009; figure 1). Here we expand on our earlier work using
computational and physical data to derive a model for sequential binding and release.
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Results
Na+ cooperatively locks HP2 in an open conformation
Boudker et al. (2007) published crystal structures with HP2 resolved in two
conformations; the TBOA-bound open conformation with Tl+ bound at site 1 and the aspartatebound, occluded conformation with Tl+ bound at sites 1 and 2. We can infer from these
structures only a partial binding order for transport: Na+ binds site 1 first, followed by amino
acid substrate binding, and HP2 closure allowing Na+ to bind site 2 locking HP2 closed.
Electrostatic mapping of EAAT3 and GltPh models predicts that Na+ coordination site 1 is
available for cation binding independent of bound amino acid substrate, while site 3 requires
coordination by the distal carboxylate of bound substrate (Holley and Kavanaugh, 2009). To
address binding order in vitro using the electrostatic maps of the EAAT3 models as a guide, we
first examined whether substrate distal carboxyl groups contribute to cation coordination.

site 3

site 2
site 1
Figure 1. EAAT3 homology model showing thallium binding sites extracted from the GltPh X-ray crystal structure
(blue) and Na+ coordination sites resolved from electrostatic mapping (red). Docked glutamate (orange sticks) is
depicted interacting with Na+ at site 3.

The γ-carboxyl group of glutamate that contributes to stable coordination of Na+ at site 3
also interacts with a highly conserved arginine residue (R447 in EAAT3) that is responsible for
recognition of acidic amino acid substrates (Bendahan et al., 2000). We employed the R447C
mutant for its unique capacity to transform EAAT3 into a neutral amino acid carrier to
determine whether the substrate γ-carboxylate affects sodium cooperativity. Radiolabled H3alanine (H3-L-ala) or H3-glutamate (H3-L-glu) uptake in oocytes expressing EAAT3 R447C or
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EAAT3 wild type (EAAT3wt) respectively was measured at different Na+ concentrations and fit
with the Hill equation. We calculated that the EAAT3 R447C mutant has a Hill coefficient
(derived from the Hill equation) of approximately nNa = 1.0 for sodium ion cooperativity during
transport, suggesting no cooperation between ions (figure 2b). This is in contrast to the Hill
coefficient for Na+ in EAAT3wt which we calculated to approximately nNa = 2.3, revealing
cooperation between at least three sodium ions (figure 2a). These results indicate that R447
contributes to Na+ cooperativity during transport, possibly through interactions with the
substrate distal carboxylate.

(a)

(b)

Figure 2. Sodium concentration dependence of tritiated glutamate uptake in EAAT3wt shows cooperation
between sodium ions (nhill = 2.31) (a) while the EAAT3 R447C mutant shows no cooperativity (nhill = 0.87) (b). The
Hill coefficients were derived from a least-squares fit of the Hill equation.

To quantify the number of sodium ions that bind before glutamate, we used voltage
camp fluorometry to measure steady-state fluorescence intensity changes in oocytes
expressing labeled EAAT3 cysteine mutants. The EAAT3 V417C mutation is located near the
tip of HP2 and was labeled with Alexa Fluor 488 C5 maleimide (molecular probes). Voltage
clamp measurements and radiolabeled uptake assays indicate that the modification of this
cysteine point mutant with a thiol reactive probe allows glutamate binding and activation of the
uncoupled anion conductance but prevents substrate transport, locking the transporter half
cycle that includes Na+ and glutamate binding (data not shown; Seal et al., 2001). Transitioning
from choline, which does not interact with the transporter (Wadiche et al., 1995), to Na+
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changes both the conductance and fluorescence; this small current change is observed also in
uninjected oocytes, but the fluorescence change is unique to EAAT3 V417C expressing
oocytes and is directly a result of Na+ interacting with the transporter. The Hill coefficient
derived from a Hill plot of the sodium dependence of fluorescence change from choline was
calculated to nNa = 1.73 with a Km = 39mM (figure 3). These results are consistent with at least
two sodium ions binding the glutamate free transporter and cooperatively interacting for HP2
movement.

(a)

(b)

(c)

(d)

Figure 3. (a)-(c). Simultaneous fluorescence and current recording from oocytes injected with V417C EAAT3 or
V417C-R447C EAAT3 and labeled with Alexa Fluor 488 C5 maleimide (-60 mV). Recordings of Na+ alone report
quenched fluorescence in all EAAT3 mutants (a)-(c), while co-application of Na+ and glutamate for V417C
EAAT3 (a) or for Na+ and alanine for V417C-R447C EAAT3 (c) report increased fluorescence. Co-application of
Na+ and TBOA report an intensity change similar to that of Na+ alone. (d). The Na+ dependence of the
fluorescence intensity for V417C EAAT3 vanishes in V417C-R447C EAAT3 when the solution was changed
from choline to the respective Na+ concentrations. Both curves fit well to the hill equation (V417C, Km = 39 mM,
nhill = 1.8; V417C-R447C, Km = 1.4 mM, nhill = 0.88).

To corroborate the fluorometry data with the electrostatic mapping and uptake data, we
designed the EAAT3 V417C R447C double mutant. Our results show that in the absence of

amino acid substrate sodium quenched fluorescence intensity and transitioning from choline to
Na+ revealed no cooperativity associated with HP2 movement between sodium ions (nNa =
0.88, figure 3D). This demonstrates that the R447C mutation disrupts cooperativity for HP2
movement in the substrate free transporter. These results conflict with the interpretation that
sodium cooperativity during uptake in EAAT3 R447C (figure 2) is disrupted because H3-alanine
does not have a contributing distal carboxyl group to contribute to site 3 Na+ coordination.
However, because the fluorometry measures HP2 movement and not transport, we sought to
clarify whether the fluorescence changes represent HP2 movement consistent with early
transport conformations. We measured fluorescence intensity changes in EAAT3 V417C with
sodium transitioning into a co-application of sodium and glutamate and found that sodium
alters the change in fluorescence differently than glutamate and sodium together (figure 3a
and 3C). This indicates that the measured HP2 movement associated with sodium alone
differs from movement that precedes transport and could reflect the HP2 open state or an
otherwise uncharacterized intermediate state.
To test whether the fluorescence changes associated with sodium alone are consistent
with the HP2 open state, we again used EAAT3 V417C to measure fluorescence intensity
changes associated with TBOA in a background of sodium. Our results report only a very slight
fluorescence change transitioning from sodium alone to a co-application of sodium with a
saturating concentration of TBOA (figure 3b) indicating that sodium orients HP2 into a
conformation similar to the TBOA-bound state.
Li+ binding occurs after glutamate binds and is sensitive to HP2 orientations
Previous studies show that Li+ can replace Na+ and support transport in EAAT3 but not in
EAAT2 (Grunewald and Kanner, 1995; Zhang and Kanner, 1999; Menaker et al., 2006; Huang
et al., 2009). We combined electrostatic mapping with short molecular dynamics simulations of
EAAT2 to determine Li+ sensitivity to subtle HP2 movements. The equation used to calculate
partial valences for each metal ion-oxygen pair is v = (Rj/R0)-N where R is the distance of an
oxygen atom to the cation, R1 is the distance given valence (v) = 1.0, and N is an empirically
derived exponent specific to each cation (Nayal and Di Cera, 1994; Nayal and Di Cera, 1996).
A plot of this equation using the ion-specific values for Na+ and Li+ indicates that the bond
strength for sodium-oxygen pairs is approximately twice that of Li+ for any given distance
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(figure 4a). Electrostatic mapping of EAAT2 structures derived from short molecular dynamics
simulations demonstrate that even slight movement in HP2 (an r.m.s.d. of 1.7Ås as measured
from distances moved between coordinating oxygens in HP2 and TM7; figure 4b) can
dramatically reduce cation coordination at site 2. Significantly, Li+ is more sensitive to HP2
perturbations than Na+ with a valence calculation of v Li = 0.66 and v Na = 0.84 (figure 4c).
Lithium’s greater sensitivity to HP2 movements supports the proposition that sequence
differences unique to EAAT2 HP2 allow an alternative HP2 closed conformation that cannot
sustain site 2 Li+ coordination (Huang et al., 2009).

(a)
3.5

Valence values for Na+ and Li+
-N

(b)

=(Rj/R0)

3.3
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3.1
2.9

Na+
Li+
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Na+
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Na+
Li+
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!1.7Å
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0
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(c)

site 1 site 2
site 3
1.04
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1.04
0.93
0.91
EAAT2-Lglu 0ps |Na+
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0.99
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Figure 4. (a) A plot of distance dependence of valence calculations for Na+ and Li+ using the VALE algorithm
shows that the bond strength between Li+ and a ligating oxygen at any given distance is half the strength of that
of Na+. (b) Short molecular dynamics simulations of an EAAT2 homology model (blue ribbon) show similar
placement of Li+ at site 2 (red sphere) relative to Na+ (blue spheres). (c) Electrostatic mapping of the EAAT2
homology model before molecular dynamics simulations and after a 25ps simulation show that movement in HP2
destabilizes Li+ coordination at site 2. The simulated movement of HP2 decreases the models capacity to
coordinate Na+ by 10% and Li+ by 27%.

We applied glutamate in the presence of lithium to oocytes expressing EAAT2 to
determine the Na+ selective site and found that glutamate did not induce steady-state transport
currents (data not shown), but did block a transient capacitive current (Figure 5a, inset;
Wadiche and Kavanaugh, unpublished observations). The block of the capacitive current was
similar to the one blocked by the non-transportable inhibitor kainate in the presence of
extracellular sodium (Figure 5a; Wadiche et al., 1995). The lithium transient current-voltage
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plot obeyed a Boltzmann function with identical slope as sodium, but shifted towards
hyperpolarized potentials, suggesting that Li+ occupied the same or similar binding sites as Na+
but with lower affinity (Figure 5b; Larsson et al., 2004). The ability of glutamate to block
transient capacitive currents when Li+ is the extracellular cation provides further evidence that
the Na+ selective site in EAAT2 binds after glutamate is bound, eliminating site 1 as a possible
candidate for EAAT2 Na+ selectivity. Integrating these data with the molecular dynamics
simulations and vale data presented above suggests cation binding site 2 as the most likely
candidate for Na+ selectivity in EAAT2.
Two K+ binding sites
The K+ ion-binding site in EAAT3 is thought to involve E374 (Kavanaugh et al., 1997)
which is approximately 9Ås from site 4 and within the valence shell of site 5 (figure 6a). We
propose that these sites are at the tail end of a pathway for K+ countertransport. As previously
reported, the overlap of site 4 with the substrate binding region as well as its high valence
value (figure 6b; Holley and Kavanaugh 2009) could explain constraints in the K+ bound form

(a)

(b)

Figure 5. Voltage-dependent interaction of lithium with hEAAT2. (a) Subtraction of current-voltage records
obtained in 100 mM lithium from records during 3 mM L-glutamate co-application in EAAT2-expressing oocytes
reveals a transient current that decays completely with a time constant of 3.0 ± 0.2 msec for command pulses
from a holding potential of +60 mV to 0 mV, (n = 6; inset). In sodium, the transient current blocked by 300 uM
kainate decays with a time constant of 7.0 ± 0.6 msec (n = 6; inset). The voltage-dependencies of the charge
movements blocked by these saturating agonist concentrations in sodium and lithium were fit to the Boltzmann
function. In EAAT2-expressing oocytes, the lithium transient current blocked by a saturating concentration of
glutamate (3 mM) was compared to the sodium transient current blocked by a saturating concentration of kainate
(300 µM). Both currents were measured over a range of membrane potentials, and their voltage-dependencies
were fit to a Boltzmann function. (b) The integrated charge blocked in EAAT2 by increasing concentrations of Lglutamate was fit to a Boltzmann function.
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that permit glutamate exclusion during the countertransport hemi-cycle (Grunewald and
Kanner, 1995; Mim et al., 2007). Valence mapping shows that when EAAT3 is mutated in silico
from a glutamate at position 374 to aspartate, coordination of K+ is reduced at site 5 (figure 6b)
from v = 1.05 in EAAT3wt to v = 0.73 in EAAT3 E374D. This agrees with the findings of
Kavanaugh et al. (1997) that show that mutation corresponding to EAAT3 E374D cannot
countertransport K+. Electrostatic mapping of the outward-facing, HP2 closed EAAT3 model
indicate both site 4 and site 5 coordinate K+ more stably than Na+ (figure 6b). However the
high valence calculations for Na+ at site 4 of the HP2 closed/apo form (v Na = 0.97) indicate that
K+ binding sites are capable of Na+ coordination. Experimental results from patch clamps
drawn from oocytes expressing EAAT3 show the recovery kinetics of peak anion currents for
intracellular Na+ and K+ (figure 7), demonstrating that sodium can function as the
countertransported cation. This supports the promiscuity predicted by the valence calculations
for site 4. Valance calculations also indicate that the inward-facing EAAT3 model cannot
coordinate K+ at site 5, possibly due to increased constraints on HP2. This suggests that K+
binding is ordered starting with site 4 and moving to site 5 in the outward-facing conformation.

(b)

(a)

site 4

E374

site 5

Sodium
EAAT3wt|open|apo
EAAT3wt|open|L-glu
EAAT3wt|occluded|apo
EAAT3wt|occluded|L-glu
EAAT3 E374D|occluded|apo

Site 4
0.84
<0.3
0.97
<0.3
0.97

Site 5
0.67
0.67
0.73
0.73
0.71

Potassium
EAAT3wt|open|apo
EAAT3wt|open|L-glu
EAAT3wt|occluded|apo
EAAT3wt|occluded|L-glu
EAAT3 E374D|occluded|apo
EAAT3wt|inward|apo

1.11
<0.3
1.44
<0.3
1.44
1.47

0.83
0.83
1.05
1.05
0.73
<0.3

Figure 6. (a) Electrostatic mapping of the HP2-loop closed form of EAAT3 predicts that the valence shell for K+
coordination at site 5 includes glutamate (L-glu) at position 374. (b) Valence calculations of EAAT3 models show
stable coordination of both Na+ and K+ at site 4 in the occluded (HP2 loop closed) apo model and stable
coordination of K+ at site 5 also in the occluded form. Calculated electrostatic coordination capacity for K+ at site 5
in the EAAT3 E374D mutant is reduced relative to wild type EAAT3 (vwt = 1.05 versus vE374D = 0.73).

The transport and trimerization domains of GltPh remain rigid during transport with a 0.6Å
r.m.s.d. when the inward-facing domains are superimposed onto their respective outwardfacing domains. Electrostatic mapping of inward-facing EAAT3 and GltPh models nevertheless
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(a)

(b)

Figure 7. (a) Recovery kinetics of EAAT3 in outside-out patches in response to paired glutamate pulses (10 mM)
with K+ or Na+ in the (intracellular) pipette. This result is consistent with the predicted K+/Na+ selectivity of
hypothetical ion binding site 4 (Holley and Kavanaugh, 2009). The time constant for the recovery was obtained by
fitting the data with a first order exponential (Na+: τ = 1.3 ± 0.08 sec;n=6; K+: τ = 24 ± 3 ms; n=15). Inset, peak
transport current recovery with either intracellular Na+ or K+ ions using the same protocol (50 ms conditioning
pulse followed by a 30 ms test pulse). (b) Recovery kinetics for outside-out patches in response to the paired
glutamate pulses with Na+ in the (intracellular) pipette is also voltage dependent.

reveal decreased coordination for Na+ at sites 2 and 3 (table 3) compared to the outwardfacing, occluded (HP2 closed) conformation. We used a series of molecular dynamics
simulations of lipid-embedded GltPh systems to determine if this reduced coordination
translates to a possible mechanism for release. Shrivastava et al. (2008) reported that short
simulations (10ns) of the aspartate free, outward-facing GltPh system exhibit HP2 movement
Site 1
Sodium
EAAT3|open|apo
EAAT3|open|L-glu
EAAT3|occluded|apo
EAAT3|occluded|L-glu
EAAT3|inward|L-glu
GltPh|inward|L-asp

0.80
0.80
1.04
1.04
1.03
1.03

site 2 site 3
<0.3
<0.3
0.93
0.93
0.75
0.75

0.72
0.72
0.62
0.91
<0.3
<0.3

Table 1. Electrostatic mapping of EAAT3 and GltPh
structures show decreased coordination of Na+ at sites 2
and 3 in the inward-facing structure compared to their
respective sites in the outward-facing, occluded (HP2
loop closed) conformation.

from the closed state to a more open conformation. Here we show Na+ positioned at site 2 is
stably coordinated with an average r.m.s.d of 0.8Ås during simulations of the outward-facing
GltPh system. As predicted by Boudker et al. (2007), simulations that include Na+ bound at site
2 show no HP2 movement indicating that site 2 locks HP2 in the closed state (figure 9). Na+
positioned at site 3 is less stable with an r.m.s.d. of 1.3Ås. Site 3 mobility is coordinated by the
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distal carboxyl group of bound aspartate which disassociates from R447 interactions after
associating more closely with the site 3 Na+ (figure 8).

(a)

R447

(b)

Figure 8. Molecular dynamics simulations of GltPh (5ns) show aspartate mobility when site 3 Na+ is included.
White sticks represent the initial time-point of the simulation and orange sticks indicate the position after the 5ns
simulation.

Simulations of the aspartate bound inward-facing GltPh system exhibit very similar Na+
site 3 mobility. More interesting however is that three trimer subunits during two simulations
(10ns each) of the inward-facing system show release or partial release of Na+ bound at site 2
(figure 10). This agrees well with the electrostatic mapping of EAAT3 and GltPh models as well
as electrophysical evidence reporting that in EAAT3 at least one Na+ must unbind before
glutamate dissociates into the cytoplasm (Otis and Jahr 1998) and suggests site 2 locks HP2
closed in the outward-facing conformation but is rapidly destabilized in the inward-facing
conformation allowing for release.

Figure 9. HP2 movement during a 10ns
simulation in GltPh is stabilized by Na+ at site 2.
The blue ribbon represents the initial structure.
The green ribbon shows HP2 movement after
the 10ns simulation with Na+ bound at site 2
while the orange ribbon show HP2 movement
when site 2 is vacant.
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(a)

(b)

site 3
site 1

site 2

Figure 10. Molecular dynamics simulations of the lipid embedded GltPh system. (a) 10ns simulation of the
outward-facing GltPh system shows coordination of Na+ at sites 1 (purple), 2 (orange), and 3 (gray). Bound
aspartate (orange sticks) shown coordinating site 3 is from the earliest time-point of the simulation. (b) Example
of a release pathway into the cytoplasm of Na+ initially bound at site 2 (orange ball) during a 10ns molecular
dynamics simulation of the lipid embedded, inward-facing GltPh system.

Discussion
We probe cation and substrate interactions with glutamate transporters to construct a
partial model for sequential binding and unbinding (figure 11). We contend that substrate
translocation requires first that Na+ bind site 1 and that Na+ cooperatively interacts with the
transporter to lock HP2 into the open conformation. This is followed by glutamate binding and
subsequent HP2 closure allowing coordination of Na+ at site 2 to lock HP2 in the occluded
position. Site 3 is coordinated by α-carboxyl groups in HP2 and the distal carboxylate of bound
substrate, suggesting that Na+ binds site 3 only after site 2 Na+ has stabilized HP2 in the
occluded position. Molecular dynamics simulations of the lipid-embedded GltPh homologue
show that the bond formed between the site 3 Na+ and bound substrate destabilizes the R447
interactions with the substrate distal carboxylate permitting greater movement of bound
substrate relative to simulations with no site 3 Na+ (figure 8). Furthermore, electrostatic
mapping of the outward and inward-facing EAAT3 models indicate that the inward-facing
conformation is less capable of coordinating Na+ at site 2 (table 1). This agrees well with
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molecular dynamics simulations of the inward-facing GltPh system showing rapid release
(within 10ns) of Na+ from site 2 (figure 10b).
To determine whether Na+ bound at site 3 plays a role in coupled transport we
employed the EAAT3 R447C mutant which transforms EAAT3 into a neutral amino acid
obligate exchanger. Consistent with our model for functional coordination of Na+ at site 3, we
found that by removing the possibility for Na+ coordination from the substrate distal carboxylate
we eliminated cooperativity between sodium ions for transport (figure 2). Complementary
voltage clamp fluorometry experiments indicate that at least two sodium ions cooperate for
HP2 movement and that this cooperativity is extinguished in the R447C mutant. The
cooperativity determined from fluorometry is measured in the absence of amino acid substrate,
suggesting that either the change in cooperativity measured by fluorometry reflects the same
change measured from the uptake assays and a functional mechanism for cooperativity would
not involve coordination of Na+ at site 3, or that the fluorometry data measures sodium
cooperativity for HP2 movement not transport and the measurements pertain to one or more
as yet uncharacterized Na+ binding sites
To distinguish between these possibilities we again used oocytes expressing labeled
EAAT3 V417C to determine whether fluorescence changes associated with sodium application
are consistent with changes associated with sodium combined with glutamate. Our results
demonstrate that transitioning from choline to sodium quenches fluorescence while
transitioning into glutamate enhances fluorescence (figure 3a). To further probe the sodiuminduced conformational state of HP2 using EAAT3 V417C we transitioned from choline to
sodium alone to a co-application of sodium and TBOA resulting in little measured change in
fluorescence (figure 3b). Although fluorometry measurements do not necessarily measure
conformational movement, a simple interpretation of the fluorescence traces in figure 3 is that
sodium causes HP2 to orient into an open conformation similar to that of TBOA-bound crystal
structure, while glutamate induces the closed, occluded conformation. This agrees very well
with a substrate depleted GltPh structure, which Boudker et al. (2007) described as “essentially
indistinguishable” from the TBOA-bound GltPh structure.
These data suggest different positions of HP2 correlate to different steps during early
binding and transport and could indicate that sodium cooperativity for HP2 movement does not
reflect sodium cooperativity for transport. That is, the Hill coefficients derived from sodium
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cooperativity for radiolabled amino acid uptake in EAAT3wt and EAAT3 R447C (figure 2)
directly relates to substrate translocation and the potential implications for cooperativity
involving Na+ bound at site 3 are not necessarily undermined by the fluorometry data. A
possible explanation involves a 41 amino acid deletion in TM4 of GltPh relative to EAAT3. This
deletion is very near to the portion of the 3-4 loop that interacts with HP2 in the TBOA-bound,
open conformation (Boudker et al., 2007). Koch et al. (2007) demonstrate that fluorescently
labeled cysteine mutations within this region report fluorescence changes in response to
different concentrations of Na+ in the absence of glutamate. The authors argue that these Na+
dependent changes could be due to HP2 movement influenced by as yet unidentified Na+
binding sites within the TM4 deletion. The inward-facing GltPh transport domain as described
by Reyes et al. (2009) does not involve TM4 or the 3-4 loop and does require HP2 to be in the
closed conformation. Excepting uncharacterized allosteric sites or TM4 interactions with the
marginal availability of site 3 in the HP2 open conformation (table 1), Na+ sites involving the
TM4 deletion would likely not be involved in transport and Na+ cooperativity for HP2 movement
can reasonably be considered separate from translocated Na+ ions.
Unlike all other EAAT subtypes, Li+ cannot support transport in EAAT2. Consistent with
previously published studies we show that EAAT2 is sensitive to Li+ only after amino acid
substrate binding (figure 4; Zhang and Kanner 1999; Huang et al., 2009). To determine a likely
candidate for the EAAT2 sodium selective (lithium sensitive) site we used short molecular
dynamics simulations of a lipid embedded EAAT2 system in conjunction with electrostatic
mapping. Our results demonstrate that Li+ coordination at site 2 is susceptible to slight HP2
movements (figure 4) suggesting that a small alteration of HP2 positioning in the occluded
form of the transporter would affect cation binding. This is consistent with Huang et al. (2009)
who implicated site 2 as the EAAT2 sodium selective site and who originally postulated that
sodium selectivity could derive from a slightly altered HP2 occluded conformation. These
results help define a possible mechanism for specificity during transport and may have
implications for other subtype specificities such as the high affinity of EAAT2 for kainate.
Previously we used electrostatic mapping to determine a K+ coordination site that
overlaps the amino acid binding site and has a high affinity for Na+ (Holley and Kavanaugh
2009). Here we expand this model to include a second K+ site (site 5, figure 6a) that directly
interacts with EAAT3 E374 which is thought to be involved in K+ countertransport. Compatible
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with Kavanaugh et al. (1997) who showed that K+ countertransport was disrupted when a
residue analogous to E374 was mutated to an aspartate, valence calculations indicate reduced
K+ coordination at site 5 for the EAAT3 E374D mutant (figure 6b). Also in agreement with our
earlier findings indicating high Na+ affinity at site 4, we show Na+ can replace K+ as the
countertransported cation (figure 7a).
(b)

(a)

(c)

Na1

(d)

(e)

(f)

HP2
closure

(g)

glu binds

Na2

(h)

Na3

(i)

K+
site4

K+
site5

Figure 11. Overview of the proposed transport model with H+ and anion conductance omitted. (a) In the absence
of sodium, HP2 moves freely, possibly sampling positions between the open and closed conformations reported
by Boudker et al. in 2007. Addition of sodium allows Na+ ions to bind two sites (possibly including site 1) that
cooperatively prop HP2 in a conformation similar to the open conformation. Concurrently, Na+ binds site 1 (b) and
then substrate binding (c). Subsequent HP2 closure (d) introduces site 2 availability for Na+ coordination (e)
which locks HP2 in the occluded conformation and allows Na+ to bind site 3 (f). Interaction of site 3 Na+ with
substrate distal carboxylate destabilizes the bond between R447 and substrate (f) allowing for a possible initial
mechanism of release in the inward-facing transporter conformation. After translocation of the Na+-glutamate
complexed transport domain to the inward-facing conformation, Na+ at site 2 is released. Substrate and Na+ at
sites 1 and 3 are released through an unknown mechanism. K+ then binds site 4 interacting with D444. After
translocation to the outward-facing orientation, K+ moves from site 4 to site 5 and interacts with E374 (i).
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Experimental Procedures
Homology modeling
Human EAAT3 sequence (obtained from GenBank, http://www.ncbi.nlm.nih.gov) and was
aligned with the Protein Data Bank (PDB) sequences for the GltPh archael homologue (2NWX,
2NWW and 3KBC) according to alignments published by Yernool et al. (2004). Homology
models were built by threading the aligned EAAT2 and EAAT3 sequences along the GltPh PDB
coordinates using the SwissProt server (http://swissmodel.expasy.org//SWISS-MODEL.html).
The resulting models were optimized through local energy minimizations of regions with high
steric and electrostatic interference using the AMBER7 force field in the Tripos SYBYL8.0
platform.
Electrostatic mapping
Valence shell mapping and calculations were performed as described previously (Nayal
and Di Cera, 1994; Nayal and Di Cera, 1996; Holley and Kavanaugh, 2009). Briefly, we
mapped homology and X-ray crystal structure models using the VALE software program
(courtesy of Enrico Di Cera and Thierry Rose; Washington University, St. Louis, MO) with a
3.4Å probe radius and a grid size of 0.1Å within 10Ås from the aspartate α-carbon imported
from the 2NWX or the 3KBC crystal structure. In order to reduce noise, no water molecules
were included in the valence mapping (Nayal and Di Cera, 1994). Consistent with recent
studies, we chose a valence cutoff of ν ≥ 0.9 for likely candidate binding sites (Ogawa and
Toyoshima, 2002; Rakowski and Sagar, 2003; Nayal and Di Cera, 1996). The threedimensional coordinates of valence maps that contain multiple, clustered valence sites within a
2Å radius were included as a single site and we reported the highest estimated valance within
each site. Root mean square deviation (r.m.s.d.) calculations were measured using the Visual
Molecular Dynamics program (VMD, www.ks.uiuc.edu/Research/vmd/).
Molecular dynamics
We developed the simulation system by embedding the trimeric GltPh crystal structure
(Yernool et al., 2004; Ryan et al., 2010; Protein Data Bank accession codes 1XFH and 3KBC
respectively) or the trimeric EAAT2 homology model in a POPE membrane using the VMD
Membrane builder and solvating the system with explicit, all-atom TIP3P water molecules
using VMD Solvate (Darden et al., 1993). This resulted in a system sizes of 150 X 150 X 77 Å3
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with approximately 130,000 atoms for each simulation system. We added Na+ and Cl- to a
concentration of 200mM to neutralize the total charge of the system. Ions were added either
randomly using VMD or were manually placed within coordination sites determined by
electrostatic mapping (Holley and Kavanaugh, 2009).
All simulations were performed using NAMD 2.7 (Phillips et al., 2005) with a 1fs time step
under periodic boundary conditions using the CHARMM27 forcefield (Mackerell et al., 1998).
The system was equilibrated by first melting only lipids in a 300ps simulation at constant
volume and constant temperature (NVT) at 303K using Langevin dynamics with a damping
coefficient of 5ps-1 to maintain constant temperature. A subsequent 500ps simulation was
performed at constant pressure (1 atm) and constant temperature (303K) with molten solvent
and lipids and fixed protein to ensure proper lipid packing. The full system was then
equilibrated for another 500ps in the NPT ensemble with a constant pressure of 1 atm.
Production runs were performed at 303K and 1 atm with non-bonded interactions cutoff at a
distance of 12Å. Long-range electrostatic interactions were calculated using the particle mesh
Ewald method (Darden et al., 1993).
Uptake-flux measurements
The human EAAT3 wild type and EAAT3 R447C cDNA subcloned into the Pl28 oocyte
expression vector were transcribed to cRNA using mMessage mMachine (Ambion).
Approximately 50nL of the cRNA were injected into stage V-VI Xenopus laevis oocytes and
radiolabled uptake was assayed 3-5 days post injection as previously described by Zerangue
and Kavanaugh (1996).
Expression and Voltage Clamp Fluorometry with Xenopus laevis oocytes
Cysteine point mutagenesis of V417C and V417C-R447C was performed with
QuikChange Site-Directed Mutagenesis Kit (Stratagene). cRNA was microinjected in stage VVI Xenopus laevis oocytes. EAAT3 mutant transporters were labeled with Alexa Fluor 488 C5
maleimide (Molecular probes, A-10254). Alexa Fluor 488 C5 maleimide was dissolved in DMSO
at 10 mM and frozen in aliquots. Labeling was done with 10 µM dye in standard recording
solutions for 30 minutes (saturation as determined by a labeling curve). Currents and
fluorescence were recorded 3-5 days later as previously described (Larsson et al., 2004;
Wadiche et al., 1995). Recording solution contained 96mM NaCl, 2mM KCl, 1mM MgCl2,
1.8mM CaCl2, and 5mM HEPES (pH7.4). In choline replacement experiments, 96mM choline
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chloride was used for the NaCl. Microelectrodes were filled with 3M KCl and had resistances
from 1 to 3 MΩ. Two electrode voltage clamp recordings were performed at 22°-25°C with a
Geneclamp 500 interfaced to an IBM-compatible PC using a Digidata 1320 A/D controlled with
the pCLAMP 6.0 program suite (Molecular Devices). The currents were low-pass filtered at 1
kHz and digitized at 5 kHz. Data were analyzed offline; modeling and fitting of substrate
concentration-dependence of the currents was performed with Kaleidagraph software (v 4.04).
Electrophysiological recording
Recording solutions contained 100 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM
HEPES-Tris, pH 7.5. In experiments where sodium was varied or replaced, equimolar cation
substitution with either lithium or choline was employed. Two-microelectrode voltage-clamp
recording was performed with a Gene Clamp 500 amplifier interfaced to an IBM compatible
PC-AT using a Digidata 1200 A/D controlled using the pCLAMP program suite (version 6.0.3;
Axon Instruments, Foster City, CA). A MacLab/2e analog/digital converter (ADInstruments,
Mountain View, CA) was used to generate continuous current records. Microelectrodes were
filled with 3 M KCl solution and had resistances of less than 1.5 MΩ. For pre-steady-state
current measurements, data were sampled at the lowest gain to avoid saturation of the
amplifier response during the peak of the capacitance transient and signal-averaged 8 times
before and after solution exchange. Currents were digitized at 1 kHz. The normalized mean
concentration response of currents induced by L-glutamate was fitted by least squares to the
Michaelis-Menten equation
I = Imax [Glu] / ([Glu] + Km)
Km values are expressed as mean ± S.E. from fits to data from individual oocytes. The cation
concentration dependence of response currents induced by L-glutamate was fitted by least
squares to the Hill equation
I = Imax [Na+]n / ([Na+]n + Kmn)
where n is the cooperativity index. Transient currents were obtained by subtraction of current
traces recorded in the presence of kainate (sodium) or glutamate (lithium) from control traces.
For each oocyte, the capacitive charge movements were calculated by time integration of the
subtracted current records using Clampfit 6.0. They were then plotted versus voltage and
fitted to the Boltzmann function
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Qtot = 1 + exp[eozδ(Vm – V0.5) / kT] +Qoffset
where Qtot is the total charge movement, V0.5 is the midpoint of the charge movement, Vm is
the membrane potential, zδ is the product of the valence of the charge and apparent fraction of
the membrane electric field sensed by that charge, Qoffset is the offset that depended on the
holding potential, eo is the fundamental charge, k is the Boltzmann constant, and T is the
absolute temperature. For comparisons among oocytes, charge movements were offset
vertically by Qoffset and normalized to the Qtot in the same oocytes.
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Chapter 4: Further computational work
Although the particular focus of my dissertation has been understanding EAAT structure
and function, the methods employed through computational modeling, obviously, may be
applied in any protein structural analysis. This chapter of my dissertation presents a sampling
of applications for computer modeling which have been applied with positive results. These
applications also suggests the utility computational modeling holds for science generally.
Introduction: Development of a homology model for clade A human immunodeficiency virus
type 1 gp120 to localize temporal substitutions arising in recently infected women
Mary Poss, David C. Holley, Roman Biek, Harold Cox and John Gerdes
There are nine different clades (genotypic subtypes) of HIV-1 (clades A, B, C, D, F, G, H,
J, and K) with clade A most common in West and Central Africa and clade B most common in
North America and Europe. Not surprisingly, most research has centered on clade B viruses
though worldwide there are more clade A infections. The work leading to the computational
modeling described below involved identifying and characterizing temporal sequence
substitutions that become fixed in viral populations during early infection with clade A viruses.
Specifically we were interested in sequence substitutions occurring in the gp120 HIV-1
envelope protein, which is a heavily glycosylated protein expressed on the viral surface and is
responsible for binding and entering host cells (Dalgleish et al., 1984; Kwong et al., 2000).
In 2000, Kwong et al. published a crystal structure derived from primary isolates of an
HIV-1 clade B gp120 complexed to a neutralizing antibody and fragments of a host CD4
receptor. Our work characterizing the clade A-specific substitutions during early infection
prompted us to evaluate the tertiary impact of these substitutions to devise possible structural
implications. In the following paper we present an homology model based on the Kwong
structure (2000) but also incorporating the structure of an NMR derived variable loop (V3 loop)
(Catasti et al., 1995; Catasti et al., 1996). The orientation and overall structure of the
incorporated V3 loop is remarkably consistent with a gp120 clade B crystal structure published
in 2005 (Huang et al., 2005) showing less than 3.0Ås r.m.s.d from the V3 loop in the crystal
structure (figure A). Our analysis of the clade A gp120 homology model showed structural
compatibility with the clade B structure and that the clade A-specific substitutions arising during
early infection are non-random and in certain cases co-locate in regions associated with
receptor binding.
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Figure A. NMR derived V3 loop (green) extracted from the clade A gp120 homology model shows similar
orientation and structure to a V3 loop (blue) in a later published gp120 crystal structure.
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The virus population transmitted by a human immunodeficiency virus type 1 (HIV-1) infected
individual undergoes restriction and subsequent diversification in the new host. However, in
contrast to men, who have limited virus diversity at seroconversion, there is measurable diversity
in viral envelope gene sequences in women infected with clade A HIV-1. In this study, virus
sequence diversity in three unrelated, clade A infected women preceding and shortly after
seroconversion was evaluated. It was demonstrated that there is measurable evolution of envelope
gene sequences over this time interval. Furthermore, in each of the three individuals, amino acid
substitutions arose at five or six positions in sequences derived at or shortly after seroconversion
relative to sequences obtained from the seronegative sample. Presented here is a model of
clade A gp120 to determine the location of substitutions that appeared as the virus
population became established in three clade A HIV-1 infected women.

B viruses. To gain a better understanding of forces acting
on gp120 of a colonizing virus population, we developed a
homology model of clade A HIV-1 gp120 to locate substitutions that arose between pre- and post-seroconversion
samples in each of three clade A-infected women for whom
extensive analysis of HIV-1 diversity (Poss et al., 1995),
plasma viral load and post-seroconversion env evolution
(Poss et al., 1998), and viral phenotype (Painter et al., 2003)
have been described.

Transmission of human immunodeficiency virus type 1
(HIV-1) from an infected to a naı̈ve host causes significant
changes in the genetic make-up of the virus population.
HIV-1-infected individuals may harbour up to 10 % virus
diversity in the viral envelope gene (env), depending on
the length of infection, but only a subset of these variants
initiate the new infection. The inoculum transmitted to a
recipient contains diverse genotypes (Learn et al., 2002)
but in men the variant pool detected close to the time of
seroconversion is essentially homogeneous in env (Wolfs
et al., 1992; Zhang et al., 1993; Zhu et al., 1993). In contrast, env diversity in clade A-infected women is 1–5 % at
seroconversion (Long et al., 2000; Poss et al., 1995). The
factors responsible for different profiles of virus diversity in
men and women near seroconversion are unknown.

To determine if there was measurable evolution near the
time of infection, we recovered full-length env sequences
from pre-seroconversion plasma viral RNA samples from
each individual and from samples obtained at 20 (Q23), 7
(Q45) or 10 and 49 weeks (Q47) from the pre-seroconversion
sample (Poss et al., 1995). The analysis employed a Markov
Chain Monte Carlo (MCMC) framework and a general
time reversible substitution model for the Bayesian estimation of evolutionary rates (Drummond et al., 2002), incorporating a prior of time to most recent common ancestor
estimated from a larger dataset of V1–2 and V3 sequences
from these subjects (Poss et al., 1998). The estimated
evolutionary rate for Q23 sequences was 2?5 % per site per
year (95 % confidence intervals 1?61–3?35) based on 16
plasma viral RNA sequences from two samples obtained
20 weeks apart. Rates of 0?28 % (0?07–0?51) were derived
for Q45 based on 17 plasma viral sequences obtained
7 weeks apart. Viral RNA sequences were not available for

Diversity in the HIV-1 glycoprotein, gp120, encoded by
env can significantly impact viral fitness by altering cell
tropism and neutralization sensitivity. Substitutions in clade
B gp120 that affect receptor and co-receptor binding and
antibody interactions have been determined by mutagenesis
studies (Boussard et al., 2002; Kwong et al., 2002; Pantophlet
et al., 2003; Saphire et al., 2001; Wyatt et al., 1998; Zwick
et al., 2003). However, it is not known whether any key
functional sites change as the virus establishes infection in
a new host. Furthermore, despite the large number of clade
A HIV-1-infected individuals worldwide, there has been
no research on the structural biology of gp120 of non-clade
0007-9974 G 2004 SGM
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Q47 at seroconversion and thus estimated rates of 0?13 %
(0?05–0?22) were based on eight viral RNA pre-seroconversion
sequences, seven proviral DNA sequences obtained 10 weeks
later at the time seroconversion was detected, and 10 proviral sequences obtained 7 months after seroconversion. In
all cases, confidence intervals excluded zero indicating that
measurable rates of evolution occurred in env. There was no
correlation between plasma viral loads and evolutionary
rates in these individuals.
Protein sequences from pre-seroconversion samples were
compared to those obtained at or near seroconversion to
determine if amino acid replacement occurred in the
evolving virus population. Although intra-sample sequence
diversity was high (Fig. 1), in all three subjects amino
acids at several positions in sequences derived at or shortly
after seroconversion were replaced when compared with
the sequences detected at the time of infection (Table 1).
Six substitutions were fixed in the seroconversion virus
population of Q23. Four of these sites have been shown by
mutagenesis studies of clade B gp120 to affect the binding
of CD4 and one to affect binding of antibodies to the
CD4-binding site (CD4BS) (Table 1). Using a null distribution of 66 positions in gp120 affecting CD4 binding
(Kwong et al., 1998; Pantophlet et al., 2003; Rizzuto et al.,
1998), there was a significantly higher number of substitutions at sites affecting binding to the CD4-binding site
than would be expected if substitutions were randomly
distributed (Fisher’s exact test, P=0?009). Substitution
T430A is of particular interest because alanine mutagenesis
of this site in clade B gp120 strongly increased binding of
antibody IgG1b12 (b12) (Pantophlet et al., 2003; Saphire
et al., 2001) but decreased binding of CD4 (Rizzuto et al.,
1998), suggesting that this substitution could affect the
structure of the receptor-binding domain. Three out of five
temporal substitutions from Q45 viruses involved sites that
affected CD4 and b12 or CCR5 binding to clade B gp120,
which is significantly more than would be expected by
chance (P=0?037). Temporal changes in Q47 sequences did
not involve sites that have been investigated for impact on
receptor, co-receptor or antibody binding, although sites
278 and 364 are adjacent to residues that contact CD4
(Kwong et al., 1998). None of the temporal substitutions in
either Q23 or Q45 sequences affected potential N-linked
glycosylation sites or involved V1, V2 or V3, and none
occurred in the gp41 portion of the glycoprotein (data
not shown). In contrast, temporal substitutions in Q47
sequences did involve one site in V1 and gp41 (data not
shown) and did result in two new potential N-linked
glycosylation sites (Table 1).

Fig. 1. Distribution of gp120 amino acid substitutions. A consensus sequence was determined for the pre-seroconversion
sequences obtained from each of three clade A-infected
women. The percentage of sequences that contained an amino
acid that differed from the pre-seroconversion consensus at
each position is shown for pre-seroconversion sequences (grey
lines, ‘I’) and sequences obtained at or after seroconversion
(dashed lines, ‘Sc’). The secondary structure elements are relative to the HXBc2 crystal and include only the regions that
appear in the crystal structure. The locations of the deleted
V1–2 and V3 loops are indicated in the bottom panel by
arrowheads. The numbers of sequences in each dataset are;
Q23–8 and 8, Q45–9 and 8 and Q47–8 and 17 for preseroconversion and post-seroconversion samples, respectively.

Of the temporal substitutions identified in these subjects,
50 % or more fell outside variable regions. It is particularly
noteworthy that none of the early temporal changes
affected V3 because fixation of amino acids in V3 did
occur over a 2 year period post-seroconversion in sequences
obtained from these individuals (Poss et al., 1998). Substitutions that arise in V3 often correlate with a phenotypic
1480

change in the virus population (Scarlatti et al., 1997; Speck
et al., 1997). The fact that the V3 region in the viruses from
these individuals does not evolve near the time of infection
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Table 1. Summary of temporal substitutions
Subject
Q23
Q23
Q23
Q23
Q23
Q23
Q45
Q45
Q45
Q45
Q45
Q47
Q47
Q47
Q47
Q47
Q47

Position*
T/K232
K/Q337
V430
N/K460
S/D461
N463
N92
W395
T415
I424
S/D461
N241
T278
S364
?
S/G411
T415

Amino acid
infectionD (%)
E
S
T
N
D
N
E
F
D
V
K
H
L
H
S
D
I

(100)
(100)
(100)
(100)
(100)
(100)
(56)
(56)
(100)
(100)
(100)
(75)
(88)
(75)
(88)
(88)
(88)

Amino acid
post-SCd (%)
G
R
A
D
N
F
D
W
T
I
E
N
S
P
N
N
T

Secondary
structure§

(100)
(100)
(100)
(100)
(100)
(100)
(85)
(85)
(62)
(54)
(77)
(88)
(100)#
(100)
(65)
(100)
(78)#

£A
a2
b21
V5
V5
V5
b1
b18-V4
b19
b19-b20
V5
b6-b7
£D
b14-b15
V4-b19
V4-b19
b19

Predicted
effect||
NR

B6DD
CD4 & b12DD§§
CD4 & b12DD
CD4 & b12DD
CD4 & b12DD
NR

CD4 & b12DD
NR

CCR5 & CD4dd
CD4 & b12DD
NR
NR
NR
NR
NR
NR

*Amino acid and position number is relative to HXBc2 (Kwong et al., 1998). Where two amino acids are
shown, the second is from primary isolate YU2 (Kwong et al., 2000a).
DAmino acid in single letter nomenclature that was present in sequences obtained from viral RNA in plasma
samples obtained before seroconversion (Poss et al., 1995). The percentage shown in parentheses is the
proportion of sequences that contain the amino acid shown.
dAmino acid in single letter nomenclature that was present in sequences obtained from viral RNA (Q23) or
RNA and proviral DNA (Q45 and Q47) at or shortly after seroconversion (Poss et al., 1995). The percentage
shown in parentheses is the proportion of sequences that contain the amino acid shown.
§Location of the substitution is referenced to the secondary structure determined from the HXBc2 crystal
(Kwong et al., 1998).
||Sites determined by mutagenesis to affect CD4BS antibody, receptor or co-receptor binding.
Mutagenesis at this site is not reported.
#Substitution creates a new potential N-linked glycosylation site.
DDPantophlet et al. (2003).
ddRizzuto et al. (1998).
§§Saphire et al. (2001).
NR, not reported.

Fig. 2(A, B). Although clade A-specific substitutions are
distributed throughout the sequence, there is a preponderance of differences in the ‘silent face’ of the gp120 outer
domain in b sheet 12 and 13 and a helix 2, which flank the
V3 loop (Fig. 2A). This a helix is known to be variable both
within and between clades, which can lead to presentation
of distinct antigenic surfaces to the immune system (Kwong
et al., 2000a). In the 3-D structure, substitutions characteristic of clade A occur at periodic intervals in the a helix
and in a continuous stretch of the apposing b12 sheet to
form a clade A-specific planar surface. In addition, there are
several clade A changes within the CD4-binding pocket
(Fig. 2B). Clade A HIV-1 gp120s, including all representatives discussed herein, contain a substitution at P369,
which is flanked by conserved CD4 contact residues D368
and E370. Substitutions of P369 decrease the binding of

and seroconversion suggests that there may be selection
against change in V3 as the virus population becomes
established.
Despite the high prevalence of non-clade B HIV-1 infection
globally, most structural, evolutionary and therapeutic
research on HIV-1 is based on clade B viruses. Thus, it is
not clear whether results obtained from clade B gp120
mutagenesis studies are applicable to clade A gp120. A
crystal structure for clade B gp120 is available (Kwong
et al., 1998, 2000a) and provides the opportunity to determine the structural relatedness of gp120 from clades A
and B. Using the clade B structure, we first identified
substitutions specific to clade A gp120 from an alignment
of consensus sequences of clade B and clade A (available
at http://hiv-web.lanl.gov/), which are shown in red in
http://vir.sgmjournals.org
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Fig. 2. Topological distribution of clade A-specific substitutions and temporal substitutions arising after infection with clade A
HIV-1. (A, B) The structure of clade B gp120 (1G9N) is shown as a ribbon diagram with sites differing between consensus
clade B and clade A gp120 depicted in red, the truncated V1–2 and V3 loops indicated in green and the V4 and V5 loops
shown in cyan. The arrow in (A) indicates the planar face containing clade A-specific substitutions. Perspective in (A) is with
the virus membrane upper right and cell membrane lower left (CD4 is not shown), and in (B) the molecule is rotated
approximately 110 6 around the vertical axis to display the CD4-binding pocket and CD4, shown as a violet tube structure.
(C, D) Homology model of clade A HIV-1 based on the sequence of Q47S6 is shown in the same orientation as the clade B
structure in (A, B). Temporal substitutions that arose in Q23, Q45 and Q47 sequences are displayed in magenta, cyan and
purple, respectively. The temporal substitutions that were shared between viruses are indicated with striping. The V3 loop has
been added to the model and adjustments have been made to accommodate the longer clade A V4 loop.

determine the spatial distribution of temporal substitutions
from three subjects. The prototype clade A model employed
the gp120 sequence of Q23Sc4 (AY069928) because previous phylogenetic analysis demonstrated that Q23 viruses
were basal in the clade A tree (Poss et al., 1997), suggesting
that they were suitable representatives of clade A gp120.
The clade A homology model was built at the Molecular
Computational Core Facility at the University of Montana,
utilizing an Octane SGI (Silicon Graphics) workstation
operated with software SYBYL 6.8 employing Biopolymer,

CD4 binding site antibody, b12 (Saphire et al., 2001), and
are a feature of clade B neutralization escape mutants
(Mo et al., 1997). Clade A-specific substitutions are also
present in the bridging sheet, which is involved in coreceptor binding (Kwong et al., 1998). It is noteworthy that
there are few clade differences in the inner domain of
gp120, a region of contact with gp41 (Kwong et al., 1998).
We developed a homology model of clade A gp120 based
on the clade B structure, 1G9N (Kwong et al., 2000a) to
1482
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Composer and ProTable modules (Tripos). The Q23Sc4
sequence was threaded against the 1G9N scaffold using the
Composer module, which considers residues that only
align with the scaffold, thereby providing a preliminary
homology model. The original IG9N structure is devoid of
the first three variable loops. For the homology model, the
V1–V2 loop regions were not considered. However, the
clade A V3 loop structure was fashioned by a protocol
related to Kwong’s method (Kwong et al., 2000b) utilizing
published NMR conformations of the gp120 clade B V3
loop region (Vranken et al., 2001). Whereas there are cladespecific regions of gp120 (shown in Fig. 2A, B), the core
clade A gp120 model structure was found to possess few
abnormal w, y and v values (using ProTable; Lovell et al.,
2000) relative to those of the X-ray-derived core clade B
gp120 structure, suggesting a noteworthy degree of core
structural similarity between the protein representations.
The clade A V4 loop is longer than that of the IG9N crystal.
Therefore, the additional amino acids were accommodated
by clipping at the V4 N-terminal side, inserting the extra
clade A amino acids, followed by adjusting select bond
rotations at the loop C-terminal end to allow loop attachment to the core structure. To obtain a refined Q23Sc4
homology model (Fig. 2C, D), side chain clashes between
the V3 and V4 loops were minimized, first by changing
select bond torsions to provide w, y and v values consistent
with established standards (Lovell et al., 2000), followed
by local V3 and V4 energetic minimizations (Tripos force
field) to their respective nearest energy wells.

the protein. Furthermore, in two of the three subjects
there were significantly more changes at sites shown by
mutagenesis of clade B gp120 to affect receptor or coreceptor binding than would be expected by chance. Further
studies of the substitutions that arise soon after infection,
will be valuable to understand selective forces acting on the
infecting virus population and to inform efforts aimed at
preventing establishment of new infections.
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Introduction: Novel Lavendamycin Analogues as Antitumor Agents: Synthesis, in Vitro
Cytotoxicity, Structure−Metabolism, and Computational Molecular Modeling Studies with NAD
(P)H:Quinone Oxidoreductase 1
Mary Hassani, Wen Cai, David C. Holley, Jayana P. Lineswala, Babu R. Maharjan, G. Reza
Ebrahimian, Hassan Seradj, Mark G. Stocksdale, Farahnaz Mohammadi, Christopher C.
Marvin, John M. Gerdes, Howard D. Beall, and Mohammad Behforouz
NAD(P)H:quinone oxidoreductase (NQO1) is over-expressed in many tumor cell types
and facilitates the activation of cytotoxic agents through a two electron reduction process
involving a bound FAD co-factor. Lavendamycin has broad antitumor activity (Boger et al.,
1987) but is too toxic for use in chemotherapy. The following study by Hassani et al. (2005)
evaluates novel lavendamycin derivatives for selective antitumor activity through interactions
with NQO1.
The computational component of this study was included to determine and differentiate
interactions between NQO1 and two of the lavendamycin analogues. We used the protein data
bank coordinates of an FAD- and substrate-bound NQO1 crystal structure as the target protein
for computational molecular docking of the two selected lavendamycin analogues. The
analogues had been gauged in vitro as either a very poor substrate (compound 31) or as a
good substrate (compound 37) for NQO1 bioactivation. This allowed for a comparative
analysis of docked poses to identify substrate interactions that promote or hinder binding and
bioreduction in NQO1.
The findings from the docking study were consistent with the in vitro evaluations showing
that docked poses of the poor substrate (31) scored lower than docked poses of the good
substrate (37) (table 7). Furthermore, high ranked poses of compound 37 oriented very similar
to the analogous substrate (compound 65) included in the NQO1 crystal structure with
aromatic rings of compound 37 stacking over rings of the FAD (figures 2c, 2d and 3a). In
comparison, none of the poses of compound 31 oriented similar to compound 65. Likewise,
analysis of the interactions between NQO1 and top ranked poses of compound 37 revealed
hydrogen-bonding between compound 37 and NQO1 residues that are involved in the electron
reduction process necessary for substrate bioactivation (figure 3b and 3c). These interactions
were not detected in any of the compound 31 poses. High-ranked docked poses of compound
37 also show hydrogen-bonding between a substituent group of compound 37 (CH2OH group
at position R3) and key NQO1 residues that could possibly confer substrate selectivity (figures

55

3b and 3c). Overall, the docking exercise demonstrated that poses of compound 37 were
oriented more consistent with known interactions between NQO1 and analogous substrates
than any of the compound 31 docked poses.
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Novel lavendamycin analogues with various substituents were synthesized and evaluated as
potential NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor agents. Pictet-Spengler
condensation of quinoline- or quninoline-5,8-dione aldehydes with tryptamine or tryptophans
yielded the lavendamycins. Metabolism studies with recombinant human NQO1 revealed that
addition of NH2 and CH2OH groups at the quinolinedione-7-position and indolopyridine-2ʹ′position had the greatest positive impact on substrate specificity. The best and poorest
substrates were 37 (2ʹ′-CH2OH-7-NH2 derivative) and 31 (2ʹ′-CONH2-7-NHCOC3H7-n derivative)
with reduction rates of 263 ( 30 and 0.1 ( 0.1 µmol/min/mg NQO1, respectively. Cytotoxicity
toward human colon adenocarcinoma cells was determined for the lavendamycins. The best
substrates for NQO1 were also the most selectively toxic to the NQO1-rich BE-NQ cells
compared to NQO1-deficient BE-WT cells with 37 as the most selective. Molecular docking
supported a model in which the best substrates were capable of efficient hydrogen-bonding
interactions with key residues of the active site along with hydride ion reception.
Introduction

tumors suggest that antitumor compounds that are
bioactivated by NQO1 may be selectively toxic to those
tumors.
The crystal structure of the apo recombinant human
NQO1 has been determined to a resolution of 1.7 Å.9
Each monomer of the physiological dimer of NQO1 is
composed of two distinct domains such that residues
1-220 and 221-273 form a major catalytic and a small
C-terminal domain, respectively.9,10,25,26 Two equivalent
active sites are located at the dimer interface and are
formed by portions of both subunits.6,9 The active site
of the enzyme is a hydrophobic and plastic pocket with
three potential hydrogen-bonding residues (Tyr-126 and
-128 and His-161) that can bind and accommodate a
broad range of structures including large quinone
compounds.9,25 The substrate binding pocket (360 Å3)
sequentially binds NAD(P)H and the quinone substrate
and is formed by residues from both monomers.9,10,25
NQO1 promotes an obligatory two-electron reduction
called a ping-pong mechanism such that in the first half
of the reaction a hydride ion from NAD(P)H is transferred to the N5 of the FAD followed by the release of
NAD(P)+.10,27,28 The hydride donation from the FADH2
N5 to the hydride-acceptor substrate (across a 4 Å
distance28) can then be done at either a carbonyl oxygen
or ring carbon followed by hydroquinone release. The
remaining proton can be provided by Tyr-126, -128, or
His-161.10,27,28 Quinone substrates can bind to the NQO1
active site in more than one orientation, and homologous
compounds with different substituents may bind to the
NQO1 active site in different orientations.25,27

The goal of current cancer drug discovery is to design
cytotoxic compounds that selectively interact with molecular targets ideally unique to tumor cells with
minimal toxicity to normal cells.1-3 One approach to
achieve selective toxicity is through bioreductive activation and identifying reductase enzymes that are overexpressed in tumor cells when compared to normal
cells.1,3-5 NAD(P)H:quinone oxidoreductase 1 (NQO1,
DT-diaphorase, EC 1.6.99.2, DTD or QR1) is a widely
distributed homodimeric flavoenzyme composed of two
closely associated monomers of 273 residues, each
containing one molecule of the noncovalently attached
FAD cofactor molecule that is required for NQO1
catalytic activity.6-10 This obligate two-electron reductase is present in cytosol (>90%)11 and nucleus12 and
catalyzes a nicotinamide nucleotide-dependent twoelectron reduction13,14 and the bioactivation of quinone
chemotherapeutic compounds such as mitomycins, indoloquinones, anthracyclines, and aziridinylbenzoquinones.15-19 Marked elevations in NQO1 activity and
mRNA content in primary tumors from lung, liver, colon
and breast,20 and lung,21 liver,22 brain,23 and colorectal24
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Scheme 1

Table 1. Structures of Lavendamycin Analogues, Reaction
Conditions and Yields

Lavendamycin (1a), a bacterially derived quinolinedione antibiotic, was isolated from the fermentation broth
of Streptomyces lavendulae in 1981.29 Lavendamycin is
structurally29,30 and biosynthetically31-33 related to
streptonigrin (SN) (2), another potent 7-aminoquinoline-

5,8-dione antitumor antibiotic. Earlier work has shown
that the use of both of these antitumor agents as
potential drugs has been precluded due to their high
degree of toxicity.30,34,35 However, in contrast to the
parent compound, we have found that a significant
number of lavendamycin derivatives have low animal
toxicity but show strong antitumor activity or are potent
inhibitors of the HIV-reverse transcriptase.36-38 These
studies have been possible only through our success in
developing short and efficient syntheses for a variety
of lavendamycin analogues possessing the full pentacyclic structure. For instance, compared to the previously reported syntheses of lavendamycin ester (1b) in
overall yields of 0.5 to 2% and in 9 to 20 steps,39,40 we
were able to synthesize 1b in 5-step methods41,42 with
overall yields of nearly 40%.
This study was conducted to clarify the role of NQO1
in the bioactivation of lavendamycin analogues. Specifically, the objectives were to analyze the effects of
functional group changes on the reduction efficiency of
lavendamycin analogues by NQO1, to verify whether
activation by NQO1 resulted in selective cytotoxicity of
these compounds and to correlate the metabolism and
biological data of the compounds with predictions of
their active site positioning, hydrogen bond formation,
and hydride ion reception capability. For this study, we
were in need of a large number of variously substituted
lavendamycins possessing zero to four substituents on
their pentacyclic system for which their syntheses are
described below. Additionally, the synthesis of a number
of quinolinediones is reported.

R1

R2

14
15
16
17
18
19
20
21
22
23

CH3CO
CH3CO
CH3CO
CH3CO
CH3CO
CH3CO
CH3CO
CH3CO
CH3CO
ClCH2CO

H
CO2CH3
CO2C4H9-n
CO2C5H11-n
CO2C5H11-i
CO2C6H13-n
CO-piperidino
CO-morpholino
CH2OH
CO2C5H11-i

% yield solvent
83
67
63
44
50
54
56
57
48
57

anisole
anisole
xylene
xylene
xylene
xylene
anisole
anisole
anisole
xylene

h (°C)a
5 (reflux)
4.5 (reflux)
4 (reflux)
4.5 (reflux)
9.5 (28-130)
5.5 (reflux)
17 (reflux)
18 (reflux)
4 (25-155)
5 (76)

a Except for compounds 18, 22 and 23 the reaction mixtures
were slowly heated to reflux over a period of approximately 3 h
and then refluxed for the designated times.

Results and Discussion
Synthetic Chemistry. A range of lavendamycin
analogues was designed and synthesized to explore the
effects of various substituents on the metabolism of

no.

58

these analogues by recombinant human NQO1. PictetSpengler condensation (Scheme 1) of 7-N-acylamino-2formylquinoline-5,8-diones 3 or 4 with tryptamine, or
derivatives of tryptophan or β-methyltryptophan (513), yielded lavendamycin analogues 14-23.
In a typical procedure, aldehydes 3 or 4 (0.1 mmol)
were mixed with the corresponding tryptamine or
tryptophan derivatives in dry anisole or xylene under
argon, and while being magnetically stirred, the mixture
was gradually heated to reflux over a period of 3 h.38,41,42
The resulting clear solution was refluxed until TLC
showed the absence of the starting materials. The
mixture was concentrated or evaporated to dryness. The
products were either precipitated from the concentrated
solutions or purified by washing with solvents. The
structures of the resulting lavendamycins, the reaction
conditions, and the yields are shown in Table 1. Table
2 presents the structures of a number of other novel
lavendamycins as well as some of our previously synthesized derivatives. Table 3 lists the structures of
quinolinediones. The lavendamycin analogues shown in
the tables are the subject of the biological tests in this
study.
Following Scheme 2, aldehydes 3 and 43 were prepared according to our reported syntheses.38,41,42 Aldehyde 4 was obtained by the reduction of 47, then
chloroacetylation of the resulting amino salt followed
by two consecutive oxidations.
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Table 2. Structures of Lavendamycin Analogues

no.

R1

R2

R3

R4

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
n-C3H7CONH
NH2
NH2
Br
NH2
NH2
NH2
NH2
H

pyrrolidino
aziridino
H
H
H
H
H
H
Cl
H
H
H
H
H
H
H

CO2CH3
CONH2
CO2CH3
CO2C8H17-n
CO2(CH2)2OH
CO2(CH2)2OPO3H2
CONH2
CONH2
CO2CH3
CO2CH3
CO2CH3
CO2C8H17-n
CONH2
CH2OH
H
H

CH3
H
CH3
H
H
H
H
H
CH3
CH3
CH3
H
H
H
H
H

refs

41, 42
38
38
38
38
38
41, 42
38
38

Table 3. Structures of Quninoline-5,8-diones

no.

R1

R2

R3

refs

3
4
40
41
42
43
44
45
46

CH3CONH
ClCH2CONH
CH3CONH
ClCH2CONH
n-C3H7CONH
n-C3H7CONH
NH2
NH2
NH2

H
H
H
H
H
H
H
Cl
Cl

CHO
CHO
CH3
CH3
CH3
CHO
CH3
CH3
CHO

41, 42
41, 42
38
38
38
38

Tryptamine (5) is commercially available and tryptophans 6, 7 and 13 were obtained by the neutralization
of the commercially available salts with ammonia (14%)
and extraction with ethyl acetate. Tryptophan esters
8-10 were prepared by the Fischer esterification of the
tryptophans with the corresponding alcohols. β-Methyltryptophan methyl ester necessary for the synthesis
of 32 and 57, the precursor of 34 was prepared according
to our own reported procedure.43
Chloroaldehyde 46 was obtained following the chemistry in Scheme 3.44
The 6-substituted pyrrolidino and aziridino lavendamycins were synthesized by an efficient Michael addition of the amines to the corresponding lavendamycins
in excellent yields according to Scheme 4.45
Amino analogues 37 and 38 were prepared by the acid
hydrolysis of acetyl derivatives 22 and 14 in high yields
as shown in Scheme 5.
Bromo analogue 34 and unsubstituted lavendamycin
39 were synthesized following the reactions presented
in Scheme 6. Quinoline aldehydes 55 and 56 were
synthesized by the selenium dioxide oxidation of the
commercially available 53 and 54 followed by the
condensation with β-methyltrytophan methyl ester or

59
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tryptamine to produce 57 and 58 which then oxidized
by bis[(trifluoroacetoxy)iodo]benzene46 to the products.
Scheme 7 presents the steps in the synthesis of the
desired piperidine and morpholine amides of trytophan.
Tryptophans 11 and 12 were prepared in relatively good
yields by a method similar to that of Tolstikov used for
the synthesis of streptonigrin derivatives.47
Electrochemistry. The aim of the electrochemical
studies was to determine the relative ease of reduction
of the lavendamycin analogues and to compare how the
electrochemical behavior of these compounds correlates
with their reduction rate by NQO1. Electrochemical
studies of a number of lavendamycin analogues were
carried out. In these studies, dried dimethyl sulfoxide
(DMSO) and tetrabutylammonium hexafluorophosphate
(Bu4NPF6) were used as solvent and the supporting
electrolyte, respectively. Cathodic and anodic peak
potentials, Epc and Epa, respectively, were measured and
the midpoint of the peak potentials was used to determine E1/2 values, E1/2 ) (Epc + Epa)/2. E1/2 values were
consistent for the potential sweep rates in the range of
50 to 500 mV/s. The E1/2 values determined from the
recorded voltammograms at the potential sweep rates
of 50, 100, 200, 400, and 500 mV/s were averaged and
reported with reference to ferrocene (Fc0/+) E1/2 value
(Table 4).
All of the lavendamycin analogues exhibited reversible electrochemistry. The analogues with electronwithdrawing groups at the R1 position showed similar
E1/2 values, between -0.85 and -0.99 V, with the
exception of compound 24 that exhibited a slightly more
negative E1/2 value which can be in part due to the
presence of an electron-donating group at the R2 position
(Table 4). The lavendamycin analogues with electrondonating groups at the R1 position showed slightly more
negative E1/2 values, between -1.01 and -1.09 V,
compared to the former group (Table 4). In general, the
lavendamycin analogues with electron-withdrawing
groups at the R1 position were easier to reduce compared
to the ones with electron-donating groups at this position. Although all of the investigated lavendamycin
analogues possessed similar E1/2 values (-0.85 to -1.13
V) (Table 4), the rate of reduction of these compounds
by NQO1 differed dramatically (Table 5). When the
electrochemical reduction potential and rate of reduction
of the lavendamycin analogues by NQO1 were compared, no direct correlation between the two factors was
found (data not shown). This finding along with our
molecular modeling studies suggest that other factors
such as lavendamycins substituent size, steric influence,
active site positioning, and hydrogen bond formation
capability may be more important than the electrochemical reduction potential and electronic effects to
determine the reduction efficiency of these compounds
by NQO1. Electrochemical studies can be used to
determine the ease of reduction of compounds, but there
is often no overall or very small association between the
rate of reduction by NQO1 and reduction potential for
quinones such as indolequinones48-50 and quinolinequinones51 as previously reported. The lavendamycin
analogues exhibited similar reduction potential values
to the quinolinequinone compounds studied by Fryatt
et al.51 Also, they were easier to reduce (E1/2 values )
-0.85 to -1.13 V) than the indolequinones previously
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Scheme 2a

a Reagents and conditions: (a) Pd-C, 5%, H (30 psi), HCl-H O, 15 h, rt; (b) (RCO) O, NaOAc, Na SO , 2.5 h, rt to 0 °C; (c) K Cr O ,
2
2
2
2
3
2
2 7
HOAc, 12 h, rt; (d) SeO2, dioxane, H2O, 9-29.5 h, reflux.

Scheme 3a

a Reagents and conditions: (a) HCl (gas), dry MeOH, 22 h, 60 °C; (b) SeO , dioxane, H O, 23 h, reflux; (c) β-methyltryptophan methyl
2
2
ester, anisole, 3 h, rt to 130 °C, then 1 h, reflux.

Scheme 4a

a

Reagents and conditions: (a) aziridine, CHCl3, 48 h, rt; (b) pyrrolidine, CHCl3, 2 h, rt.

Scheme 5a

a

Reagents and conditions: (a) H2SO4 (70%), 2-4 h, 60 °C.

studied by Beall et al. and Swann et al. (E1/2 values )
-1.19 to -1.61 V).49,50
Biological Studies. Metabolism of the novel lavendamycin analogues by recombinant human NQO1 and
cytotoxicity to human colon adenocarcinoma cells with
either no detectable NQO1 activity (BE-WT) or with
high NQO1 activity (BE-NQ) were examined. The effect
of functional group changes on reduction efficiency and
rate of reduction by NQO1 was studied using a spectrophotometic assay that employs cytochrome c as the
terminal electron acceptor52 and gives initial rates of
lavendamycin analogues reduction (Table 5). The initial
reduction rates (µmol cytochrome c reduced/min/mg
NQO1) were calculated from the linear portion (0-30
s) of the reaction graphs.

60

Large substituents at the quinolinedione-7-position
(R1) of the lavendamycin analogues were poorly tolerated and greatly reduced the metabolism rate of the
analogues by NQO1 compared to smaller substituents
(31 vs 36, 18 vs 23, and 30 vs 31) (Table 5). Large
substituents such as NHCOC3H7-n in 31 at the 7-position had the most negative impact on the rate of
reduction by NQO1 whereas NH2 followed by the
NHCOCH3 group were the best substituents for this
position (Table 5). This could partly be due to steric
hindrance between the quinolinedione moiety (5,8-dione
ring enters the active site first) and NQO1 active site
that results in unfavorable positioning of the lavendamycin analogues for hydride ion reception from FADH2
and quinone reduction. Our molecular modeling studies
also demonstrated that placing a small substituent at
the R1 position that is capable of hydrogen bonding with
key residues of the active site could be a contributing
factor to substrate specificity. Faig et al. determined
that positions of 63 (RH1), 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone,53 that point to the
inner part of the NQO1 active site could accommodate
only small substituents.25 Also, 1,4-naphthoquinones
with small substituents such as an aziridine ring or CH3
at C2 and no substituents at C3 were reported to be
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Scheme 6a

a Reagents and conditions: (a) SeO , wet dioxane, 2 h, rt to reflux, then 17-22 h, reflux; (b) tryptamime or β-methyltryptophan methyl
2
ester, anisole, 3 h, rt to reflux, then 22-39 h, reflux, then Pd-C, 5%, 28 h, reflux; (c) Bis[(trifluoroacetoxy)iodo]benzene, CH3CN-H2O,
2 h, 0 °C.

Scheme 7a

a Reagents and conditions: (a) N-hydroxysuccinimide, DCC, 2 h, 12-20 °C, dioxane (b) amine, Et N, EtOH, CH Cl rt, 1 h (c) dry
3
3
3,
ammonium formate, Pd-C, 10%, dry methanol, rt, 30 min.

Table 4. Electrochemical Reduction Potentialsa (DMSO) of Lavendamycin Analogues versus Ferrocene

no.

R1

R2

R3

R4

Epc (V)

Epa (V)

E1/2 (V) vs Fc

14
15
24
25
26
28
30
31
32
33
36
37
38
39

CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
n-C3H7CONH
NH2
NH2
NH2
NH2
NH2
H

H
H
pyrrolidino
aziridino
H
H
H
H
Cl
H
H
H
H
H

H
CO2CH3
CO2CH3
CONH2
CO2CH3
CO2(CH2)2OH
CONH2
CONH2
CO2CH3
CO2CH3
CONH2
CH2OH
H
H

H
H
CH3
H
CH3
H
H
H
CH3
CH3
H
H
H
H

-0.95
-0.92
-1.16
-0.99
-0.91
-1.02
-0.88
-0.92
-1.01
-1.10
-1.09
-1.11
-1.12
-0.88

-0.95
-0.83
-1.10
-0.93
-0.85
-0.95
-0.82
-0.89
-1.01
-1.04
-1.05
-1.06
-1.06
-0.85

-0.95
-0.88
-1.13
-0.96
-0.88
-0.99
-0.85
-0.91
-1.01
-1.07
-1.07
-1.09
-1.09
-0.87

a E
1/2 values (( 0.005 V) calculated as (Epc+ Epa)/2 are averages of the values determined from voltammograms recorded at potential
sweep rates of 50, 100, 200, 300, 400 and 500 mV/s; Epc ) cathodic peak potential; Epa ) anodic peak potential.

good substrates for NQO1.54 Dipyrroloimidazobenzimidazole compounds with both pyrrolo rings bearing bulky
substituents were determined to be poor substrates for
NQO1 due to steric interactions with residues of the
NQO1 active site.55
Comparison of analogues 32 vs 33 and 25 vs 30
determined that 6-unsubstituted (R2) lavendamycin
analogues are far better substrates for NQO1 than the
corresponding 6-substituted counterparts (Table 5). This
is likely due to active site constraints and steric effects
caused by substituents that hinder entrance or proper
positioning of the 5,8-dione moiety of the analogues
toward the key residues of the active site and the FAD
isoalloxazine ring for hydride ion reception and quin-

61

one reduction. This finding is consistent with other
studies that previously showed that increased bulkiness
of the substituents at C5 position on 64 (EO9), 3-hydroxy-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propenol,56
dramatically reduced rates of reduction by NQO1.25,52
Another study determined that indolequinones and
mitosenes with bulky amine substituents at C5 and C7
positions, respectively, are not substrates for NQO1 due
to steric effects.49
A number of substituents at the 2ʹ′-position of the
fused indolopyridine moiety (R3) were also investigated.
Among the analogues that shared an NH2 group at the
R1 position and had no substituent at R2, 2ʹ′-CH2OH
derivative (37) was the best substrate followed by the
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Table 5. Metabolism of Lavendamycin Analogues by Recombinant Human NQO1 Monitored by Spectrophotometric Cytochrome c
Assay

no.

R1

R2

R3

R4

metabolism by NQO1 (µmol/min/mg)
(cytochrome c reduction)

14
15
16
17
18
19
20
21
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
ClCH2CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
n-C3H7CONH
NH2
NH2
Br
NH2
NH2
NH2
NH2
H

H
H
H
H
H
H
H
H
H
pyrrolidino
aziridino
H
H
H
H
H
H
Cl
H
H
H
H
H
H
H

H
CO2CH3
CO2C4H9-n
CO2C5H11-n
CO2C5H11-i
CO2C6H13-n
CO-piperidino
CO-morpholino
CO2C5H11-i
CO2CH3
CONH2
CO2CH3
CO2C8H17-n
CO2(CH2)2OH
CO2(CH2)2OPO3H2
CONH2
CONH2
CO2CH3
CO2CH3
CO2CH3
CO2C8H17-n
CONH2
CH2OH
H
H

H
H
H
H
H
H
H
H
H
CH3
H
CH3
H
H
H
H
H
CH3
CH3
CH3
H
H
H
H
H

2.7 ( 1.2
0.9 ( 0.2
8.6 ( 2.6
9.2 ( 6.6
35.4 ( 6.9
11.7 ( 5.3
15.2 ( 11.5
7.5 ( 1.5
9.9 ( 5.6
1(1
0.2 ( 0.2
1.9 ( 1.7
1.5 ( 0.8
11.0 ( 2.5
15.4 ( 0.9
33 ( 12
0.1 ( 0.1
0.9 ( 0.8
21 ( 12
0.7 ( 0.3
106 ( 15
18.3 ( 13.6
263 ( 30
24.0 ( 6.5
3.4 ( 1.2

2ʹ′-CO2C8H17-n derivative (35) (Table 5). Molecular
modeling demonstrated that the CH2OH group at R3
was capable of hydrogen bond formation with the key
residues of the NQO1 active site and therefore could be
an important contributing factor to substrate specificity.
A CH2OH group at the C6 position of a series of
substituted 1,4-naphthoquinones also contributed the
most to substrate specificity for NQO1.54 Phillips et al.
determined that some of the good indolequinone substrates for NQO1 including 64 possessed a CH2OH
group at the analogous C3 position.52 Furthermore, 63,
which is an excellent substrate for NQO1, possesses a
CH2OH group at C3 position.7,53
Addition of NH2 and CH2OH groups at R1 and R3
positions, respectively, had the greatest positive impact
on substrate specificity compared to other substituents
at these positions. The best substrate was the 2ʹ′-CH2OH-7-NH2 derivative (37) with a reduction rate of 263
( 30 µmol/min/mg NQO1 (Table 5). These findings
enhance our understanding of the relationship between
lavendamycin structure and rates of reduction by
NQO1.
Cytotoxicity studies were also performed on representative lavendamycins with cell survival being determined by colorimetric MTT and clonogenic assays. We
used the BE human colon adenocarcinoma cells stably
transfected with human NQO1 cDNA.53 The BE cells
(BE-WT) had no measurable NQO1 activity whereas
activity in the transfected cells (BE-NQ) was greater
than 660 nmol/min/mg total cell protein using dichlorophenolindophenol as the standard electron acceptor.

Figure 1. Correlation of mean IC50 values obtained by the
MTT and clonogenic assays. The mean IC50 values obtained
by the MTT assay were plotted along the horizontal axis and
mean IC50 values obtained by the clonogenic assay were plotted
along the vertical axis. The correlation coefficient was 0.990
(P ) 0.0001).
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We also evaluated the correlation between the chemosensitivity results of clonogenic and MTT assays in both
cell lines for three lavendamycin analogues, 31, 33, and
37. There was an excellent positive linear correlation
between the IC50 values of the two assays for the three
lavendamycins for BE-WT (r ) 0.999, P ) 0.03), BENQ (r ) 0.999, P ) 0.025) and both cell lines (r ) 0.990,
P ) 0.0001) (Figure 1). In this study the cytotoxicity of
representative lavendamycin analogues (Table 6) has
been compared using these cell lines.
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Table 6. Cytotoxicity of Lavendamycin Analogues toward BE-WT (NQO1-deficient) and BE-NQ (NQO1-rich) Human Colon
Adenocarcinoma Cell Lines

cytotoxicity IC50 (µM)
no.

R1

R2

R3

R4

BE-NQ

BE-WT

selectivity ratio
[IC50 (BE-WT)/ IC50 (BE-NQ)]

16
26
27
29
30
31
33
34
35
36
37
38
39

CH3CONH
CH3CONH
CH3CONH
CH3CONH
CH3CONH
n-C3H7CONH
NH2
Br
NH2
NH2
NH2
NH2
H

H
H
H
H
H
H
H
H
H
H
H
H
H

CO2C4H9-n
CO2CH3
CO2C8H17-n
CO2(CH2)2OPO3H2
CONH2
CONH2
CO2CH3
CO2CH3
CO2C8H17-n
CONH2
CH2OH
H
H

H
CH3
H
H
H
H
CH3
CH3
H
H
H
H
H

20.5 ( 0.6
13.2 ( 0.7
>50
6.8 ( 0.6
0.8 ( 0.0
21.4 ( 1.2
0.5 ( 0.1
>50
3.4 ( 0.7
0.2 ( 0.0
0.4 ( 0.1
8.0 ( 0.5
12.4 ( 1.0

20.0 ( 2.3
19.3 ( 4.3
>50
8.1 ( 0.5
3.5 ( 0.7
>50
4.7 ( 0.7
>50
35.0 (3.4
1.8 ( 0.1
4.5 ( 0.2
16.8 ( 1.0
9.3 ( 1.2

1.0
1.5
1.2
4.4
2.3
9.4
10.3
9.0
11.3
2.1
0.8

Lavendamycin analogues such as 30, 33, 35, 36, and
37 that were good substrates for NQO1 (Table 5) were
also more toxic to the NQO1-rich cell line (BE-NQ) than
the NQO1-deficient cell line (BE-WT) (Table 6). Compound 37, the best substrate for NQO1 (Table 5), had
the greatest differential toxicity with a selectivity ratio
of 11 (Table 6). Antitumor and antiproliferative activity
of lavendamycin against implanted leukemia cells in
BDF1 mice and three other cancer cell lines has been
previously reported.30,57 A recent study investigating
cytotoxic activities of a series of lavendamycin analogues
against A549 human lung carcinoma cells indicated that
compounds with an amide or amine substituent at the
R3 position displayed the most potent colony formation
inhibitory effects.36 At a concentration of 10 nM, the
most potent compound of this group, MB-97, reduced
the colony outgrowth of A549 cells by 70%.36 Since MB97 also displayed promising cytotoxic and antitumor
activities in the NCI’s 60-cell line panel and in vivo
hollow fiber tumorigenesis assay, it has been considered
for in vivo testing against tumor xenografts in mice.36
Our study also determined that compound 36 (MB-97)
showed highly selective toxicity toward BE-NQ cells
(selectivity ratio ) 9). Lavendamycin analogues such as
26, 27, 31, 34, and 39 that were poor substrates for
NQO1 demonstrated no selective toxicity toward BENQ cells or had no measurable cytotoxicity (IC50 > 50
µM) (Table 6). Although compound 38 was a rather good
substrate for NQO1, it displayed only minimal selective
toxicity toward BE-NQ cells. This could be due to the
less toxic nature of 38 (high IC50 values for both cell
lines) compared to other good substrates such as 30, 33,
and 36 that have lower IC50 values (Table 6). Overall,
our results determined that the best lavendamycin
substrates for NQO1 were also the most selectively toxic
to the high NQO1 BE-NQ cell line.
Molecular Modeling. Computational and comparative molecular modeling studies were performed on two
lavendamycin analogues, 31 and 37, very poor and good
substrates of NQO1, respectively. The molecular model-

Table 7. Number of Poses of Ligands 31 and 37 in Each Score
Group of CSCORE Function
31

no.
CSCORE
number of poses

63

0
18

1
8

2
-

37
3
-

4
4

5
-

0
3

1
3

2
1

3
4

4
15

5
4

ing was performed using SYBYL 6.9.1 software suite58
(Tripos, Inc.; St. Louis, MO). Flexible docking was
performed using the FlexX module of SYBYL that is
capable of determining 30 possible conformations (poses)
for each docked ligand.59,60 Compound 65 (ARH019),
3-(hydroxymethyl)-5-(2-methylaziridin-1-yl)-1-methyl-2phenylindole-4,7-dione,49 has been suggested as an
appropriate model for molecular docking studies of other
compounds such as streptonigrin (2).25 Therefore, the
coordinates of the crystal structure of the human NQO1
complex with bound FAD and 65, obtained from the
Protein Data Bank (PDB ID code: 1H6925), were used
as a composite reference structure for the docking
experiments, wherein the coordinates of 65 served as
the reference ligand of location. The docked conformations of ligands 31 and 37 were evaluated and ranked
using FlexX and four scoring functions implemented in
the CSCORE module in SYBYL. CSCORE is the consensus score computed from FlexX and ChemScore,61
D-Score,62 G-Score63 and PMF-Score64 scoring functions,
in which docked poses are evaluated and ranked from
0 to 5; where 5 is the best fit to the model. Table 7
displays the number of conformations of ligands 31 and
37 in each score group of CSCORE function.
Ligand 37 possessed a higher number of poses with
more optimal CSCORE values compared to 31 (Table
7). To minimize the number of false positives and/or
negatives, visual screening of the binding orientations
of the poses and geometric post-docking analyses were
performed. The analyses included distance measurements, calculations, and pose geometries that determined (a) hydrogen-bonding interactions of the ligand
poses with key residues of the NQO1 active site including Tyr-126, -128, and His-161, (b) hydride ion transfer
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Figure 2. (a) View of the superposition of the docked poses 1,9 and 15 of 37 (magenta, cyan, and yellow) (CSCOREs ) 5, 4, and
4) in NQO1 active site (RMSD ) 0 Å). (b) View of the superposition of the docked poses 20, 24, and 27 of 37 (magenta, cyan, and
yellow) (CSCOREs ) 4) in NQO1 active site (RMSD ) 0 Å). (c) View of the superposition of the docked poses 3, 4, 5, 6, 7, 11, and
12 of 37 (magenta, cyan, yellow, salmon, blue, orange and green) (CSCOREs ) 4) in NQO1 active site (RMSD < 0.8 Å). (d) View
of the superposition of the docked poses 8, 10, 18, 19, and 26 of 37 (yellow, salmon, magenta, cyan, and orange) (CSCOREs ) 5,
5, 4, 4, and 4) in NQO1active site (RMSD < 0.8 Å). Residues of the active site (lime), FAD (blue), and 37 represented as stick
models. The atoms are colored: red, oxygen atoms; blue, nitrogen atoms; and white, hydrogen atoms.

from N5 of the FAD isoalloxazine ring to the ligands at
either carbonyl oxygens (O5 or O8) or at a ring carbon,
and (c) the angle between the quinone-moiety plane of
the ligands and the FAD isoalloxazine ring (residue
numbers in this paper are those used in the Protein
Data Bank coordinates, PDB ID code: 1H6925).
Of the 30 possible docked conformations of ligand 37,
24 poses (CSCORE g 2) showed binding orientations
similar to that of the reference ligand. Compound 65
has been shown to enter the active site by the 4,7-dione
moiety where the plane of the indolequinone forms a
partial aromatic-ring parallel stacking with the FAD
isoalloxazine ring and the corresponding plane-to-plane
angle is 16°.25 The binding orientation of 65 and ligands
31 and 37 in the NQO1 active site were similarly
determined by the atomic positioning of quinone carbonyl oxygens and atoms toward the isoalloxazine ring
atoms of the FAD and residues of the active site.
Compound 65 carbonyl oxygen O4 in comparison to O7
is positioned closer to Tyr-126, -128 and N5 of the
FAD.25 19 poses of ligand 37 had CSCORE g 4 (Table
7). Poses with CSCORE g 4 fell into four clusters, where
a cluster is defined as a group of poses that gives a rootmean-square (RMS) deviation less than 0.8 Å for the
quinolinedione and indolopyridine moieties atoms. Poses
1, 9, and 15 (Figure 2a) and 20, 24, and 27 (Figure 2b)

64

fell into two clusters in which the RMS deviation of the
poses equaled zero and the difference was in the binding
orientation of the CH2OH group in NQO1 active site
(Figures 2a and 2b). Poses 3, 4, 5, 6, 7, 11, and 12
(Figure 2c) and 8, 10, 18, 19, and 26 (Figure 2d) were
clustered into two groups that yielded RMS deviations
of < 0.8 Å. All of the clustered poses of 37 entered the
active site by the 5,8-dione moiety similar to 65, where
the departure of the planes of most of these poses from
a complete aromatic-ring parallel stacking with the FAD
isoalloxazine ring closely resembled that of 65 (Figure
2). Carbonyl oxygen O5 of the clustered poses compared
to O8 was positioned closer to Tyr-126, -128, and the
FAD N5 resembling compound 65 binding orientation,
suggesting that this could be the preferred binding
orientation for ligand 37 (Figure 2).
In the NQO1 active site, the hydroxyl groups of Tyr126 and -128 and/or N or NH of His-161 can form
hydrogen bonds with carbonyl oxygens and/or other
atoms of quinone substrates.10,25,27 One crucial determining factor of quinone substrates binding strength
in the NQO1 active site is the quinone oxygens’ capability of forming hydrogen-bonding interactions with Tyr126 and -128.27 Good substrates for NQO1 such as 63
and 64 are capable of hydrogen-bonding interactions
with the key residues of the NQO1 active site.6,25 Among
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Figure 3. (a) Depiction of the molecular surface of NQO1 active site region. The surface of the pocket is colored lime with FAD
(blue) and the docked pose 1 of 37 (magenta) (CSCORE ) 5) represented as stick models. (b) Molecular model of the pose 1 of 37
docked into NQO1 active site. (c) Molecular model of the pose 2 of 37 (CSCORE ) 5) docked into NQO1 active site. In b and c,
residues of the active site (lime), FAD (blue), and 37 (magenta) represented as stick models and the rest of the structure as a
secondary structure cartoon. The atoms are colored: red, oxygen atoms; blue, nitrogen atoms; and white, hydrogen atoms. Hydrogen
bonds are represented as yellow dashed lines.

the poses of ligand 37, poses 1 and 2 formed the highest
number of efficient hydrogen bonds in the active site of
the enzyme. The 5,8-dione moiety of pose 1 with
CSCORE ) 5 stacked over the isoalloxazine ring of the
FAD and the NH2 group at the quinolinedione 7-position
was placed close to His 161 (Figures 3a and 3b). The
fused three-ring indolopyridine moiety pointed toward
the outside of the active site. The CH2OH group at the
indolopyridine 2ʹ′-position was placed close to Gly-149
(Figures 3a and 3b). Pose 2 (CSCORE ) 5) also
positioned in the NQO1 active site in a very similar way
to pose 1 (Figure 3c). The carbonyl oxygen O5 of ligand
37 poses 1 and 2 formed a hydrogen bond with the Tyr128 OH and one hydrogen atom of the NH2 substituent
formed a hydrogen bond with N of His 161. The CH2OH group of the indolopyridine moiety further stabilized
the binding by making a hydrogen bond to the carbonyl
oxygen of the Gly-149 (Figures 3b and 3c). Poses 1 and
2 of ligand 37 with high CSCOREs of 5 made the most
efficient hydrogen-bonding interactions and had the
most favorable binding orientation for efficient hydride
ion reception and quinone reduction.
However, of the 30 possible docked conformations of
ligand 31, no conformation had a CSCORE ) 5 (Table
7). None of the 30 poses had a binding orientation
similar to that of the reference ligand, 65. Pose 12 with
CSCORE ) 4 had a binding orientation opposite that

65

of the original reference (Figure 4a). Neither of the
carbonyl oxygens O5 and O8 of pose 12 were capable of
forming hydrogen bonds with the key residues of the
active site unlike poses 1 and 2 of ligand 37 (Figure 4a).
The other 3 poses (11, 26, and 28) of 31 with CSCORE
) 4 entered the active site of NQO1 with the fused
three-ring indolopyridine moiety where the quinolinedione moiety pointed toward the outside of the active
site (Figures 4b and 4c). Compound 66 (ES1340),
5-methoxy-3-(phenyloxymethyl)-1,2-dimethylindole-4,7dione,18 which is a poor substrate for NQO150 has been
shown to position in the NQO1 active site such that the
4,7-dione moiety points to the outside of the active site.26
The binding orientations of the poses of ligand 31 were
not favorable for effective hydrogen-bonding interactions, hydride ion reception, or quinone reduction. The
remaining 26 poses with CSCOREs of 0 and 1 did not
merit further considerations.
The molecular modeling and docking studies demonstrated that ligand 37 possessed an increased number
of possible poses with favorable binding orientations to
promote efficient hydrogen bonding interactions, hydride ion reception and quinone reduction compared to
31. Ligand 37 due to the small hydrogen bond forming
substituents possessed structural characteristics for
favorable positioning in the NQO1 active site for reduction. Conversely, the unfavorable structural character-
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Figure 4. (a) Molecular model of the pose 12 of 31 (CSCORE ) 4) docked into NQO1 active site. Residues of the active site
(lime), FAD (blue), and 31 (magenta) represented as stick models and the rest of the structure as a secondary structure cartoon.
(b) Depiction of the molecular surface of NQO1 active site region. The surface of the pocket is colored lime with FAD (blue) and
the docked poses 11, 26, and 28 of 31 (magenta, yellow and cyan) (CSCOREs ) 4) represented as stick models. (c) Molecular
model of the poses 11, 26, and 28 of 31 docked into NQO1 active site. Residues of the active site (lime), FAD (blue), and 31
(magenta, yellow, and cyan) represented in stick models and the rest of the structure as a secondary structure cartoon. The
atoms are colored: red, oxygen atoms; blue, nitrogen atoms; and white, hydrogen atoms.

istics of ligand 31 could exclude it from proper positioning in the NQO1 active site for reduction. These findings
suggest that active site positioning contributes to the
much greater substrate specificity observed for ligand
37 than ligand 31.
Conclusions. A number of novel lavendamycin anologues were synthesized through short and practical
methods. No direct correlation between the reduction
potential and rate of reduction of the analogues by
NQO1 were found suggesting the more important role
of steric effects of these compounds in the NQO1 active
site rather than electronic effects on the reduction
efficiency by NQO1. Small substituents at R1 and R3
positions on the quinonolinedione moiety of the lavendamycin analogues were well tolerated whereas absence
of a substituent at R2 was preferred. Addition of NH2
and CH2OH groups at R1 and R3 positions, respectively,
displayed the greatest positive impact on substrate
specificity such that 2ʹ′-CH2OH-7-NH2 derivative (37)
exhibited the highest reduction rate. The best lavendamycin substrates for NQO1 were also the most selectively toxic to the NQO1-rich BE-NQ cell line. The
docking studies supported a model in which the good
lavendamycin substrate 37 was capable of efficient

hydrogen-bonding interactions with the key residues of
the NQO1 active site and hydride ion reception from
FAD while the poor substrate 31 was not. The use of
molecular modeling techniques can greatly contribute
to future rational design of good NQO1 substrates for
NQO1-directed lavendamycin antitumor agent development.
Experimental Section

66

Chemistry. General Methods. For General Methods see
ref 38 (J. Med. Chem. 2003, 46, 5773-5780). Aziridine was
prepared according to the procedure previously described by
Allen et al.65 and was kept in a refrigerator over KOH pellets.
Bis(chloroacetamido)-8-hydroxy-2-methylquinoline (50).
In a 500 mL heavy-walled hydrogenation bottle, 5.25 g (0.21
mol) of finely ground 8-hydroxy-2-methyl-5,7-dinitroquninoline
(47) and 1.75 g of palladium on charcoal were suspended in a
mixture of 90 mL of water and 9 mL of concentrated hydrochloric acid.41 In a Parr Hydrogenator, this mixture was
shaken under 30 psi of hydrogen for 20 h. The catalyst was
filtered off, and the dark red solution containing the dihydrochloride salt of 5,7-diamino-8-hydroxy-2-methylquinoline was
placed in a 250 mL round-bottomed flask with a magnetic bar.
To this stirred solution was added in sequence as quickly as
possible 12 g of sodium sulfite, 16 g of sodium acetate, and 65
g of chloroacetic anhydride. Heat was evolved with formation
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of a light colored precipitate which was dissolved after 15 min.
The solution gave a precipitate after stirring for 1 h. This
mixture was poured into 100 mL of ice-water mixture and
stirred for 5 min and then filtered. The product was washed
with 10 mL of cold ethanol and filtered. The filtrate upon
standing overnight gave more of the product. The total weight
of the product was 3.61 g (50%). It was recrystallized from
ethanol-water: mp194-196 °C; 1H NMR (DMSO-d6) δ 2.71
(s, 3H), 4.37 (s, 2H), 4.44 (s, 2H), 7.43 (d, 1H, J ) 8.8), 8.15 (d,
1H, J ) 8.8), 8.16 (s, 1H), 9.89 (br s, 1H), 10.18 (br s, 1H);
EIMS, m/z, 341/343 (M+ 1.5/1, 52), 305 (60), 292 (base), 264
(28), 228 (60), 188 (70), 160 (17); HRMS calculated for C14H13Cl2N3O3 341.033397, found 341.033888; Elemental analysis:
calculated for C, 49.14; H, 3.83; Cl, 20.72; N, 12.28, found C,
49.24; H, 3.89; Cl, 20.43; N, 12.6.
7-Chloroacetamido-2-methylquinoline-5,8-dione (41).
In a 500 mL round-bottomed flask, equipped with a magnetic
bar, 5,7-bis(chloroacetamido)-8-hydroxy-2-methylquinolie (3.42
g, 0.01 mol) was suspended in 122 mL of glacial acetic acid.
To this, a solution of potassium dichromate (8.8 g, 0.03 mol)
in 115 mL of water was added and stirred overnight at room
temperature. The solution was extracted with dichloromethane
(12 × 50 mL). The organic extracts were washed with 200 mL
of sodium bicarbonate solution, dried with magnesium sulfate,
and then evaporated under reduced pressure to give a bright
yellow solid (1.56 g, 59%). Recrystallization from ethyl acetate
gave the pure product: mp 196-200 °C (dec); 1H NMR (CDCl3)
δ 2.76 (s, 3H), 4.23 (s, 2H), 7.56 (d, 1H, J ) 8.1), 7.89 (s, 1H),
8.30 (d, 1H, J ) 8.1), 9.48 (br s, 1H); EIMS, m/z, 264/266 (M+
2.9/1), 229 (62), 215 (74), 201 (43), 188 (86), 161 (base), 132
(21); HRMS calculated for C14H9ClN2O3 264.03107 found
264.029824; Elemental analysis calculated for C, 54.19; H,
3.43; Cl, 13.40; N, 10.58, found C, 54.19; H, 3.37; Cl, 13.29; N,
10.36.
7-Chloroacetamido-2-formyl-5,8-quinolinedione (4). In
a 25 mL round-bottomed flask, equipped with a magnetic bar,
water-cooled reflux condenser, and argon-filled balloon, dione
41 (0.529 g, 2 mmol), selenium dioxide (0.332 g, 3 mmol), 12
mL of dried distilled dioxane, and 0.25 mL of water were
stirred and slowly heated to reflux over a 2 h period. To
complete the reaction, the mixture was refluxed for 17 h (TLC).
An additional 10 mL of dioxane was added and refluxed for
10 min and then filtered off hot. The filter cake was placed in
a round-bottomed flask, and 10 mL of dichloromethane was
added and refluxed for 10 min and then filtered. The filtrates
were combined and then evaporated to dryness under reduced
pressure. The solid residue was dissolved in 50 mL of dichloromethane, placed in a separatory funnel, and washed with
3% sodium bicarbonate solution. The aqueous layers were
extracted with 3 × 50 mL of dichloromethane and the
combined organic layers were dried (MgSO4) and evaporated
to give 0.25 g (45%) of a yellow product: mp 190-192 °C; 1H
NMR (CDCl3) δ 4.26 (s, 2H), 8.04 (s, 1H), 8.33 (d, 1H, J ) 8.1),
8.62 (d, 1H, J ) 8.1), 9.54 (br s, 1H), 10.28 (s, 1H); EIMS, m/z,
278/280 (M+ 2.7/1, 95), 243 (33), 229(33), 215 (55), 202 (base),
175 (61); HRMS calculated for C14H9ClN2O3 278.009435, found
278.00876.
Tryptophan n-Pentyl Ester (8). This ester was prepared
according to the method used for the preparation of 9 in 80%
yield as a thick yellow oil. 1H NMR (CDCl3) δ 0.89 (t, 3H, J )
6.6), 1.1-1.3 (m, 2H), 1.4-1.7 (m, 4H), 2.9-3.7 (m, 2H), 3.703.80 (m, 1H), 4.02 (t, 2H, J ) 6.7), 6.98 (s, 1H), 7.01-7.2 (m,
2H), 7.22 (d, 1H, J ) 7.6), 7.56 (d, 1H, J ) 7.6), 8.14 (br s,
1H); HRMS calculated for C16H22N2O2 (M+) 274.1676, found
274.1678.
Tryptophan Isoamyl Ester (9). Isoamyl alcohol was dried
over anhydrous cupric sulfate for 24 h and then distilled under
argon. Tryptophan (1.43 g, 7 mmol) was placed in a 100 mL
round-bottomed flask along with 60 mL of the dried isoamyl
alcohol and 10 mL of HCl/ether solution. The solution was
refluxed in an oil bath for 22 h. The mixture was then
rotaevaporated to dryness. A portion of the resulting tryptophan isoamyl ester hydrochloride (723 mg, 2.84 mmol) was
suspended in 36 mL of ethyl acetate. To this stirred suspen-

sion, a 14% solution of ammonium hydroxide (∼3 mL) was
added until the aqueous layer was at pH ) 8. The aqueous
layer was separated, and the organic layer was washed with
a saturated sodium chloride solution (3 × 2 mL) and water (2
mL) and dried over magnesium sulfate. The solution was
filtered and rotaevaporated to dryness. The thick liquid was
further dried under a vacuum pump at 50-60 °C for 2 days.
The total weight of the product was 1.6 g (83%): mp 50 °C
(Dec.); 1H NMR (CDCl3) δ 0.90 (d, 6H, J ) 6.3), 1.60 (m, 4H),
2.99-3.22 (m, 2H), 3.81 (m, 1H), 4.10 (t, 2H, J ) 6.7), 7.00 (s,
1H), 7.10 (m, 1H), 7.20 (m, 1H), 7.33 (d, 1H, J ) 7.6), 7.59 (d,
1H, J ) 7.3), 8.08 (br s, 1H); HRMS calculated. For C16H22N2O2
(M+) 274.1676, found 274.1676.
Tryptophan n-Hexyl Ester (10). Ester 10 was prepared
by a similar method as that for ester 9 in 87% yield as thick
oil. 1H NMR (CDCl3) δ 0.89 (t, 3H, J ) 7.0), 1.20-1,40 (m,
4H), 1.50-1.75 (m, 4H), 2.90-3.40 (m, 2H), 3.78-3.90 (m, 1
H), 4.1 (t, 2H, J ) 7.0), 7.09 (s, 1H), 7.16-7.25 (m, 2H), 7.37
(d, 1H, J ) 8.0), 7.64 (d, 1H, J ) 6.6), 8.12 (br s, 1H); HRMS
calculated for C17H24N2O2 (M+) 288.1832, found 288.1824.
N-Carbobenzyloxytryptophan Succinimide Ester (60).
In a 100 mL round-bottomed flask equipped with a magnetic
bar and an argon-filled balloon, N-carbobenzyloxytryptophan
(2.132 g, 6.3 mmol), N-hydroxysuccinimide (0.725 g, 6.3 mmol),
and 50 mL dried, distilled dioxane were placed. The reaction
mixture was stirred until a clear solution was obtained, the
flask was kept in a cold-water bath at 12 °C (dioxane freezes
at 11 °C), and N-dicyclohexylcarbodiimide (1.3 g, 6.3 mmol)
was added. A white precipitate was immediately formed. The
mixture was stirred at 15-20 °C for 2 h and then at room
temperature for another 2 h. The mixture was allowed to stand
in refrigerator overnight and then filtered. The solid was
washed with dioxane (2 × 3 mL). The filtrate was rotaevaporated to a thick liquid and then kept on a vacuum pump for 3
days to give a white solid. The total weight of the product was
3.19 g (>100%). Some dioxane (shown by NMR) was still
present in the product that was taken into consideration when
59 was used in the following reactions. An analytical sample
was obtained by silica gel plate chromatography using EtOACacetone-MeOH (1:1:0.5) as the eluant. The yield of the pure
product was 89%; mp 64 °C; 1H NMR (CDCl3) δ 2.73 (s, 4H),
3.42-3.50 (m, 2H), 5.07-5.17 (m, 3H), 7.07 (dd, 1H, J ) 7.0),
7.07-7.14 (m, 1H), 7.13 (dd, 1H, J ) 8.0), 7.17 (s, 1H), 7.34 (s,
5H), 7.54 (d, 1H, J ) 7.4), 8.27 (br s, 1H); HRMS calculated
for C23H21N3O6 435.1430, found 435.1428.
N-Carbobenzyloxytryptophan Piperidine Amide (61).
In a 50 mL round-bottomed two-necked flask equipped with a
magnetic bar and an argon-filled balloon, ester 60 (0.435 g, 1
mmol), piperidine (0.085 g, 1 mmol), dried distilled triethylamine (0.14 mL, 1.4 mmol), absolute ethanol (13 mL), and
distilled chloroform (12 mL) were placed. The reaction mixture
was stirred for 1 h at room temperature. Thin-layer chromatography showed the reaction to be completed. The mixture
was evaporated under reduced pressure to give a solid. The
material was dissolved in 90 mL of ethyl acetate and then
washed with 30 mL of water followed by 2 × 30 mL of 10%
citric acid. The solution was washed with 15 mL 1 N sodium
bicarbonate, then 5 mL of water, dried (Na2SO4), and evaporated to give a white solid. The product was dried on a vacuum
pump at 60 °C for 2 days yielding 0.32 g (80%) of the product
61: mp 64-64.5 °C; 1H NMR (CDCl3) δ 0.76-1.40 (m, 6H),
2.85-3.39 (m, 4H), 3.38-3.40 (m, 2H), 4.99-5.05 (m, 1H), 5.11
(s, 2H), 5.88 (s, 1H), 6.98 (s, 1H), 7.13 (t, 1H, J ) 7.7), 7.17 (t,
1H, J ) 6.7), 7.18 (d, 1H, J ) 6.7), 7.34 (s, 5H), 7.62 (d, 1H, J
) 7.7), 8.22 (br s, 1H); HRMS calculated for C24H27N3O3
405.2047, found 405.2048.
Tryptophan Piperidine Amide (11). In a 50 mL twonecked round-bottomed flask equipped with a magnetic bar
and an argon-filled balloon, amide 61 (0.65 g, 1.6 mmol) was
suspended in 30 mL of distilled methanol. To this mixture dry
ammonium formate (0.298 g, 4.73 mmol) and 0.298 g of 10%
Pd/C were added and stirred at room temperature. Thin-layer
chromatography showed the completion of the reaction in 30
min. The mixture was filtered and Pd/C was rinsed with 10
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mL of methanol. The filtrate was evaporated under reduced
pressure until a thick liquid with consistency and color of
honey was obtained. The thick liquid was dried on a vacuum
pump at 50-60 °C for 2 days. The product weighed 0.224 g,
(70%): mp 172-173 °C; 1H NMR (CDCl3) δ 0.77-1.37 (m, 6H),
2.88-3.37 (m, 4H), 4.12 (t, 1H, J ) 6.6), 4.73 (br s, 2H), 6.98
(d, 1H, J ) 8.0), 7.03 (dd, 1H, J ) 8.7, 7.6), 7.16 (s, 1H), 7.33
(d, 1H, J ) 8.0), 7.48 (d, 1H, J ) 7.7); HRMS calculated for
C16H22N3O (M + H)+ 272.1762, found 272.1754.
N-Carbobenzyloxytryptophan Morpholine Amide (62).
The procedure for the preparation of 62 was the same as that
for 61 yielding 0.37 g (90%) of the honey-colored product: mp
71.5-72 °C; 1H NMR (CDCl3) δ 2.37-2.83 (m 2H), 3.08-3.54
(m, 8H), 4.95-5.01 (m 1H), 5.12 (s, 2H), 5.82 (br s, 1H), 7.04
(s, 1H), 7.08-7.23 (m, 3H), 7.35 (s, 5H), 7.65 (d, 1H, J ) 7.2),
8.10 9br s, 1H); HRMS calculated for C23H25N3O4 407.1840,
found 407.1846.
Tryptophan Morpholine Amide (12). The procedure for
the preparation of 12 was the same as that for 11 to give the
product in 88% yield: mp 99-101 °C; 1H NMR (CDCl3) δ 1.82
(br s, 2H), 2.68-3.49 (m, 2H), 2.98-3.44 (m, 8H), 4.08 (t, 1H,
J ) 7.2), 7.09 (s, 1H), 7.17-7.21 (m, 2H), 7.58 (d, 1H, J ) 7.0),
8.13 (br s, 1H); HRMS calculated for C15H22N3O2 (M + H)+
273.1477, found 273.1476.
General Procedure for the Synthesis of Lavendamycins. Unless otherwise stated, lavendamycin derivatives 1423 were synthesized by the procedure described for analogue
16. For each compound, the corresponding starting materials
(Scheme 1) were mixed in the desired solvent and heated for
several hours (Table 1). The completion of each reaction was
monitored by TLC. Using a similar setup to that of 16,
lavendamycins 32, 39, 57, and 58 were also synthesized as
described in the text.
7-N-Acetyldecarboxydemethyllavendamycin (14). A
mixture of aldehyde 3 (70 mg, 0.29 mmol) and tryptamine 5
(50 mg, 0.31 mmol) in 180 mL of dry anisole was heated to
105 °C over a period of 2 h and then 10% Pd/C (70 mg) was
added and refluxed for 17 h. The reaction mixture was filtered
while hot, and the solid was washed with chloroform and then
acetone. Rotaevaporation of the filtrate gave 14 as a yellow
solid (91.6 mg, 83%): mp > 280 °C; Rf ) 0.42 (Al2O3, 0.03/100
MeOH/CH2Cl2); 1H NMR (CDCl3) δ 2.37 (s, 3H), 7.30-7.40 (m,
1H), 7.62-7.71 (m, 1H), 7.74 (d, 1H, J ) 8.0), 7.99 (s, 1H),
8.13 (d, 1H, J ) 4.8), 8.21, d, 1H, J ) 8.0), 8.45 (br s, 1H),
8.54 (d, 1H, J ) 8.0), 8.61 (d, 1H, J ) 4.8), 9.10 (d, 1H, J )
8.0), 11.64 (br s, 1H); HRMS calculated for C22H14N4O3 (M+)
382.1066, found 382.1069.
7-N-Acetyldemethyllavendamycin Methyl Ester (15).
Analogue 15 was prepared according to the method used for
16. A mixture of 0.3 mmol of each of 3 and 6 in 180 mL of dry
anisole was heated (see Table 1 for temperature and time).
The reaction mixture was evaporated to give a light yellow
solid. The solid was washed with acetone to give 64 mg of a
pure yellow product. More product (34 mg) was obtained from
the filtrate (total yield, 67%): mp > 280 °C; Rf ) 0.41 (0.01/20
MeOH/CH2Cl2); 1H NMR (CDCl3) δ 2.38 (s, 3H), 4.12 (3, 3H),
7.40 (unresolved dd, 1H, J ) 7.6), 7.76 (unresolved dd, 1H, J
) 7.6), 8.03 (m, 1H), 8.27 (d, 1H, J ) 8.2), 8.48 (br s, 1H), 8.62
(d, 1H, J ) 8.2), 9.03 (s, 1H), 9.26 (d, 1H, J ) 8.2), 11.82 (br
s, 1H); HRMS calculated for C24H16N4O5 (M)+ 440.1120, found
440.1119.
7-N-Acetyldemethyllavendamycin n-Butyl Ester (16).
In a 500 mL three-necked round-bottomed flask equipped with
a Dean-Stark trap, a magnetic bar, and under an argon flow,
7-acetamido-2-formylquinoline-5,8-dione (3, 133 mg, 0.51 mmol)
and tryptophan butyl ester (7, 124 mg, 0.52 mmol) were
dissolved in 162 mL of dry xylene and, while being stirred,
heated to reflux over a 3-h period. The yellow lemon solution
was refluxed for 5 h and evaporated in vacuo, and the residue
was dissolved in chloroform. The small amount of the brownish
solid was removed, and the solution was concentrated to near
dryness. Acetone, 2 mL, was added and the resulting solid
material was filtered, washed with a small portion of acetone,
and dried under vacuum. The orange solid weighed 155 mg

(63%): mp 256-257 °C; Rf ) 0.74 (1/100 MeOH/CH2Cl2); 1H
NMR (CDCl3) δ 1.05 (t, 3H, J ) 7.0), 1.5-1.62 (m, 2H), 1.841.94 (m, 2H), 2.36 (s, 3H), 4.51 (t, 2H, J ) 7.0), 7.4 (unresolved
dd, 1H, J, Jʹ′ = 7.3, 1H), 7.64-7.70 (m, 1H), 7.72 (d, 1H, J )
8.1), 7.97 (s, 1H), 8.24 (d, 1H, J ) 8.1), 8.4 (br s, 1H), 8.53 (d,
1H, J ) 8.4), 8.94 (s, 1H), 9.17 (d, 1H, J ) 8.4), 11.77 (br s,
1H); HRMS (FAB) calculated for C27H25N4O5 (M + 3H)+
485.1825, found 485.1827.
7-N-Acetyldemethyllavendamycin n-Pentyl Ester (17).
Analogue 17 was synthesized according to the procedure used
for 16 in 44% yield as an orange solid: mp 232-233 °C; Rf )
0.68 (1/100 MeOH/CH2Cl2); 1H NMR (CDCl3) δ 0.99 (t, 3H, J
) 6.9), 1.40-1.80 (m, 4H), 1.8-2.0 (m, 2H), 2.35 (s, 3H), 4.48
(t, 2H, J ) 6.6), 7.30-7.40 (m, 1H), 7.50-7.65 (m, 2H), 7.86
(s, 1H), 8.17 (d, 1H, J ) 8.0), 8.29 (br s, 1H), 8.36 (d, 1H, J )
8.4), 8.89 (s, 1H), 9.02 (d, 1H, J ) 8.4), 11.56 (br s, 1H); HRMS
(FAB) calculated for c28H27N4O5 (M + 3H)+ 499.1981, found
499.1980.
7-N-Acetyldemethyllavendamycin Isoamyl Ester (18).
Compound 18 was prepared according to the method similar
to that of 16. A mixture of 0.5 mmol of each of the starting
materials 3 and 9 in 160 mL of dry xylene was heated to 78
°C over a period of 4 h and then heated to 125 °C over 10 min
and kept at 125-130 °C for 5.5 h. The reaction mixture was
allowed to cool to room temperature, and the brown solid
impurity was filtered. The filtrate containing the product was
concentrated to near dryness and then washed with a small
amount of acetone to give 84 mg of an orange yellow solid.
More product was obtained from the concentration of the
filtrate (total yield, 128 mg, 50%): mp 257.5-258 °C; Rf ) 0.64
(1/100 MeOH/CH2Cl2); 1H NMR (CDCl3) δ 1.06 (d, 6H, J ) 6.3),
1.8-1.9 (m, 3H), 2.38 (s, 3H), 4.54 (t, 2H, J ) 6.8), 7.35-7.45
(m, 1H), 7.63-7.80 (m, 2H), 8.01 (s, 1H), 8.27 (d, 1H, J ) 7.7),
8.45 (br s, 1H), 8.58 (d, 1H, J ) 8.3), 8.97 (s, 1H), 9.22 (d, 1H,
J ) 8.3), 11.80 (br s, 1H); HRMS calculated for C28H24N4 O5
(M+) 496.1760, found 496.1756.
7-N-Acetyldemethyllavendamycin n-Hexyl Ester (19).
This compound was synthesized using the method for the
preparation of 16. The orange solid was obtained in 54%
yield: mp 228-230 C; Rf ) 0.51 (1/100 MeOH/CH2Cl2); 1H
NMR (CDCl3) δ 0.94 (t, 3H, J ) 7.0), 1.36-1.50 (m, 4H), 1.501.60 (m, 2H), 1.80-2.0 (m, 2H), 4.48 (t, 2H, J ) 6.8), 7.307.42 (m, 1H), 7.60-7.70 (m, 2H), 7.90 (s, 1H), 8.16 (d, 1H, J )
8.0), 8.33 (s, 1H), 8.60 (d, 1H, J ) 8.4), 8.87 (s, 1H), 9.07 (d,
1h, J ) 8.4), 11.64 (s, 1H); HRMS calculated for C29H29N4O5
(M + 3H)+ 513.2138, found 513.2139.
7-N-Acetyldemethyllavendamycin Piperidine Amide
(20). In a method similar to that used for the preparation of
16, a mixture of 0.55 mmol of aldehyde 3 in 300 mL of dry
anisole was heated to 70 °C, and then in a dropping funnel, a
solution of 0.55 mmol of tryptophan piperidine amide in 6 mL
of dry pyridine was dropwise added and heated for the required
amount time (Table 1). The reaction mixture was cooled to
room temperature, and the solid was filtered, washed with 10
mL of dichloromethane followed by 25 mL of ethyl acetate,
and then vacuum-dried to yield 120 mg of a brown product.
The filtrate was evaporated, and from the solid residue more
product (34 mg) was recovered through flash chromatography
using chloroform as the eluting solvent (total yield, 56%): mp
250 °C (dec); Rf ) 0.39 (0.01/5 MeOH/CH2Cl2); 1H NMR (CDCl3)
δ 1.70-1.77 (m, 6H), 2.43 (s, 3 H), 3.71-3.89 (m, 4H), 7.287.32 (m, 1H), 7.59-7.61 (m, 2H), 7.99 (s, 1H), 8.09 (d, 1H, J )
8.4), 8.32 (d, 1H, J ) 8.4), 8.41 (s, 1H), 8.92 (d, 1H, J ) 8.4),
11.44 (br s, 1H); HRMS calculated for C28H24N5O4 (M + H)+
494.1828, found 494.1834.
7-N-Acetyldemethyllavendamycin Morpholine Amide
(21). In a method similar to that used for the synthesis of 16,
compound 21 was synthesized according to the method used
for 20 as an orange solid in a total yield of 57%: mp > 300 °C;
Rf ) 0.38 (0.03/5 MeOH/CH2Cl2); 1H NMR (CDCl3) δ 2.40 (s,
3H), 3.79-3.96 (m, 8H), 7.38-7.41 (m, 1H), 7.65-7.8 (m, 2H),
8.03 (s, 1H), 8.20 (d, 1H, J ) 8.1), 8.5-8.65 (m, 3H), 8.97 (d,
1H, J ) 8.3), 11.67 (br s, 1H); HRMS calculated for C27H24N5O5
(M + 3H)+ 498.1777, found 498.1781.
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7-N-Acetyldecarboxydemethyl-2ʹ′-(hydroxymethyl)lavendamycin (22). Compound 22 was prepared by the
condensation of 0.15 mmol of 3 and 0.15 mmol of 13 in
60 mL of anisole. The mixture was heated to155 °C over
a period of 4 h and then allowed to cool to room temperature.
The yellow solid product was filtered, washed with acetone,
and dried under vacuum (29.4 mg, 48%): mp > 280 °C;
Rf ) 0.39 (EtOAC); 1H NMR (CDCl3) δ 2.31 (s, 3H), 4.88
(d, 1H, J ) 5.9), 5.58 (t, 1H, J ) 5.9), 7.33-7.38 (m,
1H), 7.63-7.71 (m, 2H), 7.82 (s, 1H0, 8.41 (d, 1H, J )
7.7), 8.54 (d, 1H, J ) 8.0), 8.96 (d, 1 H, J ) 8.0), 10.29
(br s, 1H), 11.67 (br s, 1H); HRMS calculated for C23H16N4O4
(M+) 412.1171, found 412.1175.
7-N-Chloroacetyldemethyllavendamycin Isoamyl Ester (23). A mixture of 0.18 mmol of 4 and 0.18 mmol of 9 in
75 mL of dry xylene was heated slowly to 76 °C over 5 h. The
mixture was filtered hot to remove the impurity, and the
filtrate was concentrated under reduced pressure to about 10
mL. The solution was kept in a refrigerator overnight to give
a dark orange-brown solid. The solid was filtered and washed
with cold ethyl acetate yielding 25 mg of the product. Further
concentration of the filtrate afforded more product (total 40.5
mg, 43%): mp 280-284 °C; Rf ) 0.40 (0.008/5 MeOH/CHCl3);
1
H NMR (CDCl3) δ 1.05 (d, 6H, J ) 6.3), 1.76-1.95 (m, 3H),
4.29 (s, 2H), 4.52 (t, 2H, J ) 6.8), 7.39 (unresolved dd, 1H, J
) 8.0), 7.78 (d, 1H, J ) 8.0), 7.95 (s, 1H), 8.23 (d, 1H, J ) 8.0),
8.54 (d, 1H, J ) 8.3), 8.93 (s, 1H), 9.18 (d, 1H, J ) 8.3), 9.56
(s, 1H), 11.76 (br s, 1H); HRMS calculated for C28H23ClN4O5
530.1357, found 530.1358.
7-N-Acetyl-6-pyrrolidinolavendamycin Methyl Ester
(24). To a stirred solution of 7-acetyllavendamycin methyl
ester41,42 (3, 50 mg, 0.11 mmol) in dry chloroform (30 mL) was
added pyrrolidine (0.2 mL, 170 mg, 2.4 mmol), and the
resulting red-brown solution was allowed to stir at room
temperature for 2 h. The reaction mixture was rotaevaporated
to dryness. The solid was washed with ether (10 mL) and dried
under vacuum pump to afford 51 mg (88%) of the product as
a reddish brown powder: mp 210 °C (dec); Rf ) 0.13 (Et OAC/
CH2Cl2 1/1); 1H NMR (DMSO-d6) δ 1.75-1.96 (br m. 4H), 2.11
(s, 3H), 3.11 (3H, s), 3.11 (s, 3H), 3.78-3.58 (br m, 4H), 3.98
(s, 3H), 7.48-7.41 (m, 1H), 7.70-7.76 (m, 1H), 7.82 (d, 1H, J
) 7.9), 8.45 (d, 1H, J ) 7.9), 8.50 (d, 1H, J ) 8.2), 8.78 (d, 1H,
J ) 8.2), 9.33 (s, 1H), 12.36 (s, 1H); EAB-HRMS calculated
for C29H25N5O5Na (M + Na)+ 546.1753, found 546.1779.
7-N-Acetyl-6-aziridinodemethyllavendamycin Amide
(25). To a stirred solution of 7-acetyldemethyllavendamycin
amide38 (5, 50 mg, 0.12 mmol) in dry chloroform (25 mL) and
dry ethanol (25 mL) was added aziridine (0.7 mL, 58 mg, 13.5
mmol), and the resulting reddish brown solution was allowed
to stir at room temperature for 48 h. Then the reaction mixture
was rotaevaporated to dryness. The solid was washed with
ether (10 mL) and further dried under a vacuum pump to
afford 52 mg (93%) of the product as a reddish brown powder:
mp > 260 °C; Rf ) 0.88 (MeOH/CH2Cl2 1/10); 1H NMR (DMSOd6) δ 2.17 (s, 3H), 2.39 (s, 4H), 7.38-7.44 (m, 1H), 7.68 (s, 1H),
7.69-7.74 (m, 1H), 7.83 (d, 1H, J ) 8.2), 8.49-8.55 (m, 2H),
8.62 (s, 1H), 9.07 (s, 1H), 9.45 (d, 1H, J ) 8.2), 9.57 (s, 1H),
12.05 (s, 1H); HRMS calculated for C25H19N6O4 (M + H)+
467.1468, found 467.1480.
7-Amino-6-chloro-2-formylquinoline-5,8-dione (46). In
a dry 100 mL round-bottomed two-necked flask, equipped with
a magnetic bar and water-cooled reflux condenser under argon,
7-amino-6-chloro-2-methylquinoline-5,8-dione44 (30, 133.8 mg,
0.6 mmol), selenium dioxide (106.6 mg), 20 mL of dried and
distilled 1,4-dioxane, and 0.09 mL of water were stirred at
reflux in an oil bath for 23 h. The reaction was monitored by
TLC. The mixture was hot filtered, and the solid was washed
with hot chloroform. The filtrate was rotaevaporated to dryness. The dried material was dissolved in 480 mL of chloroform
and washed with saturated sodium chloride solution (4 × 60
mL). The solution was dried over magnesium sulfate and
rotaevaporated to dryness and then further dried under a
vacuum pump. The product weighed 105.2 mg (74%): mp 220
°C (dec); 1H NMR (CDCl3) δ 5.6 (br s, 2H), 8.28 (d, 1H, J )

8.1), 8.67 (d, 1H, J ) 8.1), 10.30 (s, 1H); HRMS calculated for
C10H6ClN2O3 (M+H)+ 237.0061, found 237.0068.
6-Chlorolavendamycin Methyl Ester (32). In a setup
similar to that used for the synthesis of 16, 7-amino-6-chloro2-formylquinoline-5,8-dione (31, 118.5 mg, 0.5 mmol) was
placed with β-methyltryptophan methyl ester43 (115 mg, 0.5
mmol) in 300 mL of dry anisole. The solution was stirred and
heated slowly to 130 °C over 3 h. The reaction mixture was
refluxed for 1 h. The mixture was then cooled to room
temperature under argon. The solvent was rotaevaporated to
dryness, and then the solid was washed with acetone (20 mL).
The resulting solid was vacuum filtered and dried under a
vacuum pump. The product weighed 131.9 mg (59%): mp >
270 °C, Rf ) 0.09 (CHCl3, twice developed); 1H NMR (CDCl3)
δ 3.22 (s, 3H), 4.08 (s, 3H), 5.70 (br s, 2H), 7.38-7.45 (m, 1H),
7.65-7.71 (m, 1H), 7.80 (d, 1H, J ) 8.0), 8.38 (d, 1H, J ) 7.7),
8.61 (d, 1H, J ) 8.4), 9.10 (d, H, J ) 8.4), 11.89 (br s, 1H),
CIMS m/e (relative intensity) 446.1 (M+, 100), 416.0 (10.3),
386.0 (64.4), 351.1 (22.0), 113.0 (9.0); HRMS calculated for
C23H15N4O4Cl 446.0849, found 446.0781.
5,7-Dibromo-8-hydroxy-2-methylquinoline (55). The
procedure for the preparation of 55 was similar to that of 56,
except that after the evaporation of the combined filtrates the
dry residue was dissolved in 100 mL of chloroform, filtered,
and then concentrated to small volume. The solution was kept
in the refrigerator for a day to give a yellow product (455, mg,
29%): mp 234-235 °C; 1 H NMR (DMSO-d6) δ 8.14 (d, 1H, J
) 8.8), 8.25 (s, 1H), 8.63 (d, 1H, J ) 8.8), 10.19 (s, 1H), 11.31
(br s, 1H); HRMS calculated for C10H5Br2NO2 328.8667, found
328.8667.
3-Carbomethoxy-1-(5,7-Dibromo-8-hydroxquinoline-2yl)-4-methyl-β-carboline (57). In a setup similar to that used
for 16, 5,7-dibromo-2-formyl-8-hydroxyquinolie (165.5 mg, 0.5
mmol) and β-methyltryptophan methyl ester (115.5 mg, 0.5
mmol) in 70 mL of dry anisole were mixed. Heat was
introduced, and the temperature was raised to reflux over a
3-h period and then refluxed for 39 more h. The reaction
mixture was evaporated under reduced pressure, and the solid
was dried under vacuum. The crude yellow solid weighed 217
mg, (80%). An analytical sample was obtained as follows: The
material was stirred in a small volume of dichloromethane
giving an orange solid. The filtrate was allowed to stand at
room temperature to produce more of the pure 57: mp 248 °C
(dec); Rf ) 0.62 (0.3/5 pet. ether/EtOAC); 1H NMR (CDCl3) δ
3.13 (s, 3H), 3.99 (s, 3H), 7.43 (dd, 1H, J ) 8.1, 7.0), 7.72 (dd,
1H, J ) 8.1, 7.0), 7.91 (d, 1H, J ) 8.1), 8.17 (s, 1H), 8.44 (d,
1H, J ) 8.1), 8.68 (d, 1H, J ) 8.8), 8.95 (d, 1H, J ) 8.8), 12.23
(br s, 1H); HRMS calculated for C23H15Br181Br1N3O3 540.9454,
found 540.9459.
7-Bromodeaminolavendamycin Methyl Ester (34). In
a 500 mL round-bottomed flask equipped with a condenser, a
dropping funnel, a magnetic bar, and an argon-filled balloon,
a mixture of 63.5 mg (0.117 mmol) of the crude 57 in 200 mL
of acetonitrile-water (2/1, v/v) was dropwise added to a cold
solution of 110.7 mg (0.257 mmol) of bis(trifluroacetoxy)iodobenzene in 33 mL of acetone-water (2/1, V/V) at 0 °C over
2 h and 40 min. The reaction mixture was stirred at this
temperature for 6 more h. The mixture was evaporated under
reduced pressure to remove acetonitrile and then extracted
with chloroform (3 × 40 mL). The combined extracts were dried
(MgSO4) and evaporated to give an impure orange product.
Flash chromotography (CHCl3/EtOAC 250/3) gave 25.75 mg
(46%) of the orange product 34: mp 209 °C (dec); Rf ) 0.62
(0.4/5 EtOAC/CH2Cl2); 1H NMR (CDCl3) δ 3.21 (s, 3H), 4.08
(s, 3H), 7.35-7.45 (m, 1H), 7.60 (s, 1H), 7.65-7.7 (m, 1H), 7.81
(d, 1H, J ) 8.0), 8.35 (d, 1H, J ) 8.0), 8.50 (d, 1H, J ) 8.2),
9.09 (d, 1H, J ) 8.4), 11.90 (br s, 1H); HMRS calculated for
C23H14BrN3O4 475.0162, found 475.0143.
Decarboxy-2ʹ′-(hydroxymethyl)-demethyllavendamycin (37). In a dry 5 mL round-bottomed flask equipped with
a condenser, a magnetic bar, and an argon-filled balloon, a
mixture of acetamido compound 22 (24 mg, 0.0582 mmol) in 1
mL of 70% sulfuric acid solution (H2SO4/H2O 70/30, v/v) was
heated in an oil bath at 60 °C for 2 h. The reaction mixture
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was treated with a saturated solution of sodium carbonate to
pH of 9 and then extracted with EtOAC (5 × 20 mL). The
combined organic layers were washed with brine (2 × 10 mL),
dried (MgSO4), and evaporated under reduced pressure to give
19 mg (88%) of a red solid: mp 255-260 °C (dec); Rf ) 0.59
(0.4/5 MeOH/CH2Cl2); 1H NMR (DMSO-d6) δ 4.85 (d, 2H), 5.54
(br s, 1H), 5.93 (br s, 2H), 7.33 (dd, 1H, J ) 7.2), 7.64 (dd, 1H,
J ) 7.2), 7.69 (d, 1H, J ) 8.0), 8.36-8.38 (m, 2 H), 8.46 (d,
1H, J ) 8.0), 8.88 (d, 1H, J ) 8.0), 11.64 (br s, 1 H); HRMS
calculated for C21H14N4O3 370.1066, found 370.1072.
Decarboxydemethyllavendamycin (38). In a method
similar to that of 37, 20 mg (0.052 mmol) of compound 14 in
2.4 mL of 70% H2SO4 was heated at 60 °C for 4 h to give 38 as
a red solid (15 mg, 85%): mp > 270 °C; Rf ) 0.47 (0.2/5 MeOH/
CH2Cl2); 1H NMR (DMSO-d6) δ 5.94 (br s, 2H), 7.3-7.4 (m,
1H), 7.65-7.8 (m, 2H), 8.36-8.38 (m, 2H), 8.48 (d, 1H, J )
8.0), 8.59 (d, 1H, J ) 8.4), 8.91 (d, 1H, J ) 8.4), 11.77 (br s,
1H); HRMS calculated for C20H12N4O2 340.0960, found 340.0597.
2-Formyl-8-hydroxyquinoline (56). In a 500 mL roundbottomed flask equipped with a magnetic bar, an argon-filled
balloon, and a water-cooled condenser, 8-hydroxy-2-methylquinoline (54, 2 g, 12.4 mmol), selenium dioxide (1.74 g, 15.8
mmol), 300 mL of dried and distilled 1,4-dioxane, and 1.5 mL
of water were mixed. The reaction mixture was heated, and
the temperature was raised to reflux over a 2.5 h period. The
mixture was refluxed for 21.5 h when thin-layer chromatography showed the completion of the reaction. The reaction
mixture was filtered off, and the selenium metal was washed
with 160 mL of dichloromethane. The combined filtrates were
evaporated under reduced pressure to dryness. The residue
was sublimed (at 81 °C, 0.15 mm/Hg) to give a pure yellow
solid (1.337 g, 61%): mp 95-96 °C; 1H NMR (CDCl3) δ 7.27
(d, 1H, J ) 7.9), 7.42 (d, 1H, J ) 8.3), 7.62 (t, 1H, J ) 7.8),
8.03 (s, 1H), 8.1 (d, 1H, J ) 12.7), 8.31 (d, 1H, J ) 8.2), 10.21
(s, 1H); MS m/z 174 (M+H)+, 173 and 172; Analysis for C10H7NO2 calculated C, 69.36; H, 4.07; N, 8.09, found C, 69.34; H,
4.2; N, 8.06.
1-(8-Hydroxyquinoline-2-yl)-β-carboline (58). In a 100
mL three-necked round-bottomed flask equipped with a condenser, a magnetic bar, and flowing argon, 2-formyl-8-hydroxyquinoline (56, 35.5 mg, 0.2 mmol), tryptamine (32.6 mg, 0.2
mmol) and 20 mL of dried distilled anisole were mixed
together. The mixture was heated, and the temperature was
raised to reflux over the course of 4 h and then refluxed for 22
h. To the mixture was added 10 mg of 5% Pd/C, and after 7
more hours of reflux another 5 mg of Pd/C was added and then
refluxed for 20 more hours. The mixture was filtered and
rotaevaporated to dryness. The material was recrystallized
from acetone giving 48 mg (76%) of a yellow solid: mp 276279 °C; Rf ) 0.12 (0.4/5 MeOH/CH2Cl2); 1H NMR (DMSO-d6)
δ 7.28 (m, 1H), 7.34 (dd, 1H, J ) 7.6), 7.52 (d, 1H, J ) 5.0),
7.65 (dd, 1H, J ) 8.0, 7.8), 7.77 (d, 1H, J ) 8.0), 8.32 (d, 1H,
J ) 5.0), 8.36 (d, 1H, J ) 8.0), 8.51 (d, 1H, J ) 8.8), 8.59 (d,
1H, J ) 5.0), 8.82 (d, 1H, J ) 8.8), 10.35 (s, 1H), 12.16 (br s,
1H); HRMS calculated for C20H13N3O 311.1058, found 311.1045.
Deaminodecarboxydemethyllavendamycin (39). Compound 39 was obtained in a procedure similar to that of 34
except that the reaction was performed in a 250 mL flask. A
solution of 3-carbomethoxy-1-(8-hydroxyquinoline-2-yl)-β-carboline (58, 15 mg, 0.048 mmol) in 120 mL of acetonitrile-water
(2/1, v/v) was dropwise added to a solution of bis[(trifluoroacetoxy)iodo]benzene (41.5 mg, 0.096 mmol) in 7.5 mL of acetonitrile-water at 0 °C over a 2 h period. The mixture was
allowed to stir at this temperature for another 2 h and then
evaporated in vacua to remove acetonotrile. The residue was
extracted with dichloromethane (3 × 25 mL), dried (MgSO4),
and evaporated to give 12 mg (77%) of the orange product 39:
mp 227-229 °C (dec); Rf ) 0.33 (0.003/5 MeOH/CH2Cl2); 1H
NMR (CDCl3) δ 7.07 (dd, 1H, J ) 10.4), 7.16 (dd, 1 H, J )
10.4), 7.31 (dd, 1 H, J ) 7.2), 7.62 (dd, 1H, J ) 7.2), 7.75 (d, 1
H, J ) 8.0), 8.10 (d, 1H, J ) 5.0), 8.17 (d, 1H, J ) 7.8), 8.50
(d, 1H, J ) 8.4), 8.58 (d, 1H, J ) 5.0), 9.02 (d, 1H, J ) 8.4),
11.69 (br s, 1H); HRMS calculated for C20H11N3O2 325.0851,
found 325.0862.

Electrochemistry. Cyclic voltammetry (CV) for 14 lavendamycin analogues was conducted using a BAS CV-50W
electrochemical analyzer equipped with a standard threeelectrode cell. This cell was designed to allow the tip of the
reference electrode to approach closely to the working electrode. Voltammetric experiments were performed using Ag/
AgCl as the reference electrode, a glossy carbon (GC) rod as
the working electrode, and a platinum (Pt) wire as the
auxiliary electrode. Potential data are referred to the Ferrocene (0/+) couple, which is oxidized in DMSO at +0.52 V vs
Ag/AgCl. Positive-feedback iR compensation was routinely
applied. The working electrode was regularly polished using
alumina. Typically, a solution containing 1 mM of the lavendamycin analogues and 0.1 M supporting electrolyte (tetrabutylammonium hexafluorophosphate, Bu4NPF6) was prepared
using dried dimethyl sulfoxide (DMSO). All samples were
purged with argon prior to use and kept under a continuous
flow of argon during the course of the experiments. All CV
data were recorded at a potential range between 0.00 and
-2.00 V and at potential sweep rates of 50 to 500 mV/s. All
measurements were performed at 22 ( 1 °C.
Biological Studies. Cell Culture. BE-WT and BE-NQ
cells were a gift from Dr. David Ross (University of Colorado
Health Sciences Center, Denver, CO). Cells were grown in
minimum essential medium (MEM) with Earle’s salts, nonessential amino acids, L-glutamine and penicillin/streptomycin
and supplemented with 10% fetal bovine serum (FBS), sodium
bicarbonate and HEPES. Cell culture medium and supplements were obtained from Gibco, Invitrogen Co., Grand Island,
NY. The cells were incubated at 37 °C under a humidified
atmosphere containing 5% CO2.
Cytochrome c Assay. Lavendamycins analogues reduction
was monitored using a spectrophotometric assay in which the
rate of reduction of cytochrome c was quantified at 550 nm.
Briefly, the assay mixture contained cytochrome c (70 µM),
NADH (1 mM), human recombinant NQO1 (0.1-3 µg) (gift
from Dr. David Ross, University of Colorado Health Sciences
Center, Denver, CO), and lavendamycins (25 µM) in a final
volume of 1 mL of Tris-HCl (25 mM, pH 7.4) containing 0.7
mg/mL BSA and 0.1% Tween-20. Reactions were carried out
at room temperature and started by the addition of NADH.
Rates of reduction were calculated from the initial linear part
of the reaction curve (0-30 s), and results were expressed in
terms of µmol of cytochrome c reduced/min/mg of NQO1 using
a molar extinction coefficient of 21.1 mM-1 cm-1 for cytochrome
c. All reactions were carried out in triplicate.
MTT Assay. Growth inhibition was determined using the
MTT colorimetric assay. Cells were plated in 96-well plates
at a density of 10000 cells/mL and allowed to attach overnight
(16 h). Lavendamycin analogues solutions were applied in
medium for 2 h. Lavendamycin analogues solutions were
removed and replaced with fresh medium and 96-well plates
were incubated at 37 °C under a humidified atmosphere
containing 5% CO2 for 4-5 days. MTT (50 µg) was added, and
the cells were incubated for another 4 h. Medium/MTT
solutions were removed carefully by aspiration, the MTT
formazan crystals were dissolved in 100 µL of DMSO, and
absorbance was determined on a plate reader at 560 nm. IC50
values (concentration at which cell survival equals 50% of
control) were determined from semilog plots of percent of
control vs concentration. Selectivity ratios were defined as the
IC50 value for the BE-WT cell line divided by the IC50 value
for the BE-NQ cell line.
Clonogenic Assay. Cells were harvested from logarithmicphase growing cultures and plated at densities of 1000 cells
per 100-mm dish to yield a readily quantifiable number of
colonies at the end of the experiment. After 24 h, cells were
treated with lavendamycin analogues, 2% DMSO (drug vehicle), or no treatment (control) for 2 h at 37 °C. After 2 h,
drug-containing medium was replaced with fresh drug-free
medium. Cells were incubated at 37 °C under a humidified
atmosphere containing 5% CO2 for 12 days. Then, the medium
was removed, and colonies were washed twice with PBS, fixed
and stained with 0.1% (w/v) Coomassie Blue dye in 30%
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methanol and 10% acetic acid for 1-2 min. Surviving colonies
(>50 cells) were counted and the surviving fraction determined
by dividing the number of colonies in a treatment dish by the
number of colonies in the control dish. IC50 values (concentration at which cell survival equals 50% of control) were
determined from semilog plots of percent of control vs concentration. Selectivity ratios were defined as the IC50 value for
the BE-WT cell line divided by the IC50 value for the BE-NQ
cell line.
Molecular Modeling. Coordinates Preparation. The
coordinates of the crystal structure of human NQO1 complex
with bound FAD and 65, obtained from the Protein Data Bank
(PDB ID code: 1H6925), were used as a reference structure
for the docking experiments, and compound 65 served as the
original reference ligand. The physiological dimer in the crystal
unit was used for docking purposes. The coordinates were
locally minimized. The coordinates were subjected to energy
minimization with minimal iterations (100) by Powell minimization standard method using Minimize Subset option. This
option automatically selected 24 seed amino acid residues
surrounding the superposed ligand 37 (refer to the Docking
section below) to perform the local minimization. Default
parameters and values within the minimization dialogue were
used except where otherwise mentioned. This procedure
yielded a weighted root-mean-square distance of 0.26 Å
between the 24 corresponding nonminimized and minimized
residues in the structures. Docking calculations were performed using one of the two identical active sites.
Ligand Preparation. The structures of ligands were
sketched and prepared as MOL2 files employing the Sketch
Molecule module of SYBYL 6.9.1 software suite58 (Tripos, Inc.;
St. Louis, MO). Initially sketched ligands were subjected to
energy minimization (10000 iterations) by Powell minimization
standard method. Initial Optimization and Termination parameters were set to None and Energy Change options,
respectively. Default parameters and values within the minimization dialogue (Minimize Details) were used except where
otherwise mentioned. The final ligand conformational coordinates were stored as MOL2 files within the database.
Docking. Flexible docking was performed using the FlexX
module of SYBYL 6.9.1 software suite.58 FlexX is an automatic
docking program for conformationaly flexible ligands, employs
the three-dimensional structure of the target protein in PDB
format, and is capable of determining 30 possible conformations for each docked ligand. The final ranking order of
conformations is based on the free binding energy. This
program automatically selects the base fragment of a ligand
(the ligand core). The base fragment is then placed into the
active site of the target protein using the algorithmic approach
called pose clustering that is based upon a pattern recognition
paradigm. Subsequent incremental reconstruction of the complete ligand molecule is then performed by linking the remaining components.59,60 In this study, to define the active site, the
energy-minimized ligand 37 was superpositioned to the coordinates of the original reference ligand 65 such that overlap
was optimal. Ligand 37 was again energy minimized in the
context of the active site, and therefore the position of the
ligand within the pocket was optimized. The active site was
then defined as all the amino acid residues confined within
6.5 Å radius sphere centered on the superposed ligand 37. FAD
was introduced to the active site as a heteroatom file in MOL2
format.
Scoring Functions. The docked conformations of ligands
were evaluated and ranked using FlexX and four scoring
functions implemented in the CSCORE module in SYBYL.
CSCORE is a consensus scoring program that integrates
multiple well-known scoring functions such as FlexX and
ChemScore,61 D-Score,62 G-Score,63 and PMF-Score64 to evaluate docked conformations. Individual scoring functions are
used to predict the affinity of the ligand binding to a target
protein. CSCORE creates columns in a molecular spreadsheet
that contain raw scores for each individual scoring function.
The consensus column contains integers that range from 0 to
5; where 5 is the best fit to the model. Docked conformations

whose scores exceed the threshold for a particular function
contribute one to the value of the consensus, whereas those
with scores below the threshold add a zero.
Molecular Graphics System. The molecular graphics
images and surface representations were prepared by PyMOL
molecular graphics system version PyMOLX11Hybrid 0.9766
(Delano Scientific, San Carlos, CA). The data of the coordinates
of the NQO1 complex with bound FAD and docked conformations of ligands were prepared in PDB format as PyMOL input
files. PyMOL session files of the NQO1 active site with docked
conformations of ligands and the superimposition of clustered
conformations were created. The images were then stored as
graphic files.
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Introduction: Unexpected behavior arising from the quaternary structure of glutamate
transporters.
G.P. Leary, D.C. Holley, E.F. Stone, B.R. Lyda, C.S. Esslinger, L.V. Kalachev, and M.P.
Kavanaugh
β-2-fluorenyl-aspartylamide (2-FAA) is an aspartate analogue and a recently described
competitive inhibitor of the EAATs with selectivity for EAAT3 (Bridges et al., 2008). In this
manuscript we show that the subtype selectivity is derived not from binding affinity but instead
from a slower dissociation rate. We used EAAT3 homology models based on the 3-bromo-DLthreo-β-benzyloxyaspartate (3-Br-TBOA)-bound GltPh crystal structure (Boudker et al., 2007)
as a scaffold for computational docking of 2-FAA to determine a mechanism for the
dissociation rate. Our docking study shows that high-ranked docked poses of 2-FAA interact
with a conserved hydrophobic pocket in EAAT3 (figure 1). Though 2-FAA is structurally similar
to 3-Br-TBOA (figure B), the docking profile presented in this manuscript suggests an
alternative to the binding orientation presented in the 3-Br-TBOA-bound crystal structure.
Specifically, our results show two possible orientations for 2-FAA with higher ranking poses
assuming an ‘upward’ orientation with 2-FAA’s fluorene head group interacting with the
conserved hydrophobic pocket in EAAT3 and lower ranking poses oriented in a ‘downward’
pose more similar to that of 3-Br-TBOA in the GltPh crystal structure (figure 1b, for simplification
3-Br-TBOA is depicted as TBOA in figure 1b).
ChemScore
2-FAA
22.39
2-FAA
18.94
TBOA
18.07
TBOA
3-Br-TBOA 20.19
3-Br-TBOA 18.04

ΔG
-29.88
-24.23
-22.14
-23.09
-23.90

orientation
up
down
up
down
up
down

Table a. Docking of 2-FAA, TBOA, and 3-Br-TBOA into an EAAT3 homology model show two possible binding
orientations.

Though not included in this manuscript, we also found that DL-threo-βbenzyloxyaspartate (TBOA, a competitive inhibitor from which 3-Br-TBOA was derived)
assumed only upward orientations. Conversely, docked poses of 3-Br-TBOA ranked slightly
higher in the downward orientation (table A), suggesting that the 3-Br-TBOA-bound GltPh
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crystal structure could be inadequate as a comprehensive model for structure-based inhibitor
design.

Figure b. Stick representations of inhibitors docked into an EAAT3 homology model. 2-FAA poised in the
ʻupwardʼ orientation is colored salmon while the ʻdownwardʼ oriented pose is colored wheat. 3-Br-TBOA is
colored light blue and shown only in the downward orientation. TBOA (light grey) from the GltPh crystal structure
(2NWX) was imported as a reference.

For brevity and simplicity, I have included only the portions of the manuscript that specifically
relate to my research.
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Unexpected behavior arising from the quaternary structure of glutamate
transporters
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Kavanaugh1*
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Abstract
β-2-fluorenyl-aspartylamide (2-FAA) is a structurally novel inhibitor of excitatory amino acid
transporters (EAATs) that exhibits nanomolar potencies for blocking glutamate uptake and
approximately ten-fold selectivity for the neuronal transporter EAAT3. We recorded currents in
voltage-clamped Xenopus oocytes expressing human EAATs and used concentration jumps to
measure binding and unbinding rates of 2-FAA in the presence or absence of glutamate by
monitoring steady state glutamate transport currents or pre-steady state Na+-dependent
charge movements, respectively. The binding rates of the drug were not significantly different
for EAAT1, EAAT2, or EAAT3 but were approximately one order of magnitude slower than that
of glutamate. The selectivity of 2-FAA for EAAT3 resulted from an approximately ten-fold
slower dissociation rate of the drug. Unexpectedly, the rate of recovery from block in the
absence of glutamate was about 8 times slower than the rate measured in the presence of
saturating glutamate. This result is inconsistent with pseudo first-order unbinding kinetics
previously assumed for glutamate transporter block and suggests a significant probability of
drug rebinding in neighboring subunits. In agreement with this, co-expressing wild-type
subunits with an excess of mutant subunits (R447C) that do not bind glutamate or drug
increased the unblocking rate similar to the effects of glutamate. We propose a model in which
electrostatic and steric factors arising from the EAAT quaternary structure restrict diffusion near
the three ligand binding sites, resulting in an apparent dissociation rate that is significantly
slower than the true first-order subunit unbinding rate. Fitting this model to the 2-FAA block
data reveals the quaternary structure increases the probability, by a factor of three, that a
molecule will bind to the transporter opposed to being lost to diffusion.
Introduction
The human excitatory amino acid transporters (EAAT1-5) are secondary active
transporters that terminate excitatory synaptic transmission within the central nervous system
by removing glutamate from the extracellular space. EAATs move glutamate across the
membrane against its concentration gradient by stoichiometrically coupling transport to the
sodium, potassium, and proton electrochemical gradients, with cotransport of 3Na+, 1H+, and 1
glutamate and countertransport of 1 K+ (Levy et al., 1998; Zerangue and Kavanaugh, 1996). A
crystal structure for a homologous archaeal transporter from Pyrococcus horikoshii revealed
the transporter to be a homotrimer with individual binding sites located within each subunit.
Individual glutamate transporter subunits in a trimer function independently, both in terms
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glutamate flux and an ancillary chloride conductance (Grewer et al., 2005; Koch et al., 2007;
Leary et al., 2007). This has led to a teleological question concerning the reason for a trimeric
structure. One notable feature integral to the trimer structure is the central cavity or bowl
formed by the junction of the three wedged-shaped subunits. Because the surface of this
water-filled cavity is predominately hydrophilic and it dips far into the plane of the membrane,
one possibility is that it serves to lower the energy barrier for glutamate and co-transported
ions to cross the membrane (Gouaux and Mackinnon, 2005). Further clues about the
mechanistic role of the quaternary structure have come form the recent structural
determination of the the inward-facing form of GltPh, which reveals that relatively static intersubunit contacts may be involved in facilitating the relative motion of the central core of each
subunit to deliver the binding site to the internal face while the outer helices remain relatively
fixed (Reyes et al., 2009).
Several years ago a structurally novel aspartic acid amide, β-2-fluorenyl-aspartylamide
((S)-4-(9H-fluoren-2-ylamino)-2-amino-4-oxobutanoic acid; (2-FAA) was reported to be a
glutamate transporter blocker (IC50 25-90 nM) with ten-fold selectivity for EAAT3 over EAAT1
and EAAT2 (Bridges et al., 2008). The molecule is an aspartamide with a fluorenyl ring
extended from the amino group of the side chain (figure 1b).
Measuring microscopic rate constants of glutamate transporters has been technically
challenging due to the requirements for use of techniques involving glutamate photo-uncaging
or piezo-element driven fast application of glutamate or inhibitors to membrane patches
containing transporters (Wadiche and Kavanaugh, 1998; Otis and Kavanaugh, 2000). In this
work we take advantage of the high affinity of 2-FAA for glutamate transporters to use a slightly
modified two-microelectrode voltage clamp chamber in which we can apply concentration
jumps to oocytes in conditions where measurement of drug kinetics are not limited by solution
exchange times. We conclude that 2-FAA is selective for EAAT3 solely because of a slower
unbinding rate compared to EAAT2 and EAAT1. Further, we provide evidence that the effective
macroscopic rate of recovery from drug block is up to eight-fold slower than the unbinding rate
from an individual subunit, and we propose that the quaternary structure of the transporter
plays a previously unknown role in restricting diffusion and enhancing the efficiency of ligand
capture by the transporter.
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Experimental Methods
Computational modeling. Human EAAT3 sequence (obtained from GenBank, http://
www.ncbi.nlm.nih.gov) was aligned with the Protein Data Bank (PDB) sequences for an
archaeal homologue (GltPh, 2NWW.pdb) according to Yernool, et al. (Boudker et al., 2007,
Yernool et al., 2004). The EAAT3 homology model was constructed by threading the aligned
sequence along 2NWW coordinates using the SwissProt server (http://swissmodel.expasy.org//
SWISS-MODEL.html). The resulting model was optimized through local energy minimizations
of regions with high steric and electrostatic interference using the AMBER7 force field in the
Tripos SYBYL8.0 platform. Representations of 2-FAA, and TBOA were docked using GOLD v.
3.0.1 (http://www.ccdc.cam.ac.uk/) into the EAAT3 model and evaluated using the ChemScore
scoring function. Each of the top thirty poses for each of three separate docking runs were
evaluated for their capacity to hydrogen bond with EAAT3 R447 and D444 residues. ΔG
values were extracted from ChemScore output to quantify relative Kd values. Poses with the
lowest estimated ΔG values determined by ChemScore were incorporated into the homology
model and visualized using PyMol1.0
Results
Computational docking of 2-FAA to EAAT3
We docked 2FAA into EAAT3 homology models using the GOLD docking program to
determine possible mechanisms responsible for 2-FAA’s nanomolar affinity. Our results
indicate structural positioning of the inhibitors that differ from the pose of TBOA in the 2NWW
GlTPh crystal structure (Boudker et al., 2007). Specifically, the highest ranking docked poses
position 2-FAA’s fluorene head group with a grouping of non-polar residues in TM7, TM8 and
the HP2 loop (figure 1A, 1B), while the benzene ring of the crystal structure TBOA is oriented
toward the solvent accessible tip of the HP2 loop (figure 1b). We found only lower-ranking
poses of 2-FAA adopt orientations similar to TBOA in the GltPh crystal structure with binding
affinities approximately one order of magnitude lower than the higher ranked poses described
above (the ranked score determined by ChemScore of the highest ranked pose shown in
figure 1B is 22.4 with a ΔG of -29.9 and a Kd of 5.8µM while the lower ranked poses score
18.9 with a ΔG of -24.2 and a Kd of 57µM).
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(b)

(a)

R447

Figure 1: a. A surface rendering of a EAAT3 homology model threaded through Gltph (2NWW.pdb) using the
SWISS-MODEL homology modeling server. 2-FAA is oriented in the binding site based on computational docking
experiments using the GOLD docking program (v.3.0.1) with the ChemScore scoring function. The structure was
visualized using PyMol version 1.0. b. The EAAT3 docking study revealed an alternative binding pocket from that
of TBOA in the 2NWW GlTPh crystal structure. The fluorene group of docked 2-FAA (orange) is shown interacting
with polar (green) and non-polar (dark-blue) residues in TM7, TM8 and in the HP2 loop. TBOA (yellow)
determined in the GlTPh crystal structure overlays docked 2-FAA to show the alternative orientation described by
Boudker et al., 2007.

2-FAA
2-FAA

ChemScore ΔG
22.39
-29.88
18.94
-24.23

Kd( µM) orientation
5.8
up
57
down

Table 1. ChemScore evaluation of 2-FAA docked poses shows an increased affinity of EAAT3 homology model for
the ʻupwardʼ orientation.

Discussion
Experimentally, the Ki for an inhibitor is most commonly estimated using the Schild
Analysis or derivation from the IC50 using the Cheng-Prusoff equation. Our attempts at a Schild
analysis for 2-FAA were unsuccessful and inaccurate due to experimental challenges
associated with long and repeated drug application. The Cheng-Prusoff conversion of the IC50
from the steady state currents gave comparable estimates of the Ki; however, with this
method , it is critical to take into account the time for the drug to reach a steady state block.
For a potent drug like 2-FAA, not being at steady state in a 5 min radiolabeled uptake
experiment would result in a drastic underestimate of the IC50 and thus Ki. Because of the high
affinity/slow off-rate of the 2-FAA, it was possible to study its microscopic kinetics with high
resolution in oocytes expressing EAATs using a moderately fast-flow chamber designed for this
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purpose. Blocking and unblocking rates measured using varying concentrations of 2-FAA at
EAAT1-3 are consistent with the differences in measured affinities for EAAT1-3. This technique
offered us the advantage of distinguishing the binding event from the unbinding, suggesting
that unbinding from EAAT3 was 7-8-fold slower than EAAT1 or 2, accounting solely for the
difference in Ki.
Computational docking studies with 2-FAA are also in agreement with a significantly
increased affinity relative to TBOA as well as a different binding orientation than determined for
TBOA though x-ray crystallography (Boudker et al., 2007). This new orientation of the molecule
falls in a hydrophobic pocket of the binding site which helps to explain why there is a general
increase in potency of molecules for all EAATs with an increase in the lipophilic nature of the
side chain. This agrees with current research that shows no affinity change for TBOA in EAATs
expressing mutations of a methionine described by Boudker et al (2007) as interacting with
the benzyl ring of TBOA (Rosental & Kanner, 2010). Though we could not use the Schild
analysis to determine if 2-FAA was a competitive inhibitor, this unique but local docking of 2FAA within the known binding site supports the interpretation of it as a competitive inhibitor, as
well as the fact that saturating concentrations of glutamate could still recover the Imax following
block by 2-FAA, if performed within the same hour.
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Chapter 5: Discussion and future directions
The multiple published crystal structures of the GltPh archaeal EAAT homologue have
provided abundant opportunity to supplement, augment, and contextualize decades of
research into EAAT structure and function. Much of the work presented here focused on cation
and substrate interactions with EAAT3, ultimately resulting in development of an incomplete
but consistent model for sequential binding and unbinding of cations and glutamate during
transport (chapter 3, figure 11). Specifically, we describe previously uncharacterized Na+ and
K+ coordination sites and attempted to deconstruct the sequence of events that lead to
transport of sodium and glutamate and subsequent countertransport of K+. Our research,
however, is merely the start of possible computational work that could lead to truly unraveling
the mechanisms behind EAAT transport. In the following paragraphs I will explore two methods
for future computational experiments that would potentially expand our initial findings.
B-factors
Most crystal structures are published with isotropic (non-directional) temperature factors,
or B-factors. B-factors are a measure of how much an atom vibrates around the coordinates of
the atom specified in an X-ray crystal structure and relate to the resolution of each atom in a
structure by the equation
B = 8π2 * u2
where u is the root mean square deviation from an atom’s position (Mair and Wilkins, 1975).
Thus, under ideal conditions B-factors suggest mobility of an atom relative to other atoms
within the same structure (elements that can confound interpretation of movement using Bfactors include localized artifacts such as unit cell packing constraints and the symmetry of unit
cells [Carugo and Argos, 1997; Rapp and Pollack, 2005]). A mean B-factor for high-resolution
structures is usually around 60Å2 which indicates that the resolution of an average atom is
smeared around a radius of 0.87Ås.
The GltPh structures are of moderate resolutions, ranging from approximately 3.2Ås to
3.5Ås and two of the published structures are sufficiently resolved to reveal Tl+ and Na+
densities. The mean B-factor for the inward facing structure and highest resolved outwardfacing structure (3KBC.pdb and 2NWX.pdb respectively) are both approximately 100Å2
ranging from more stable atoms with B-factors of approximately 94Å2 to atoms with more
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thermal activity with B-factors of approximately 106Å2 (Boudker et al., 2007; Reyes et al.,
2009). Figure 1 depicts single trimer subunits colored to show B-factors for the protein
backbone of the outward-facing, thallium- and aspartate-bound structure (figure 1a) and the
inward-facing, sodium- and aspartate-bound structure (figure 1b). The variable thickness of the
cartoon in figure 1 was calculated from B-factors using the above equation to show the root
mean square deviation of protein backbone atoms. The cartoon thickness therefore
approximates the range of movement of the protein backbone, showing limited vibrational
variation throughout the protein. Relative B-factor variations, though, can be informative and
suggest regions with higher mobility. The C-terminal region of HP2 in the inward facing
structure (indicated by the arrow in figure 1b), for example, is an area with higher B-factors,
suggesting potential mobility, which, due to its proximity to the substrate binding site could
indicate involvement in substrate and cation release. A statistical analysis of regions with high
B-factors that correlate to regions showing electrostatic potential could be informative.

(a)

(b)

HP1 & TM7 loop
Figure 1. Cartoon depictions of outward-facing (a) and inward-facing (b) GltPh subunits colored by B-factors,
with regions of higher B-factors colored more red and regions with lower B-factors colored blue. Thickness of
the cartoon was calculated to depict possible range of movement. The arrow indicates a possible region of
interest showing higher B-factors near the amino acid binding site.
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Coarse-grain molecular dynamics
Glutamate transport is a fairly rapid process taking only milliseconds to complete each
transport cycle (Grewer et al., 2000). Though physiologically rapid, this timeframe poses a
problem for molecular dynamics simulations. Currently, using a system that approximates
close-range interactions of each atom through force fields derived from classical molecular
mechanics (i.e. assuming Newtonian interactions prevail in a system allowing for the exclusion
of computationally expensive quantum calculations), only very short simulations are possible.
For example, we are using graphical processing units to accelerate our molecular dynamics
simulations. Even with accelerated processing, we can only achieve two nanoseconds of
simulation per day for systems with 120,000 explicit atoms. This of course prohibits micro-, let
alone millisecond timeframes (at two nanoseconds per day we would require 5500 years for a
one millisecond simulation). One possible method that would alleviate some of the more
computationally expensive calculations is coarse-grain molecular dynamics. As the name
suggests, the resolution of certain atomic interactions would be reduced. Explicit
representations of atoms within methylene groups in lipid bi-layers, for example, could be
united to pseudo-atom approximations. In our system with nearly 400 lipid molecules, we
would enjoy approximately 1/3 fewer calculations per time-step without sacrificing accurate
involvements relevant to transport.
Concluding remarks
The continued development of databases in genomics, proteomics, protein structure,
systems biology, and epidemiology has yielded unprecedented amounts of information. The
ability to manipulate or to otherwise interpret or reinterpret data to find trends, create predictive
models, or simulate systems will become increasingly valuable as databases expand. While
investigations into EAAT structure and function constituted the bulk of this dissertation, the
greater goal was to begin interpreting the functional implications hidden within protein
structures using computational biology. Peace out.
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